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Colon cancer is a major contributor to cancer-related mortality worldwide. Death 
from colon cancer occurs in the majority of the cases from widespread metastatic 
disease. Surgery alone can cure a large proportion of colon cancer patients pre-
senting with non-metastasized disease (1;2). Without any adjuvant treatment, up 
to fifty percent of these patients will not develop disease recurrence or metastasis 
following surgery (2-4).
Despite optimal surgical therapy, between 30-50% of initial stage II or III colon can-
cer patients will still suffer from metastatic disease (2-4). This risk can significantly 
be reduced by applying postoperative or adjuvant chemotherapy. Studies have 
however shown that only a selected proportion of the stage II and III patients will 
actually benefit from adjuvant treatment because not all patients within this cohort 
will develop a distant metastasis and because of low response rates to therapy, in 
the case of stage II disease this might even only be 15% of the patients (5;6). The 
decision to offer adjuvant therapy, especially for stage II disease, should therefore 
be balanced against the possible risks of treatment-related toxicity (6). This makes 
it essential for the clinician to be able to precisely identify the high risk patient 
cohort.
Nowadays, treatment allocation is based on tumor staging using only the TNM 
(Tissue Node Metastasis) criteria developed by the IUCC (Union Internationale 
Contre le Cancer) and the AJCC (American Joint Committee on Cancer) that are 
applied worldwide (7). The application of the TNM criteria, based on tumor mor-
phological characteristics, falls short in the identification of the high risk patient 
population. Prognostic biomarkers that provide additional information on patient 
outcome might improve staging criteria. Therefore, increasing attention is now 
being directed towards the discovery of prognostic biomarkers to identify high risk 
colon cancer patients. Several methods have been used, but two main approaches 
can be distinguished.
A genomic approach that involves the simultaneous examination of a large number 
of genes using complex platforms, including multigene-based mutation assays and 
gene expression microarray technologies. The power of this approach lies within its 
capacity to tackle tumor heterogeneity with the goal to develop a unique genetic 
signature to provide the opportunity to match therapy to the characteristics of 
the individual patient’s tumor (8). So far, despite numerous studies reporting on 
different prognostic gene sets, only two genomic profiles have been validated in 
independent patient cohorts. These are the ColoPrint and the 12-gene colon cancer 
recurrence score (9-11). The colon cancer recurrence score has been offered by 
the Genomic Health company since January 2010 for clinical use as the Oncotype 
DX® Colon Cancer Assay and is now available to support treatment planning for 
stage II and stage III colon cancer patients (12). A point of discussion in the use of 
these signatures is the lack of strong biological basis (13). As only a small number 
of the genes from the different gene expression signatures actually overlap and 
only a weak interaction was observed between the gene expression signatures and 
tumor stage (13-16). This lack of interaction between gene expression signatures 







study of the colon recurrence score developed by the NSABP (National Surgical 
Adjuvant Breast and Bowel Project) but also in the second validation study of the 
ColoPrint (9;11). Furthermore, in this last study the results for risk recurrence, based 
on the Coloprint and those based on several clinical tumor biology-based factors 
such as, T-stage and tumor grade were disconcordant in 50% of the patients indi-
cating a lack of interaction of the signature with actual tumor biology (9). Prob-
ably in the future of the clinical decision making process besides gene expression 
signature, other clinico-pathology-based markers may be used to achieve the most 
accurate risk assessment.
The second approach is a more tumor biology-directed approach, with a focus 
on biological determinants of the tumor’s metastatic potential. The biological 
hallmarks of cancer are six biological capabilities a cell acquires during the pro-
cess of tumorigenesis (17). They include sustaining proliferative signaling, evading 
growth suppressors, resisting cell death, enabling replicative immortality, induc-
ing angiogenesis, and activating invasion and metastasis. Recently, two ‘emerg-
ing hallmarks’, features that tumors gain during their development, were added: 
reprogramming of energy metabolism and evading immune destruction (17;18). In 
this thesis we focus especially on three hallmarks of tumor development in colon 
cancer in order to indentify biomarkers of disease recurrence and to develop new 
treatment strategies based on this biological approach. In part 1 the focus is on 
markers of apoptosis and proliferation, and in part 2 on tumor-immune interac-
tions.
AIMS AND OUTLINE
Part 1 Biomarkers of apoptosis and proliferation
A key factor in colonic tissue homeostasis is the balance that exists between cel-
lular apoptosis, or programmed cell death, and the level of cellular proliferation 
(19-21). Several hallmarks of cancer development such as sustaining proliferative 
signaling, evading growth suppressors, resisting cell death, enabling replicative 
immortality together determine a balance between cell proliferation and cell death. 
The outcome of this balance determines tumor growth (17). Therefore, biomarkers 
representing these pathways might harbor the potential to identify high risk stage 
II colon cancer patients. Previously, we have been able to determine a prognostic 
value of the level of apoptosis in rectal cancer patients (22;23). In colon cancer 
this value has been debated (20;24-27). The aim of the first part of this thesis was 
to determine the clinical prognostic value of apoptosis and proliferation in colon 
cancer patients and to develop biomarkers with the potential to be used in a clini-
cal setting to identify high risk stage II colon cancer patients. Chapter 2 provides 
a review of the current literature of biomarkers of apoptosis in colorectal cancer 
in order to identify any biomarker that has already been proven to be of clinical 
prognostic value. In chapter 3 a combined analysis of biomarkers of proliferation 








cancer patients, is evaluated for its prognostic quality. Chapter 4 describes the 
development and identification of a new prognostic, biochemically determined, 
biomarker based on tumor cell proliferation in stage II colon cancer patients: the 
CDK1 SA (Cyclin Dependent Kinase 1 Specific Activity). Finally in chapter 5 a bio-
marker combination consisting of two biochemical assays reflecting the level of 
apoptosis and proliferation in colon cancer tissue is studied for the clinical identifi-
cation of high risk stage II colon cancer patients.
Part 2 Tumor immune interactions
In part 2 the focus is on one of the emerging hallmarks in cancer biology: evading 
immune destruction (18). Studying tumor immune interactions not only provides 
us with new biomarkers of tumor aggressiveness, it will also open a door to new 
cancer treatment strategies. Besides focusing on chemotherapy as adjuvant treat-
ment strategy for high risk stage II patients, exploiting possibilities of activating 
the patient’s immune system as a therapeutic modality is becoming an emerging 
modality as well. Chapter 6 gives an overview of the colorectal cancer vaccines 
that have been studied in clinical trials until now including the first studies with the 
p53-SLP vaccine which is used in a clinical phase I/II trial as described in chapter 7. 
Although the results of these studies are hopeful, as we were capable of elicit-
ing vaccine-specific T-helper responses, optimal patient selection in advance may 
make real clinical breakthroughs possible. Therefore, in chapter 8 we focus on the 
determination of key factors in tumor-immune interactions such as tumor expres-
sion of HLA class I and local presence of Foxp3- and CD8-positive cells and their 
prognostic value. In chapter 9 we combine this knowledge into a clinical prognostic 
tumor-immune phenotype that might eventually aid us in the identification of high 
risk stage II colon cancer patients and select those that might benefit from adju-
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Research towards biomarkers that predict patient outcome in colorectal cancer 
(CRC) is rapidly expanding. However, none of these biomarkers have been recom-
mended by the American Association of Clinical Oncology or the European Group 
on Tumor Markers. Current staging criteria result in substantial under- and over 
treatment of CRC patients. Evasion of apoptosis, a characteristic feature of tumori-
genesis, is known to correlate with patient outcome. We reviewed the literature on 
immunohistochemistry-based studies between 1998 and 2011 describing biomark-
ers in this pathway in CRC and identifying 26 markers. Most frequently described 
were p53, Bcl-2, survivin and the Fas and TRAILR1 receptors and their ligands. 
None of the studies reviewed provided sufficient evidence for implementing a sin-
gle marker into current clinical practice. This is likely due to the complex biology of 
this pathway. We suggest focusing on the combination of key markers within the 
apoptosis pathway that together represent an ‘apoptotic tumor profile’, which bet-









Colorectal cancer (CRC) is currently one of the major contributors to cancer-related 
deaths worldwide (1;2). The amount of data emerging from studies aimed at opti-
mizing the diagnostic process and treatment of this disease is rapidly increasing. 
This makes the process of tumor development in CRC one of the most thoroughly 
studied and best characterized models of tumorigenesis. By emphasizing the need 
of early detection and development of new and improved treatment regimens, 
an increased understanding of the disease did led to decreased mortality rates of 
nearly 5 percent over the last decade (3-10). However, CRC -related morbidity and 
mortality affects approximately 800,000 individuals each year worldwide (2). The 
survival of CRC patients largely depends on disease stage at the time of diagno-
sis and varies widely between the stages. In clinical practice, however, treatment 
allocation and outcome prediction is still solely based on the International Union 
Against Cancer (UICC) Tissue Node Metastasis (TNM) classification (11). Addition 
of several pathology -based tumor characteristics is currently used to identify 
high-risk stage II patients that may benefit from adjuvant chemotherapy. These 
include perforation of the bowel wall at presentation, tumor invasion at the T4 
level, venous tumor invasion, lymph node yield less than 10, and poor or no dif-
ferentiation of the tumor cells (12). There is substantial evidence that even with 
the addition of these risk factors of poor outcome, TNM classification falls short 
in daily practice and may cause over- or, even worse, under-treatment of patients 
(11;13-15;15-18).
In an attempt to improve treatment outcoumes for CRC patients, both the Ameri-
can Society of Clinical Oncology’s Tumor Markers Expert Panel (ASCO TEMP-2006) 
and its European counterpart; The European Group on Tumor Markers (EGTM-
2007) have reviewed the available literature to determine the clinical applicability 
of a number of widely studied biomarkers (19-21). Their conclusions were clear and 
consistent: despite the overwhelming amount of literature, no biomarkers have 
been recommended for clinical use. Therefore, to improve current staging criteria, 
new biomarkers must be identified and validated for clinical use. Pepe et al. have 
developed a five-step program that can be used for the development of new bio-
markers (22). The first step is biomarker discovery in a preclinical, exploratory set-
ting. Subsequently, the clinical value of these biomarkers must be determined and 
verified in a large retrospective study. Those results then need to be the validated 
and eventually confirmed by a prospective randomized controlled trial. It is not 
until these steps are completed successfully that biomarkers are ready for intro-
duction into clinical practice. The first step which involves identifying or discovering 
new biomarkers, can be accomplished by studying the process of tumorigenesis 
and its related pathways. Cancer cells harbor at least six features that distinguish 
them from normal cells, one of which is the characteristic ability to evade pro-
grammed cell death or apoptosis (23). In normal tissues apoptosis plays a pivotal 
















system (24;25). Disturbance of this process in tumor cells results in the impaired 
removal of mutated cells and contributes to tumor progression. In addition, evasion 
of apoptosis enables malignant cells to escape from tumor immune surveillance 
and to acquire resistance to cancer therapy. In previous retrospective studies, the 
status of the apoptotic pathway in a tumor was shown to be of prognostic value in 
colorectal cancer patients (26-37). Therefore, we focused on this pathway in our 
search for new potential prognostic biomarkers in colorectal cancer. In this review, 
we provide an overview of studies designed to determine the prognostic value of 
biomarkers within the apoptotic pathway in colorectal cancer. Furthermore, we will 
discuss some of the difficulties and controversies that can arise when studying this 
tightly regulated and complex process. The goal is to identify key biomarkers in the 
apoptotic pathway that may be used clinically to determine cancer prognosis. We 
first discuss the route of apoptosis to identify the key proteins in this process and 
then link this information to studies that examined the prognostic value of these 
proteins in colorectal cancer. Since immunohistochemistry (IHC) is still the most 
widely applied and available technique in pathology to determine the expression 
status of tumor-associated proteins and to study the clinical prognostic relevance 
of biomarkers, we limited our search to IHC studies.
DATA COLLECTION AND ANALYSIS
In order to review the literature on prognostic biomarkers related to the pathway 
of apoptosis, determined using IHC in CRC patients, we performed a search of the 
Pubmed, Embase and Web of Science databases. We used broad search terms, 
as recommended in the Stroup guidelines (38), to identify publications of inter-
est published between January 1998 and June 2011. Key search terms included 
colorectal cancer, biomarker, apoptosis, prognosis, and immunohistochemistry. The 
following search strategy (simplified) shows how some of these terms were com-
bined in our Web of Science Search; “TS=((colorectal or colon or colonic or rectal or 
rectum) SAME (neoplasm or cancer or tumor or carcinoma)) AND TS=((prognostic 
or tumor or cancer or neoplasm or biological or intracellular or signaling or intra-
cellular signaling) SAME (marker or protein or peptide)) AND TS=((prognosis or 
prognostic or morbidity or mortality or recurrence or relapse or (disease SAME 
progression))) AND TS=(immunohistochemistry or immunolabeling or immunocyto 
histochemistry). After amalgamating the results from the three medical databases 
and discarding the duplicates, this strategy yielded a total of 2923 unique citations. 
To extract papers for review, we screened the results for title and abstract. We 
used the following criteria to determine whether a study was considered eligible 
for the review:
a) The study contained data on a marker directly involved in the pathway of 
apoptosis;
b) The study was performed in primary tumors from CRC patients;








d) The study contained an analysis of the relationship between expression of 
the marker and clinical outcome. We selected only studies that used logistic 
regression or survival curve -based statistical analysis methods to evaluate the 
impact of a marker;
e) A full publication in English with details of the method used was available.
RESULTS
Overall, we were able to indentify 26 potentially prognostic biomarkers that are 
directly involved in the apoptotic pathway, which will be discussed in detail below 
(figure 1). These markers were all studied using IHC in the 124 eligible publications 
that remained after applying our selection criteria from the total of 2923 publica-
tions. Expression patterns of these apoptotic (bio)markers were related to patient 
outcome using logistic regression or survival curve -based analysis methods. Most 
of the papers, over 800, were excluded because they described the expression of 
markers related to the pathway of apoptosis in other types of cancers than colo-
rectal cancer, despite the fact that our search terms included colorectal cancer 
as a major search term. Over 900 citations were excluded because they did not 
describe the marker in primary colorectal cancer lesions but rather in metastatic 
lesions. Table 1 provides an overview of our selection criteria and the correspond-
ing number of citations that were excluded based on these criteria.
The general pathway of apoptosis is illustrated in figure 1 and includes the markers 
that discussed in this review. Although this figure represents a simplified version of 
the pathway, it shows that the process of apoptosis is highly regulated at multiple 
levels. Based on the stimuli presented, two pathways initiating the apoptotic pro-
cess can be identified (39). The extrinsic pathway is triggered by external death 
signals that cause the formation of intracellular signaling complexes at the death 
receptors. This type of apoptosis is usually activated in immune responses (40). 
The second pathway, known as the intrinsic pathway, is activated by many different 
stimuli, including growth factor deprivation and DNA damage, caused by factors 
such as UV or gamma-irradiation or by chemotherapeutic agents. Exposure of cells 
to these stimuli initiates a set of intracellular death signals mediated by the p53 
protein that activates the apoptotic process. Mitochondria play an important role 
in the intrinsic pathway with a major regulatory role for the Bcl-2 family members. 
Although already intimately connected via caspase-8 and Bid, both pathways con-
verge at the level of the caspase -cascade that eventually leads up to the proteo-
lytic activation of the executioner members such as caspase-3 (41). The function 
of the caspase proteins is again highly regulated by a group of so-called inhibitor 
of apoptosis proteins (IAPs) (42). In general, executioner caspases will cleave sev-
eral substrates, thus acting as a cellular disassembly machine. Cleavage of these 
substrates is eventually responsible for the morphological features that hallmark 

















To discuss the results of our literature review in an orderly fashion, markers are 
grouped and discussed based on their location in the pathway as described in 
figure 1, starting with the extrinsic pathway of apoptosis and ending with the IAPs. 
In addition, table 2 provides a general overview of the number of studies identified 
that describe the prognostic value of a particular marker, grouped by their func-
tion and location in the pathway of apoptosis in the order at which they will be 
discussed in this review.
The Death Receptor Family and the extrinsic pathway of apoptosis
The most studied signaling pathway in apoptosis is the extrinsic pathway, activa-
tion of which is primarily facilitated by the death receptors (DRs). Based on our 









































The pathway of apoptosis. A simplifi ed schematic view of the intrinsic and extrinsic pathway of 
apoptosis and their regulators as described in this review. A regular arrow indicates a positive 
(stimulating or activating) eff ect of a regulator on a component in the pathway it points out to. 
A  plus sign indicates that there is an interaction between two components. The combination of 
these two components exerts a stimulating eff ect on the progression of the apoptotic cascade. 
A dotted arrow indicates an inhibitory eff ect of a regulator on another member or on an activating 
stepwithin the apoptotic pathway. The markers in italic white in the grey boxes were found to have 
the most clinical prognostic signifi cance in colorectal cancer patients, based on the studies that 
resulted from our search of the literature. These markers, their function, and whether they are of true 









Selection of relevant studies on clinical prognosis of apoptosis-related markers
Exclusion criteria and the number of citations that were excluded based on these criteria
(Total number of citations reviewed n=2923)
Exclusion Criteria Numer of cita-
tions excluded
A. The study describes data on a marker not directly involved in apoptosis
B. The study was not performed in primary colorectal cancer patients
C. The study was not performed using immunohistochemistry
D. The study did not contain validated outcome results
E. An English full text version was not available
Total number of citations excluded based on these exclusion criteria








Table 1 provides an overview of the exclusion criteria that were used to select the most relevant 
citations. The criteria were applied to the 2923 citations retrieved in our search of literature in three 
major online medical databases. The material and methods section provides further background on 
the postulation of these criteria and outline of our literature search.
The number of citations excluded from further analyses based on each criterion is listed. Based 
on the criteria A, B, C, D, and E, 2799 citations were excluded from the selection. Therefore, 
124 citations remained for in depth review of the prognostic value of the markers studied.
pathway of which the prognostic relevance was studied in CRC patients. These 
markers included: Fas receptor (FasR), TRIAL1, TRAILR2, TRAILR3, TRAILR4, FasL, 
TRAIL, and c-Flip (table 2). A unique feature of the extrinsic pathway is that DRs 
can induce apoptosis independently of the p53 tumor suppressor gene. DRs are 
members of the tumor necrosis factor receptor superfamily, of which eight family 
members have been characterized (43;44). The most common receptors are FasR 
(CD95, DR2) with its ligand FasL and TRAILR1 and -R2 (DR4 and DR5) with their 
ligand TRAIL (Tumor necrosis factor (TNF)-Related Apoptosis-Inducing Ligand). 
All DRs contain cysteine-rich extracellular domains that allow them to recognize 
their ligands with great specificity. They also harbor intracellular sub-domains bet-
ter known as the Death Domains (DDs) (45). DDs allow them to interact with adapter 
molecules such as FADD (Fas-associated Death Domain) (46). Signal transduction 
within the extrinsic pathway starts with the binding of the ligands to the DRs, fol-
lowed by the formation of multi-protein signaling complexes called death inducing 
signaling complexes (DISCs) at the intracellular domains of the DRs (47;48). The 
DISC complex auto-activates pro-caspase 8 through interaction with a FADD pro-
tein. Activated caspase-8 will eventually activate the effector caspase-3 by proteo-
lytic cleavage (48-51). Downregulation of any of the DRs or downstream apoptotic 
proteins might cause severe limitations in the induction of apoptosis through the 
extrinsic pathway. There are two other mechanisms involved in the regulation of 
the extrinsic signaling pathway. First, TRAIL can also bind to two decoy receptors 
(DcR) in addition to the DRs, including DcR1 and DcR2 (also known as TRAILR3 
and TRAILR4, respectively). However, neither decoy receptors can transduce an 

















Overview of markers of the apoptosis pathway
Overview of the markers reviewed, the total number of citations including the references that 
described the prognostic relevance of these markers












Bcl-XL Anti-apoptotic Bcl-2 family member 1 (90)
Bag1 Enhancing anti-apoptotic function of Bcl-2 2 (90;151)
Apaf-1 Formation of the apoptosome 8 (90;113;118;121;152-155)
Bax Pro-apoptotic Bcl-2 family member 8 (90;123;123;146;147;156-159)
Bad Pro-apoptotic Bcl-2 family member 1 (160)
Bid Pro-apoptotic Bcl-2 family member 2 (90;160)
Bim Pro-apoptotic Bcl-2 family member 1 (161)
Noxa Pro-apoptotic Bcl-2 family member 1 (161)
Puma Pro-apoptotic Bcl-2 family member 1 (161)
Caspase-8 Initiator Caspase of instrinsic pathway 2 (60;155)
Extrinsic pathway
FasR Death receptor 2 (56;57)
TrailR1 Death receptor 2 (57;59)
TrailR2 Death receptor 2 (57;59)
DcR1 Decoy death receptor 1 (57)
DcR2 Decoy death receptor 1 (57)
FasL Death receptor ligand 1 (56)
TRAIL Death receptor ligand 3 (57;59;60)
c-Flip Inhibitor of extrinsic apoptosis induction 2 (56;60)







Inhibitor of the Caspase cascade
Inhibitor of the Caspase cascade
Inhibitor of the Caspase cascade
Inhibitor of the Caspase cascade











Listed are biomarkers related to the pathway of apoptosis that emerged from the review of the 
literature. The biomarkers were studied by immunohistochemical analyses and their expression was 
related to clinical outcome in colorectal cancer patients. For each marker, the number of publications 
in which these markers were studied and their primary function within the pathway of apoptosis are 
listed.
* The systematic review of Munro et al., in which the available literature on the prognostic value of 
p53 expression until 2005 was reviewed extensively, was used as a starting point for our search in of 








mediated apoptosis may, therefore, be a function of the ratio of DcR to DR. If there 
is significant upregulation of the DcRs or downregulation of the DRs, TRAIL will 
bind to the DcRs instead of the DRs, and the apoptotic signaling is interrupted 
(52). Secondly, cellular Flice-Like Inhibitory Protein (c-FLIP) is, simelarly to FADD, a 
DD-containing protein and can competitively bind to FADD in the DISC formation 
process instead of the DD domain of the DRs (figure 1). This protein, particularly 
in the c-FLIPL isoform, shows strong structural similarities to pro-caspase-8, and 
might be a potentially strong inhibitor of the extrinsic apoptotic pathway. There 
are two other features that are unique to the extrinsic pathway, but contribute 
considerably to the complexity of its regulation. The first feature is an indirect 
link with the intrinsic pathway, which can be activated through the formation of 
tBid, a truncated form of the BID protein. In a subset of cells known as type II 
cells, DISC formation occurs less frequent, resulting in less caspase-8 activation 
and subsequently truncation of the Bid protein into tBid  (53). tBid induces oli-
gomerization of Bax or Bad, upon which the mitochondria release cytochrome c, 
this eventually induces apoptosis further down the intrinsic pathway. Because of 
the mitochondrial involvement, the regulation of apoptosis in Type II cells is subject 
to regulation by the Bcl-2 family proteins. This regulation, which will be discussed 
in detail in this review, provides the cell with an apoptosis-evading mechanism 
such as downregulation of DR expression that may occur in a cell during tumori-
genesis (54). A second feature unique to the extrinsic pathway is explained by the 
so-called ‘Fas-Counterattack hypothesis’ (55). In normal tissue homeostasis, the 
Fas/FasL-induced extrinsic pathway of apoptosis plays a major role in immune sur-
veillance. Activated T lymphocytes express FasL and upon recognition of a tumor 
cell as a target (via MHC-presented peptides on the tumor cell surface), a tumor 
cell expressing the FasR may be eliminated by induction of apoptosis. However, it 
is known that tumor cells can also express FasL and thus are able to counterattack 
cells from the immune system (55). By downregulation of FasR expression as well 
as by upregulation of FasL expression, tumor cells can escape immune surveillance.
In summary, the key players of the extrinsic pathway are the DRs, specifically 
TRAILR1, R2 and FasR and their ligands. The way tumor cells try to disrupt signal-
ing through these DRs to overcome apoptosis has been widely studied in many 
types of cancers. Our search identified 12 studies in which one or more of these 
DRs and their ligands were studied. In 5 of the 12 studies, one of the DR pathway-
related markers (FasR, FasL, TRAILR1 and TRAIL) was found to be of significant 
prognostic value (56-60) (table 3). Hypothetically, based on the biology of the 
process of tumorigenesis, downregulation of expression of the DRs or upregula-
tion of expression of their ligands would indicate a more aggressive tumor type, 
and hence worse clinical outcome parameters. Interestingly, most studies reported 
that upregulation of the expression of Fas and TRAIL was significantly related to 
worse outcome parameters. The expression of FasL and FasR was studied by both 
Korkolopoulou et al. and Strater et al. (56;58). In the smaller study by Korkolopou-
lou et al. involving 90 patients, normal cells did not express FasL, but tumor cells 

















Extrinsic pathway of apoptosis
Overview of the literature on statistically significant,  














FasR Strater(58) 128 Colon II-III Up DFS 0.4 0.034




















TRAIL McLornan(60) 253 Colorectal II-III Up OS 1.210 0.026
Abbreviations: DFS (Disease Free Survival), OS (Overall Survival), REC (Recurrence), Up 
(Upregulation of the expression of the marker). This table provides the references of the studies that 
describe the prognostic value of FasR, FasL, TRAILR1, or TRAIL, identified in this review. For each 
marker the important study characteristics are listed.
survival (OS) (56). Tumor cells also showed expression of the Fas receptor with a 
mainly cytoplasmatic and granular staining pattern. According to the authors, this 
indicates that although Fas receptor was present, it had no true functional proper-
ties. Therefore, according to the authors, the seemingly contradictory result of a 
worse outcome despite upregulation of the DR expression could be explained by 
the Fas-Counterattack hypothesis. In the second study by Strater et al., overex-
pression of Fas receptor correlated with a significantly better disease free survival 
(DFS) (58). Unfortunately, this study did not describe the exact location of FasR 
expression in the cell. Therefore, it is difficult to determine whether their results 
confirm Korkolopoulou results or actually oppose them. We were therefore not 
able to determine whether the Fas-Counterattack hypothesis has true clinical value 
in CRC.
With respect to DR4 and its ligand TRAIL we could identify three studies report-
ing on the prognostic value of these biomarkers in CRC (57;59;60). In all studies, 
upregulation of expression of DR4 or its ligand were related to worse outcome 
parameters such as higher levels of recurrence and shorter OS. This apparent con-
tradiction with expectations based on biology of tumorigenesis can, according to 
Van Geelen et al.,be explained by the fact that DR4 is also known to have effects 
on cell proliferation through the activation of nuclear factor kappa B (NF-țB), as 
described in a number of studies (60-63).
In conclusion, we were able to identify five studies that report on FasL, FasR, 
TrailR1, or TRAIL 2 as significant prognostic markers in colorectal cancer patients. 
Conclusions varied, which might be due to differences in patient selection and/or 
study methods. However, more importantly, their conclusions were in contradic-
tion with what is expected based on the biology of the apoptosis pathway. This can 
be explained by the fact that the functionality of this extrinsic part of the apoptotic 
pathway in the included studies was only investigated using changes in protein 








was not considered in the majority of these studies. The process of tumorigen-
esis attracts many cells that are part of the immune system into the tumor micro-
environment. The presence of these cells such as activated CD8+ T cells or Foxp3+ 
regulatory T cells has been shown to be of prognostic relevance in CRC (64;65). 
Moreover, activated T cells produce CD95 ligand and can hereby trigger apop-
tosis in target cells such as tumor cells (66). As described above, some tumors 
cells might be able to counteract this mechanism and remove attacking antitumor 
T cells by increasing their own CD95L expression. However, this counterattack the-
ory has not yet been conclusively demonstrated in vivo. Therefore, until additional 
preclinical, exploratory research has been performed to clarify how the pathway 
of apoptosis and the immune system interact, none of the related markers appear 
suitable for clinical prognostic application.
P53 tumor suppressor gene and the intrinsic pathway of apoptosis
The p53 tumor suppressor gene, likely the most well known protein within the 
intrinsic pathways of apoptosis, encodes for a transcription factor that regulates 
the expression of genes involved in the pathway of apoptosis, as well as angio-
genesis, cell cycle progression and genomic maintenance (67;67;68). Within the 
intrinsic pathway it exerts its function at the beginning of the intrinsic apoptotic 
pathway. It causes the cell cycle to arrest at the G1 phase in response to DNA 
damage; in case the DNA damage turns out to be irreparable, the p53 protein will 
activate the appropriate cellular signaling cascades to execute apoptosis. In 50% 
of human colorectal cancers p53 is absent or mutated, which has major implica-
tions for the execution of apoptosis in colorectal cancer (69). Mutations in p53 can 
be determined using IHC because mutated proteins accumulate in the nucleus due 
to their increased half-life (70). Different mutations have different effects and can 
implicate either loss or gain of function of the p53 protein. Two research groups 
carried out major systematic reviews on the relationship between p53 abnor-
malities and outcome in colorectal cancer patients (71;72). Munro et al reviewed 
a total of 168 IHC-based studies as well as mutation-based studies (71). Russo et 
al. pooled data from studies analyzing p53 DNA mutations only (72). Together, 
these studies reported on p53 expression and mutations in relation to survival in 
18,766 patients. Their key finding was that abnormal expression of p53, detected 
using IHC, was related to an increased risk of death. They concluded that mutations 
in exon 5 were associated with an adverse outcome, predominantly in proximal, 
right-sided tumors. Both studies suggested an impact of mutated p53 on clini-
cal outcome, though this relationship was only modest despite the overwhelming 
amount of data analyzed. The results of these studies were taken into account 
in the review of prognostic biomarkers in CRC by the ASCO Clinical Oncology’s 
Tumor Marker Expert Panel in 2006. The ASCO panel’s recommendation was that 
with current methods of detection, using either mutation analysis or IHC, p53 sta-
tus was a poor guide for prediction of prognosis in colorectal cancer patients (19). 
Since the published literature on IHC-based p53 studies until 2005 has already 

















P53 as a clinical prognostic marker
 Overview of the literature on p53 expression in which p53 was proven to be an independent 
prognostic indicator of outcome in CRC patients
Reference Population 
size







Noske(76) 116 Colorectal III OS - 0.048
Munro*(71) 12257 Colorectal I-IV OS 1.32 <0.0001
Torsello(73) 58 Colorectal
(<40 years age)
I-IV OS 2.48 0.046
Lim(75) 213 Colorectal I-III OS 1.843 0.028






Abbreviations: OS (Overall Survival), DFS (Disease Free Survival).
This table provides the references of all the studies that were identified in this review to report on 
upregulation of p53 expression as a statistically significant, independent predictor of outcome in 
CRC patients.
*This article describes a review of multiple studies on the prognostic value of upregulated p53 
expression determined with immunohistochemistry (IHC) in colorectal cancer patients.
have been  published since. We identified an additional 30 studies reporting on the 
expression of p53 determined with IHC that were published after Munro’s review 
in 2005. Four of these 30 papers confirmed the results of Munro et al. and claimed 
p53 to be a significant, prognostic marker in colorectal cancer (73-76). Table 4 
provides an overview of their study characteristics. From this table, it can be con-
cluded that although p53 has been widely studied, the studies reporting on statis-
tically significant prognostic relevance show differences in population size, tumor 
type selection, and disease stage selection. When we examined these publications 
in more detail, we also noticed that they varied in their IHC methods. Previously, a 
comparative study by Baas et al. has demonstrated the monoclonal antibody DO7 
to be superior over 5 other antibodies in the detection of the p53 gene protein in 
archival tissue of colorectal carcinomas (77), suggesting that this antibody should 
be used as a gold standard for IHC of p53. This particular antibody was used in 3 
out of the 4 studies listed (73;75;76). Furthermore, the sample sizes of all studies 
were rather small at an average of 103 patients; and a closer look at these popula-
tions showed that most also seemed highly selected on clinical parameters. For 
example, Jurach et al. only included stage II and III rectal cancer patients and the 
small cohort of Torsello et al. consisted only of patients under age 40 (73;74). The 
only relatively large study by Lim et al. that analyzed the results of 231 stage I, II 
and III CRC patients, showed a correlation between upregulation of p53 expression 
and poor OS (75). This correlation was more pronounced in their stage III patient 
selection, but disappeared when only the adjuvant-treated patients were analyzed. 
Their results appeared to be confirmed by the study of Noske et al. (76). However, 
in this study the prognostic value of p53 was only present in a multivariate analy-








downstream cell cycle inhibitor. The expression of p53 alone in univariate analysis 
was only borderline significant at a p-value of 0.045 in this cohort of 116 stage II/
III patients. As a single marker, p53 expression showed no independent statistical 
significance with respect to the prediction of outcome. Hence, neither of the four 
studies, although they claimed p53 to be an independent prognostic predictor of 
outcome in CRC, were able to add more significance to the conclusions drawn by 
Munro et al. (71). Therefore, their results are likely not sufficiently significant to alter 
the recommendations of the ASCO of 2006 with respect to the applicability of p53 
as a prognostic biomarker in colorectal cancer (19).
The Bcl-2 family members and the intrinsic apoptotic pathway
Downstream of p53, the mitochondria play a major role in the initiation and execu-
tion of the intrinsic pathway of apoptosis. The B-cell CLL/Lymphoma 2 (BCL-2) 
family members are mainly responsible for regulating the intrinsic pathway and 
can be categorized into two groups. The first group consists of anti-apoptotic pro-
teins that are structural and functional homologs of Bcl-2. The most important 
members of this group are Bcl-2 itself and its splice variant Bcl-2 XL (78;79). They 
are mainly bound to the mitochondrial outer membrane (MOM) by their trans-
membrane (TM) domain, where they stabilize the MOM to prevent cytochrome c 
release into the cytosol of the cell under normal homeostatic circumstances (80). 
Therefore, they can be considered anti-apoptotic proteins (81).
The second group of Bcl-2 family members has pro-apoptotic capacities. These 
members include Bcl-2 associated X protein (BAX) and proteins such as Bad, Bid, 
Bim, Bik, Noxa and Puma, which are, based on their structure, also known as BH3-
only proteins (78). These proteins are usually bound to the cytoskeleton or cytosol, 
but upon stimulation they interact with and inhibit their anti-apoptotic counter-
parts such as Bcl-2 (78). The relative ratio or balance between the expression of 
both groups of Bcl-2 family members will determine whether stimulation of the 
intrinsic pathway of apoptosis results in apoptosis as is graphically pointed out in 
Figure 1. If the pro-apoptotic factors predominate, cytochrome c will be released 
into the cytosol where it binds to the apoptosis-activating factor 1 (Apaf-1) to form 
an apoptosome. More downstream in the apoptotic pathway, this apoptosome will 
form a complex together with an initiator caspase, caspase-9. This caspase will 
subsequently activate the executioner caspases, caspase-3 and -7 (78;82). Deregu-
lation of apoptosis during tumor development can be caused by a disturbance in 
the homeostatic balance of the Bcl-2 family members.
Our search resulted in 55 studies describing the prognostic relevance of mark-
ers related to the Bcl-2 protein family. In the majority of these studies, 38 in total, 
the expression of Bcl-2 was studied using IHC. In only 9 out of these 38 stud-
ies a statistically proven prognostic relevance of this marker could be established 
(table 5) (73;83-90). The 9 studies generally used the same methods to determine 
Bcl-2 expression and all but one were performed on whole paraffin-embedded 
tissue sections. Furthermore, they were very consistent in their conclusions: in all 

















Bcl-2 as a clinical prognostic marker
Overview of the studies reporting on Bcl-2 as significant,  
prognostic marker within the pathway of apoptosis.
Reference Popula-
tion size















Schwander (84) 160 Colorectal I-III Up REC - 0.0242


















Krajewska(90) 106 Colorectal II Up OS 0.25 0.0009
Leahy(86) 102 Colorectal I-III Up OS 0.5 0.005
Ilyas(87) 66 Colorectal II Up REC 0.77 0.02
Torsello(73) 58 Colorectal
(<40 years age)
IV Down OS 3.02 0.015
Elkablawy(88) 52 Colorectal I-IV Up OS - 0.016
Abbreviations: DFS (Disease Free survival), OS (Overall Survival), REC (Recurrence), RFS 
(Recurrence Free Survival), Up (Upregulation of marker expression), Down (Downregulation of 
marker expression).
Table 5: A list of 9 studies, identified by this review, describing a statistically significant, prognostic 
effect of Bcl-2 in colorectal cancer patients. For each maker, the important study characteristics are 
listed.
disease free, overall, or recurrence free survival. This is contradictory to what is 
assumed given the anti-apoptotic function of Bcl-2: upregulated Bcl-2 expression 
would be more likely to be a marker of a more aggressive tumor phenotype. The 
most plausible explanation for this paradoxical finding is the fact that Bcl-2 not 
only has an anti-apoptotic function, it can also exert a distinct negative influence 
on cell cycle progression which can eventually slow down tumor growth. This may 
explain the survival benefit for several patients with upregulated Bcl-2 expres-
sion (83-85;89). Whether the anti-cell cycle progression or the anti-apoptotic role 
of Bcl-2 predominates during tumorigenesis may depend on disease stage. In early 
carcinogenesis, the anti-apoptotic function of Bcl-2 plays a large role, causing 
genetic alterations to accumulate. In later stages, Bcl-2 functions more as a cell 
cycle progression inhibitor, lowering the rate of tumor proliferation. This hypoth-
esis is supported by the inverse correlation between Bcl-2 and the percentage of 
cells in S-phase found by Buglioni et al. (83). The studies describing the prognostic 
relevance of Bcl-2 would therefore be more informative if disease stage would and 
the expression of the other family members were taken into account. This would 
provide us additional insight in the biologic function and effects on the apoptotic 








Inhibitors of apoptosis family proteins and the execution of apoptosis
The actual apoptotic cell death machinery, responsible for the execution of apopto-
sis and resulting in the morphologic features characteristic for apoptosis, consists 
of a very complex cascade of interacting proteins. The key components include 
the caspase proteins, as described above. At many levels regulation takes place 
to ensure appropriate functioning of the caspase machinery. The key regulators of 
the caspase cascade are the inhibitors of apoptosis proteins (IAPs) that exert their 
function through binding of activated caspases. So far, eight IAPs have been iden-
tified in mammals, the most well-known being livin, X-linked inhibitor of apoptosis 
(XIAP) and survivin (26;91;92). All IAP family proteins have one or several specific 
Baculoviral IAP repeats (BIRs). They require at least one BIR to exert their anti-
apoptotic function. The function of the IAPs is also strictly regulated, by their own 
set of inhibitors such as Smac/Diablo and Omi/HtrA2 (26). Under normal circum-
stances, when apoptotic stimuli are present, cells release Smac/DIABLO from their 
mitochondria into the cytosol where the complex exerts its pro-apoptotic effect 
by interacting with the IAPs in order to release bound caspases into the cyto-
sol (93). The most frequently studied IAP in our search results was surviving, likely 
because the role of survivin in apoptosis has been the subject of controversy over 
the last few of years. Of the 8 studies describing the prognostic effects of survivin, 
4 demonstrated a statistically prognostic effect of survivin (35;90;94-99) (table 6). 
Initially it was thought that survivin and the other IAPs selectively bind active cas-
pase-3/ -7 and -9, promoting their degradation and thereby inhibiting apopto-
sis (100). Survivin, however, lacks the structural motif to bind to caspases and 
likely only inhibits activated caspase-9 with the help of XIAP (101-103). In contrast 
to other IAPs, surviving is undetectable in normal adult tissues, but abundantly 
expressed in transformed cell types and a variety of human cancers, such as can-
cers originating in the colon, stomach, pancreas, lung, prostate, and breast (104). 
Although all four studies were able to show a significant relation between survivin 
expression and clinical outcome, the direction of this effect was not the same. 
When looking at these studies in detail it was noticed that they did not apply the 
same methods of analysis of the IHC results. This is of importance because survivin 
can be expressed in two cellular compartments: either in the cytoplasm or in the 
nucleus with different functions (98;105;106). In general, survivin is known to be 
involved in the regulation of cell viability as well as in the regulation of cell division. 
It is hypothesized that the nuclear subset is involved in controlling cell proliferation 
and the cytoplasmatic pool is more involved in regulating cell survival (107). Sarela 
et al. found a relationship between survivin expression and a shorter DFS when 
scoring mainly the cytoplasm for survivin positivity (94). Ponnelle et al. showed 
a positive influence of both cytoplasmatic and nuclear expression on survival in 
a very small patient population of only 46 patients. This only reached statistical 
significance for the cytoplasmic group (95). Fang et al. showed a negative effect 
of survivin expression on OS, disease recurrence, and the development of liver 
metastasis  (108). The same was true for the study by Sprenger et al. in which 
















expression (99). In this study, low pre-treatment expression was related to a sig-
nificantly better DFS. Unfortunately, neither of the groups elaborated on the spe-
cific location in the cell at which they scored survivin expression. The image of a 
tissue microarray (TMA) core that was immunohistochemically stained for survivin 
expression provided in the publication by Fang et al. suggests that the staining 
pattern was predominantly cytosplasmatic (108). In conclusion, it seems that local-
ization of survivin expression is in fact of great importance as it is probably related 
to the protein function and hence should be taken into account in future studies. 
This may be applicable to all of the other IAP family members as none have been 
studied widely with standardized scoring methods in large series.
DISCUSSION
This review gives an overview of the literature published on IHC-based prognos-
tic biomarkers related to the pathway of apoptosis in colorectal cancer between 
January 1998 and June 2011. Particularly, we discussed those markers that were 
proven to be of independent, statistically significant, prognostic value by placing 
them in the context of their function within the apoptotic pathway. Based on this 
biological background information, we then analyzed the conclusions drawn by 
the authors of the studies included to see whether their conclusions could provide 
valuable grounds to proceed investigating these markers for prognostic clinical 
application. The markers we discussed are all major regulatory players in this path-
way such as p53, the Fas receptor and the DR4 with their respective ligands, the 
Bcl-2 protein family, and survivin. In general, we concluded that none qualified 
as a single prognostic biomarker for colorectal cancer patients, despite the fact 
that it has been well-established that the outcome of the pathway of apoptosis is 
of prognostic value (29-37;99). Based on the information derived from all of the 
Table 6
Survivin as a clinical prognostic marker
Overview of the studies reporting on Survivin as significant,  
prognostic marker within the pathway of apoptosis
Reference Popula-
tion size







Sarela(94) 49 Colorectal II Up OS 9.1 0.03
Ponnelle(95) 46 Colorectal I-IV Up OS 0.35 0.045
Fang(108) 630 Colon I-IV Up OS 1.63 0.018
Sprenger(99) 116 Rectal II-III Down DFS - 0.038
Abbreviations: OS (Overall Survival), Up (Upregulation of marker expression), Down 
(Downregulation of marker expression).
This table provides the characteristics of all of the studies, identified by this review, that describe 
a significant prognostic effect of survivin expression determined by immunohistochemistry in 








studies discussed, we postulate several explanations for this lack of sufficient clini-
cal prognostic significance for individual markers of the apoptotic pathway. First, 
study characteristics of investigations of one specific biomarker varied widely. This 
sometimes provided a marker with prognostic significance, but only in a highly 
selected group of patients. For example, in the case of p53, some of the stud-
ies were able to reproduce the results of the review of Munro et al. (71), but only 
when a selected patient cohort was studied which consisted of patients with better 
survival rates after surgery, as was the case in the study by Lim et al (75). In this 
study, the prognostic value of p53 was only present in the stage II/III cohort when 
both adjuvant and non-adjuvant treated patients were included, which were prob-
ably the patients with such good outcome perspectives after surgery that adjuvant 
treatment was deemed unnecessary. The prognostic value disappeared when only 
the adjuvant-treated cases were analyzed. This makes the applicability of p53 as a 
general prognostic marker at time of diagnosis and treatment allocation question-
able for the entire colorectal cancer patient population. Second, well-standardized 
IHC protocols were applied for none of these markers. Possibly even more impor-
tantly, there seemed to be no standardized methods for quantifying expression 
level or a specific location in the cell at which the expression of a marker should 
be evaluated. This may greatly influence the interpretation of the results of these 
studies, as for instance the specific location of expression in a cell might be directly 
related to its biological function and thereby to its effect on the outcome of the 
apoptotic pathway and patient prognosis. Caution should be taken in the method 
of quantification, particularly for FasR and survivin expression. In the case of the 
FasR expression, a high level of expression found in the cytoplasm but not on 
the cells membrane can indicate the presence of decoy receptors (56). This might 
be an indication that the so-called Fas-Counterattack hypothesis is indeed true, 
making it essential to evaluate the subcellular location of expression (55). In addi-
tion, in the case of survivin, staining location seemed to be of great importance as 
both nuclear and cytoplasmic expression showed a different relation with outcome 
in the studies reviewed (94;95;99;108). We concluded that location of expres-
sion might implicate different biological functions of the same protein. Third, we 
showed that the pathway of apoptosis is strictly regulated at several levels by both 
stimulatory and inhibitory proteins that highly interact with each other. Using only 
one marker to describe the outcome of these interactions, therefore, seems inap-
propriate. To complicate matters even more, the function of a protein might differ 
depending on progression of the process of tumorigenesis as was shown for Bcl-2 
expression (83). Intervention of key proteins of apoptosis in other pathways makes 
cellular outcome unpredictable when using expression of single proteins as prog-
nostic biomarkers.
Overall, we can conclude that studying outcome of the pathway of apoptosis, or 
deciding on a patient’s prognosis and treatment, using single markers seems inap-
propriate given the complexity of this pathway. We already highlighted the delicate 
balance that exists between expression and effects on apoptosis of the members 
















effect of expression of single proteins without the knowledge of the expression 
status of any of the others involved seems inappropriate. Therefore, we would like 
to propose suggestions to improve the clinical applicability of these markers. Most 
importantly, we suggest that the apoptotic profile of a tumor should be determined 
rather than expression of single markers. This should include several markers that 
together represent the outcome of all regulatory thresholds within the pathway. An 
apoptotic profile would better represent the true function of the markers involved 
and provide insight on the outcome of the apoptotic pathway in individual tumors; 
thus, an apoptotic profile fulfills the need for prognostic biomarkers in colorectal 
cancer (22).
In the literature studied for this review, several authors already made an attempt 
to establish such a multi-marker apoptotic phenotype (59;60;83;99). However, in 
these studies, the selection of biomarkers was based on the markers that showed 
some prognostic relevance in their series as a single biomarker without any respect 
to the biology of the pathway. In addition, in most cases the markers used in these 
‘multi-marker phenotypes’ all belonged to just one sub-regulatory unit of the path-
way. For example, Van Geelen et al. and McLornan et al. both studied multiple 
markers with respect to the DRs, but did not include any of the more downstream 
regulator proteins (59;60). Furthermore, in many of the studies the statistical 
methods used to analyze the results of these multi-marker phenotypes lack power. 
A solution to this problem might be to approach the data as one would do in the 
case of gene expression array data by performing hierarchical clustering in order 
to develop a profile (109). Until then, the biomarkers that will eventually make up 
this apoptotic profile remain to be determined. In the meantime, we suggest that 
further studies focus on analyzing the clinical relevance of not only the outcome 
of (de) -regulation of the apoptotic pathway in colorectal cancer but also on the 
outcome of the (de) -regulation of the pathway of proliferation. Under normal cir-
cumstances a key factor in tissue homeostasis is the balance that exists between 
the level of cell death and the level of cell proliferation (110;111). Deregulation of 
either of these pathways can therefore cause disturbance of this balance, which 
may result in and maintain tumorigenesis. This hypothesis has been studied previ-
ously with success in a cohort of 100 colorectal cancer patients in which an AI:PI 
ratio was determined (112). This Apoptotic Index: Proliferation Index, based on M30 
IHC for the level of apoptosis and Ki67 IHC for the proliferation index, was signifi-
cantly to patient outcome. It remains to be seen if studies in larger patient popula-
tions will confirm these results.
In conclusion, to determine the prognostic relevance of biomarkers of the path-
way of apoptosis in colorectal cancer using immunohistochemistry, multiple 
markers that together reflect the apoptotic status in individual tumors should be 
studied together. The introduction of such a multi-marker apoptotic phenotype 
or - profile into clinical practice demands standardization of technical assays and 
quantification methods. For future studies, therefore, we recommend to consider 
the full pathway when starting the exploratory phase towards the discovery of 








 Moreover, we recommend to apply hierarchical clustering-based statistical analysis 
and use knowledge of the biology of the pathway to identify promising markers. 
And furthermore, we recommend to even consider to take in to account markers 
representing the pathway of proliferation when studying the prognostic effects 
of the apoptotic pathway in colorectal cancer. These measures will lead to multi-
marker profiles that can then be validated in large retrospective studies and can 
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Background: Disturbance of the balance between proliferation and apoptosis is an 
important hallmark of tumor development. The goal of this study was to develop a 
descriptive parameter that represents this imbalance and to relate this parameter 
to clinical outcome in all four stages of colon cancer.
Material and methods: The study population consisted of 285 stage I-IV colon 
cancer patients of which a tumor tissue micro array (TMA) was available. Sections 
of this TMA were immunohistochemically stained and quantified for presence of 
Ki67 and cleaved caspase-3 tumor expression. These results were used to develop 
the combined apoptosis proliferation (CAP) parameter and correlated to patient 
outcome.
Results: The CAP parameter was significantly related to clinical outcome; patients 
with CAP ++ (high level of both apoptosis and proliferation) showed the best out-
come perspectives (Overall Survival (OS), p=0.004 and Disease Free Survival 
(DFS), p=0.009). The effect of the CAP parameter was related to tumor microsat-
ellite status, and indirectly to tumor location, where left-sided tumors with CAP + - 
(high level of proliferation, low level of apoptosis) showed a worse prognosis (DFS 
p-value 0.02) and right-sided tumors with CAP + - had a better prognosis (DFS 
p-value 0.032). With stratified analyses, the CAP parameter remained significant 
in stage II tumors only.
Conclusions: The CAP parameter, representing outcome of the balance between 
the level of apoptosis and proliferation, can be used as a prognostic marker in 
colon cancer patients for both DFS and OS, particularly in left sided, microsatellite 









A key factor in tissue homeostasis, especially of the intestinal mucosa, is the balance 
that exists between the level of cell death and the level of cell proliferation (1-3). 
Two important hallmarks of the process of tumorigenesis are responsible for dis-
turbance of this balance and therefore contribute to the initiation and maintenance 
of tumor growth and development (4;5). These hallmarks are: deregulation of the 
proliferative signaling pathway and deregulation of the pathway of apoptosis (5). 
Both result in either non- or malfunction of important enzymes or unrestricted 
release of growth-promoting signals that under normal circumstances are neces-
sary to maintain tissue homeostasis (6-13). The level of cell proliferation and apop-
tosis can be studied with immunohistochemistry (IHC) taking advantage of all of 
the benefits of this technique, such as speed, routine availability, low costs, and 
high level of automation. The level of apoptosis can be evaluated through staining 
specifically the activated, cleaved form of the pro-apoptotic enzyme caspase-3 in 
the tumor cell cytoplasm. Caspase-3 is the final enzyme to become activated in the 
caspase cascade, which is the common pathway in the execution of apoptosis after 
the intrinsic and extrinsic apoptosis induction pathways converge. Therefore, the 
expression level of activated or cleaved caspase-3 should give a reliable measure 
of the level of apoptosis (14). The proliferation activity of a tumor can be esti-
mated by determining the expression levels of specific cell cycle-related proteins 
also by using IHC. A widely used marker is the Ki67 antigen, which is expressed in 
nuclei during all cell cycle phases except during the G0 phase (15). Previous studies 
showed contradicting results with respect to the relation of the level of apoptosis 
or proliferation in tumor resection specimens and patient outcome in colon can-
cer (16-23). We hypothesize that, because tissue homeostasis depends on the bal-
ance between cell death and proliferation levels, the level of disbalance between 
these processes indicate tumor aggressiveness. Therefore, combined and not 
separate analysis of these parameters might be of prognostic relevance in colon 
cancer patients.
In this study we determined both the level of tumor cell apoptosis and proliferation 
in resection specimens of a large cohort of colon cancer patients. We combined 


















The patient cohort consisted of 470 colorectal cancer patients treated with surgery 
for their primary tumor in the LUMC between 1991 and 2001. Clinico-pathological 
and follow-up data were collected retrospectively from hospital records and the 
hospital’s oncology database. This research was performed according to the code 
of conduct for responsible use. Patients with a history of cancer other than basal 
cell carcinoma or cervical carcinoma in situ, patients that received radio- and/or 
chemotherapy treatment prior to resection, patients with multiple synchronous 
colon tumors, and patients with rectal cancers were excluded from the analysis 
(n=185). The entire study cohort consisted of 285 patients. Right-sided tumors 
were defined as those originating proximal to the splenic flexure and left-sided as 
those originating distal to the splenic flexure.
Primary Antibodies
The following antibodies were used in the immunohistochemical stainings: Mouse 
monoclonal antibody anti-Ki67 (DAKO Glostrup Denmark Art.M7240 clone MIB-1) 
to determine the level of tumor cell proliferation and rabbit polyclonal antibody 
anti-ASP-175 (Cell signaling Danvers, USA, Art.9661) was used for cleaved cas-
pase-3 identification to determine the level of apoptosis.
Immunohistochemistry
Qualified pathologist evaluated the tumor material from all patients included for 
histo-pathological characteristics according to current standards during the rou-
tine hospital diagnostic process. Formalin-fixed paraffin-embedded tumor blocks 
of the primary tumor were collected from the pathology department. Sections 
were cut for haematoxylin and eosin staining, and representative tumor regions 
based on histological assessment were used for preparation of tumor tissue 
microarray (TMA) blocks. From each donor block, three 0.6 mm tissue cores were 
punched from tumor areas and transferred into a recipient paraffin block using a 
custom-made precision instrument.
Immunohistochemistry (IHC) staining was performed on 4 µm sections that were 
cut from each receiver block and mounted on glass. For each primary antibody, 
all slides were stained simultaneously to avoid inter-assay variation. Tissue sec-
tions were deparaffinized and rehydrated. For antigen retrieval, 0.01 M EDTA buffer 
(pH 8) was used for 10 minutes at maximum power in a microwave oven for anti-
Ki67. Citrate buffer 0.1M (pH 6) was used for anti-ASP-175. Endogenous peroxidase 
was blocked for 20 minutes in 0.3% hydrogen peroxide in methanol. Sections were 
incubated overnight with either anti-Ki67 or anti-ASP-175 at predetermined opti-
mal dilutions. After 30 minutes of incubation with Envision anti-mouse (K4001; 
DAKO Cytomation, Glostrup, Denmark) or Envision anti-rabbit (K4003); DAKO 
Cytomation, Glostrup, Denmark), sections were visualized using diaminobenzidine 








finally mounted in malinol. Sections with phosphate buffer saline (PBS) instead 
of primary antibody, which underwent the complete staining protocol served as 
negative controls.
Evaluation of immunohistochemistry
Microscopic analyses of Ki67 and cleaved caspase-3 expression was performed by 
two independent observers (M.S.R: 100% and T.C.A.: 30%) in a blinded manner. 
For Ki67, the percentage of tumor cells that showed nuclear staining was assessed. 
For determination of tumor cell apoptosis, the absolute number of caspase-3 
expressing tumor cells in each tumor punch that showed cytoplasmatic and peri-
nuclear staining was counted. The Cohen’s Kappa for inter observer variability was 
0.73 and 0.6 for Ki67 and cleaved caspase-3 respectively. Therefore, there was 
substantial agreement between the two observers and all scores were averaged. 
For analysis a cut-off at the median was chosen, dividing the samples in low (<27% 
positive tumor cells) or high nuclear Ki67 expression (t27%). The use of this per-
centage of positive cells as a cut-off point is supported by Fluge et al. (19). Cleaved 
caspase-3 was quantified into two categories of IHC cytoplasmatic tumor staining 
levels. Negative staining; implied no positive tumor cells in either of the three cores, 
in all other cases the staining was denoted as positive. Representative images of 
the Ki67 and caspase-3 staining are shown in Figure 1.
Determination of microsatellite stability status
DNA was extracted from 2mm tumor-cores. Paraffin was dissolved in xylene, tissue 
was rehydrated in ethanol (100%/70%) and dried for 10 minutes at 37°C. Nucle-
ospin 96 Tissue kit (Machery-Nagel, Düren, Germany) was used for DNA extraction 
according to the manufacturer’s protocol.
Microsatellite stability status was tested using the MSI Analysis System Version 1.2 
(Promega, Mannheim, Germany) and interpreted by an experienced pathologist, as 
described previously (24).
Statistical Analysis
Statistical analyses were performed using the statistical package SPSS (version 
17.0 for Windows; SPSS, inc). The Student’s T-test, the Mann-Withney U test and 
the Chi-squared test were used to evaluate associations between Ki67 or cleaved 
caspase-3 and various clinico-pathological parameters. The Overall Survival (OS) 
was defined as time between primary tumor resection and time of death and Dis-
ease Free Survival (DFS) as time between primary tumor resection and time of 
death or relapse of disease, whichever came first. The Kaplan-Meier method was 
used for calculation of survival probabilities and the Log-rank test for comparison 
of survival curves. Cox regression was used for univariate and multivariable analy-
sis for OS and DFS. Significant variables (in univariate analysis) were included in 


















Representative images of Ki67 and cleaved caspase-3 immunohistochemical staining in colon cancer 
tissues
(A) Ki67, tumor with low expression (B) Ki67, tumor with high expression (C) Tumor showing 
absence of cleaved Caspase-3 tumorcell expression and (D) Tumor showing presence of cleaved 









Patient characteristics, and cleaved caspase-3 and Ki67 expression levels
The study cohort consisted of 285 patients. In 41 cases for Ki67, and 38 for cleaved 
caspase-3 the results of the IHC could not be analyzed due to loss of the tumor 
material during IHC or due to staining artifacts. Representative images of the bio-
markers and their staining categories are shown in figure 1. The mean percent-
age of tumor cells expressing Ki67 in the tumor tissue cores was 29.2% with a 
median of 27.5%. For analysis we used the median as cutoff based on skewness 
of the data distribution. This resulted in 121 patients (49.6%) with tumors showing 
low expression level (below median) of Ki67 and (‘low’ tumor cell proliferation 
level) and 123 patients (50.4%) with high expression level (above median) of Ki67 
(‘high’ tumor cell proliferation level). In 85 (34.4%) patients the tumor tissue cores 
showed no staining of cleaved caspase-3 and therefore no apoptotic activity of 
tumor cells. The remaining 65.6% of the samples showed positive staining and thus 
ongoing tumor cell apoptosis.
The clinico-pathological characteristics of the patient cohort and their relation to 
expression levels of the biomarkers are listed in table I. Interestingly, tumor loca-
tion was significantly related to both cleaved caspase-3 expression level and Ki67 
expression level. Microsatellite instability also showed statistical significance, but 
was only significantly related to cleaved caspase-3 expression and not to Ki67 
expression. In the tumor samples without cleaved caspase-3 expression, 2.4% of 
the cases showed microsatellite instability vs. 16.7% in the tumors with expression 
of cleaved caspase-3 (p-value 0.004). Additional analysis showed in our patient 
cohort a strong, significant correlation between tumor location and microsatellite 
stability status with significantly more microsatellite instable tumors (MSI) located 
on the right side of the colon and the majority of the microsatellite stable (MSS) 
tumors located on the left side of the colon (70%), whereas this was only 8% in 
microsatellite instable tumors (MSI) (p=<0.001).
Relation of single marker expression with patient outcome
The level of tumor cell proliferation based on Ki67 expression level was signifi-
cantly related to OS and DFS: high tumor expression level correlated significantly 
to a better patient OS and DFS (OS, Logrank p-value 0.002; DFS, Logrank p-value 
0.003) (Figure 2). Tumor cell apoptotic level, as represented by cleaved caspase-3 





























































































































































Abbreviations: MS Status; Microsatellite Status, cCaspase3; cleaved caspase 3.
This table describes the baseline characteristics of the entire cohort of 285 patients in the 
first column. The Ki67 immunohistochemistry results could be analyzed in 244 cases and Ki67 
expression (above the median of 27.5% expression level) was found to be present in 123 and absent 
in 121 patients. The other columns describe the relation of either Ki67 absence or presence in the 
tumor resection specimens to clinico-pathological parameters. The cleaved caspase 3 results were 
available for analysis in 247 patients. In this population 85 tumor samples showed no presence 
of cleaved caspase 3, expression was present in 162 tumor samples of patients. The fourth and 
fifth column describe the relation of either cleaved caspase 3 absence or presence to clinico-
pathological parameters. Only significant (p<0.05) differences between marker expression as 


















































Abbreviations: cCaspase3; cleaved caspase.
Survival curves stratified for Ki67 and cleaved caspase-3 tumor expression in colon cancer
(A) Kaplan Meier curves for OS and DFS in the study population of 285 colon cancer patients 
stratified for Ki67 tumor expression (B) Kaplan Meier curve OS and DFS in the study population of 

















Description of the CAP (Combined Apoptosis and Proliferation) parameter
CAP ++ Ki67 expression above the median and presence of cleaved caspase-3 IHC
CAP +- Ki67 expression above the median and no presence of cleaved caspase-3 IHC
CAP -+ Ki67 expression below the median and presence of cleaved caspase-3 IHC
CAP -- Ki67 expression below the median and no presence of cleaved caspase-3 IHC
Abbreviations: IHC; immunohistochemistry.
This table provides the definitions of the CAP parameter. This parameter resulted from 
data combination on the tumor cell apoptotic level based on the cleaved caspase-3 
immunohistochemistry results with the data on the tumor cell proliferation level based on the Ki67 
expression levels as determined with IHC.
Combined analysis of tumor cell apoptosis and proliferation in relation to 
patient outcome
To analyze the effect of the balance between apoptosis and proliferation levels 
in the tumor resection specimens on patient outcome, the results of the Ki67 
expression analysis were combined with those of the cleaved caspase-3 expres-
sion analysis in a combined apoptosis-proliferation (CAP) parameter (table II). The 
CAP parameter was not significantly related to TNM stage (p-value 0.211), but was 
significantly related to the tumor microsatellite status (p-value 0.008). Tumors of 
both the CAP -+ (Ki67 below median, presence of cleaved caspase-3) and ++ (Ki67 
above median, presence of cleaved caspase-3) patients showed significantly more 
often microsatellite stability compared to the CAP +- (Ki67 above median, absence 
of cleaved caspase-3) and CAP -- (Ki67 below median, absence of cleaved cas-
pase-3) patients (p-value 0.03). Patients with a CAP ++ tumor showed the best 
survival outcomes with respect to OS and DFS (figure 3). In the entire cohort 
patients with a CAP -+ tumor had the worst outcome perspectives. Because tumor 
microsatellite status was significantly related to the presence of cleaved caspase-3, 
the next step would be to perform the survival analysis with the CAP parameters 
stratified for tumor microsatellite status. Unfortunately the number of MSI tumors 
that was successfully determined was too small to perform this analysis specifi-
cally for MSI within this population. We therefore used tumor location, which we 
previously showed to be highly correlated to tumor microsatellite status, as a sur-
rogate marker in this analysis (figure 4). These Kaplan Meier curves showed in 
left-sided tumors comparable curves to those presented in figure 3 of the total 
cohort, but the course of the curves changed in right-sided tumors.The CAP ++ 
and the CAP -- population within the cohort of left-sided tumors had the best out-
come perspectives as opposed to the CAP -+ and +- population that had similar 
but worse outcome perspectives. The CAP + - actually had, within this left-sided 
cohort, the worst outcome perspectives (DFS p-value 0.02). In right-sided tumors, 
the CAP ++ and CAP +- population had the best outcome perspectives as opposed 
to the CAP – and CAP -+ population that had worse outcome perspectives. We 
conclude based on these results that combined analysis of apoptosis and prolifera-
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Survival curves stratified for combined tumor apoptosis-proliferation (CAP) expression in colon 
cancer.
Kaplan Meier curves for OS and DFS in the study population of 285 colon cancer patients stratified 
for combined tumor apoptosis-proliferation (CAP) expression. This parameter is described in detail 
in Table II and in the results section.
cancer patients. The impact of this parameter on patient outcome, however, varies 
with tumor location and therefore highly likely with tumor microsatellite status.
Univariate and multivariate analysis
Both for OS and DFS a multivariable analysis was performed including the vari-
ables; sex, age at time of operation, TNM stage, tumor grade, administration of 
adjuvant therapy, microsatellite status, tumor location and the CAP parameter. Age 
and TNM stage were found to be independent predictors of OS and DFS (Table III & 
IV). To test whether the effect of the CAP parameter on outcome differed between 
patients with left- and right-sided tumors, an interaction term was implemented 
that was borderline significant (p-value 0.06). Although the CAP parameter was 
not significantly related to TNM stage, stratified analyses for TNM stage showed 
that the effect of CAP on outcome only remained significant in the stage II patient 
population. Therefore analysis was again performed with an interaction term, and 
again this term was borderline significant (p-value 0.05).
Based on these results we conclude that although the CAP parameter is not a sta-
tistically independent prognostic indicator of survival in the total patient cohort, 
the CAP parameter, which is influenced by location, microsatellite stability status 
and TNM stage, does behold prognostic significance in certain subsets of patients 
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p-value: 0.006 p-value: 0.020
p-value: 0.027 p-value: 0.032
Figure 4
Survival curves stratified for combined tumor apoptosis-proliferation (CAP) expression in colon 
cancer and stratified for location of the tumor.
(A) Kaplan Meier curves for OS and DFS stratified for the CAP parameter in patients with left sided 
colon tumors (originating distal to the splenic flexure). (B) Kaplan Meier curves for OS and DFS in 
patients with right-sided tumors (originating proximal to the splenic flexure). The CAP parameter is 









Univariate and multivariable analyses of Overall Survival (OS)
Univariate analysis Multivariable analysis














































This table provides the data for the univariate en multivariable analysis of OS. The univariate analysis 
included sex, age, tumor grade, adjuvant therapy administration, microsatellite status, TNM stage, 
the CAP parameter, microsatellite status and tumor location. The CAP parameter, age and TNM 
stage were all significant predictors of OS in univariate analysis. In multivariable analysis only TNM 
stage and the patient age at time of surgery retained significance. The CAP parameter is therefore 
not an independent predictor of overall survival in stage I-IV in this cohort of colon cancer patients. 
Table IV
Univariate and multivariable analyses of Disease Free Survival (DFS)
Univariate analysis Multivariate analysis












































This table provides the data for the univariate en multivariable analysis of DFS The univariate 
analysis included sex, age, tumor grade, adjuvant therapy administration, microsatellite status, 
TNM stage, the CAP parameter, microsatellite status and tumor location. The CAP parameter, age 
and TNM stage were all significant predictors of DFS in univariate analysis. In multivariable analysis 
only TNM stage and the patient age at time of surgery retained significance. The CAP parameter 


















Our study shows that a combined parameter, CAP, describing the level of tumor 
cell proliferation and apoptosis is significantly related to patient outcome in a stage 
I-IV colon cancer patient cohort with respect to DFS and OS. Although counter 
intuitively, patients with CAP ++ tumor, showing high levels of both proliferation 
and apoptosis, showed the best clinical outcome perspectives. The effect of the 
CAP parameter, however, varied with TNM stage and tumor location and was sig-
nificantly related to tumor location and tumor microsatellite status. These results 
confirm our hypothesis that clinical outcome is dependent on both tumor cell pro-
liferation and apoptosis.
The processes of both tumor cell proliferation and apoptosis both have been 
extensively studied with varying results in many types of cancer. In general, high 
tumor cell proliferation levels were associated with aggressive tumor development 
and progression (21;25). However, other studies reported on an inverse associa-
tion between tumor cell proliferation level and clinical outcome (8;18;23;26). These 
latter results are in line with what we have found: a better outcome perspective 
in colon cancer patients with high levels of tumor cell proliferation. In this study 
we were not able to establish a relationship between the level of apoptosis as a 
single marker and patient outcome in colon cancer patients. Although there are 
studies that describe a link between tumor cell apoptosis and clinical outcome, for 
example Jonges et al. who described cleaved caspase-3 expression as a prognostic 
marker in colon cancer patients (20), the majority of the studies have presented us 
with more ambiguous results (1;16;17;27;28).
The contradicting results derived from studies reporting on either proliferation or 
apoptosis in colon cancer strengthened our hypothesis that a balance between 
both these processes determines patient’s clinical outcome. Michael-Robinson et 
al. previously reported on a cohort of 100 colorectal cancer patients in which they 
determined an Apoptotic Index: Proliferation Index (AI:PI) ratio (26). This AI:PI ratio 
was based on M30 IHC for the apoptosis level and Ki67 IHC for the proliferation 
level. They were able to determine a relationship between the proliferation index 
and outcome comparable to our results: they also related their AI:PI index signifi-
cantly to patient outcome. In previous studies the use of the apoptotic index has 
been criticized as researches found the use of the parameter to be accompanied 
with high amounts of interobserver variability (29). Therefore we didn’t use a con-
tinuous variable based on counted percentages, but developed a more descriptive 
parameter, the CAP, to determine the combined effect of apoptosis and prolifera-
tion within our patients tumor samples. The differences in outcome parameters 
and also patient selection make it difficult to perform a one-to-one correlation of 
the results of Michael-Robinson et al. and our results. Their conclusions though do 
affirm our hypothesis. Interestingly, the survival difference they found between 
a high and low AI:PI index was similar in both MSS and MSI patients. Our results 
showed that the effect of the CAP parameter differed between tumors emerging 








the patients with CAP -- and ++ tumors performed better with respect to outcome. 
In the right-sided cohort the CAP +- performed significantly better than the CAP -- 
cohort. This is comparable to what we have previously found and described by 
Jonges et al. (20). The effect of apoptosis on patient outcome is related to tumor 
location. Based on our results we hypothesize that it is either tumor microsatellite 
status as suggested by both Jonges and Michael-Robison, or tumor location which 
might influence the balance between tumor cell proliferation and apoptosis and 
therefore patient outcome (20;26). The concept of the effect of tumor location is 
in accordance with what has recently been described by The Cancer Genome Atlas 
Network in their publication in Nature in 2012, who tested the hypothesis that dif-
ferences between tumors originating from the left or the right side of the colon 
is not based on their microsatellite status but it might be caused by the different 
embryonic origins of the right- and left-sided colon (30).
It is not unlikely that the tumor microsatellite status influences the balance between 
tumor cell proliferation and apoptosis. Microsatellite instable tumors are known to 
have high levels of proliferation and tend to accumulate gene mutations leading 
to increased production of abnormal peptides (31;32). This phenotype has been 
hypothesized to cause an immune reaction resulting in higher levels of apoptosis, 
eventually resulting in better patient outcome (33).
In conclusion, the CAP variable described in this study reflects the balance between 
the apoptosis and proliferation in colon cancer tissue and showed to be related to 
patient outcome. These results confirm our hypothesis that apoptosis and prolif-
eration together determine patient outcome in colon cancer and this relation is 
influenced by tumor location and/ or by tumor microsatellite instability. This was 
shown by the different effects of the CAP parameter on patient outcome in the left 
and right-sided colon cancer patients cohorts and the statically significant relation 
of the level of apoptosis with tumor microsatellite status, also described in previous 
studies (20,26). Important steps have been taken towards the implementation of 
a CAP like parameter into clinical practice, such as the development of the CDK1 
SA (Cyclin Dependent Kinase 1 Specific Activity Assay), a biochemical assay that 
can replace the Ki67 IHC, and the improvement of the existing biochemical assays 
to measure cleaved caspase-3 activity for easy clinical use (24). Further studies 
should focus on the design of clinical tests combining both proliferation-based 
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Background: There are no established biomarkers to identify tumor recurrence 
in stage II colon cancer. As shown previously, the enzymatic activity of the cyclin 
dependent kinases 1 and 2 (CDK1 and CDK2) predicts outcome in breast cancer. 
Therefore, we investigated whether CDK activity identifies tumor recurrence in 
colon cancer.
Methods: In all, 254 patients with completely resected (R0) UICC stage II colon 
cancer were analyzed retrospectively from two independent cohorts from Munich 
(Germany), and Leiden (Netherlands). None of the patients received adjuvant treat-
ment. Development of distant metastasis was observed in 27 patients (median 
follow-up: 86 months). Protein expression and activity of CDKs were measured on 
fresh-frozen tumor samples.
Results: Specific activity of CDK1 (CDK1SA), but not CDK2, significantly predicted 
distant metastasis (concordance index = 0.69, 95%CI: 0.55–0.79, p=0.036). Cut-
off derivation by maximum log-rank statistics yielded a threshold of CDK1SA at 
11 (specific activity units, p=0.029). Accordingly, 59% of patients were classified 
as high-risk (CDK1SA t11). Cox proportional hazard analysis revealed CDK1SA as 
independent prognostic variable (hazard ratio = 6.2, 95% CI: 1.44–26.9, p=0.012). 
Moreover, CKD1SA was significantly elevated in microsatellite stable tumors.
Conclusion: Specific activity of CDK1 is a promising biomarker for metastasis risk 









Each year >1 million individuals worldwide develop colon cancer with a disease 
specific mortality rate of almost 33% (1-3). Approximately 40% of resected colon 
cancers are from stage II (T3-4N0M0). The 5 year survival rates vary between 88% 
in T3N0 patients, and 75% in T4N0 patients. Chemotherapy is widely accepted as 
adjuvant treatment for stage III patients, whose 5 year survival (stage III A and B) is 
higher than 75% (4). Use of chemotherapy for stage II, T4 patients remains contro-
versial despite their worse survival rates. This indicates that the allocation of treat-
ment based solitary on conventional staging methods is not optimal (5-9). Over 
the last decade there have been important developments towards the discovery 
of new prognostic and predictive markers that might improve staging methods. 
The American Society of Clinical Oncology’s Tumor Markers Expert Panel (ASCO 
TEMP-2006) and its European counterpart, the European Group on Tumor Markers 
(EGTM-2007) have recently reviewed the literature on these biomarkers. However, 
all biomarkers reviewed lacked the significant, discriminative value that is required 
to become implemented into clinical practice (10-12). There is a stringent need for 
new assays that are able to identify stage II colon cancer patients who might benefit 
from adjuvant therapy. Genomic instability and altered cell proliferation are major 
contributors to tumor growth and aggressiveness. Measuring these hallmarks of 
colon cancer in a quantitative fashion could be a suitable option for risk stratifica-
tion. The proliferation rate of tumor cells has so far been studied with methods such 
as 3H-thymidine/BrdU incorporation, mitotic index, or Ki-67/PCNA immunohisto-
chemistry, but none of these tests have reached clinical application (13;14). There-
fore, analysis of the highly conserved drivers of the cell cycle, the cyclin-dependent 
kinases (CDKs) 1 and 2, may be a more promising approach (15). CDK expression is 
constitutive in tumors but their enzymatic activity changes markedly according to 
the specific cell cycle phase. On the molecular level, the activity of CDK is regulated 
by subunits known as cyclins, and by phosphorylation of conserved tyrosine and 
threonine residues. Over-expression of cyclins, as well as inactivation of CDK inhib-
itors, are well documented as prognostic markers for esophageal, gastric, colo-
rectal, breast and lung cancer (16-22)However, expression analysis of cyclins and 
other factors may not necessarily indicate the enzymatic activity of CDKs, which 
is crucial for the cell cycle status of the cancer cells. We have recently reported an 
assay that measures the specific activity of CDK 1 and CDK2 (23-25), based on a 
well standardized biochemical assay that requires only small amounts of fresh fro-
zen tissue and is (23). The hallmark of this approach is the extraction of functional 
CDK enzyme from tumor tissue, followed by determination of its kinase activity. 
We hypothesize that intratumoral kinase activity of CDKs predicts the prognosis 
of tumor patients with great fidelity, because it directly represents a quantifiable 
readout for two hallmarks of tumors: increased proliferation and genomic instabil-
ity. Two large, independent cohorts of breast cancer patients demonstrated that 
this assay had prognostic value (24;25). A CDK-based risk score validated in these 














recurrence. The aim of this study was to determine the ability of CDK-based analy-
sis to predict recurrence in patients with locally restricted colon cancer. The study 
was carried out retrospectively on two independent patient cohorts derived from 
large surgical oncology centers in the Netherlands and Germany. Our results dem-
onstrate that the specific activity of CDK1 identifies stage II colon cancer patients 
with a high risk of distant disease recurrence. This patient group may benefit from 




The study was approved by the local ethics committees at LUMC and TUM. 
Informed, written consent had been obtained prior to the study. Fresh frozen sam-
ples of 271 of stage II colon carcinomas were analyzed, collected at Leiden Uni-
versity Medical Center (LUMC, 1985 - 2005), and at Klinikum rechts der Isar (TUM, 
1987 to 2006). All patients had curative (R0) tumor resection, and none of them 
received adjuvant or neoadjuvant therapy. Tumor tissue was dissected immedi-
ately after resection by a pathologist, snap frozen in liquid nitrogen and stored 
at -80°C. Development of distant metastasis was observed in 27 patients (11%) 
after a follow-up of 7.2 years (median). Five samples (1.8%) were excluded due to 
tumor cell content of less than 10 percent. All remaining tissue samples underwent 
C2P-analysis, 12 cases were excluded due to assay failure, or CDK expression level 
below detection threshold (n=3). Of note, all 12 excluded cases were free of tumor 
recurrence. Hence, 254 samples were available for further analysis (n=217 from 
TUM, and n=37 from LUMC).
Determination of CDK-specific activities
Ten to 20 sections of 100 µm thickness were cut with a cryostat and subjected to 
CDK analysis. One section of 7 µm thickness was cut from the middle of each block 
and evaluated by a pathologist after standard H&E staining. Cases with tumor cell 
content <10% were excluded. The system to measure the CDK specific activity 
(CDKSA) is called “C2P” (for “Cell Cycle Profiling”; Sysmex, Kobe, Japan; Ishihara 
et al, 2005; Kim et al, 2008). In brief, lysates of frozen material were applied to 
a well of 96-well PVDF filter plate (Millipore, MA, USA). Expression of CDKs was 
detected quantitatively by sequential reactions with primary anti-CDK antibodies, 
biotinylated anti-rabbit antibodies, and fluorescein-labeled streptavidin. To meas-
ure the kinase activity, CDK molecules were immunoprecipitated from the lysate 
using protein beads, as reported in detail earlier (Ishihara et al, 2005; Kim et al, 
2008). CDKSA was calculated as CDK kinase activity units (aU/µL lysate) divided 
by its corresponding CDK expression units (eU/µL lysate). Both, aU (CDK activity 
unit), and eU (CDK expression unit) were defined as the expression and activity 








of the CDK1SA and CDK2SA within the LUMC and the TUM cohort can be found in 
supplementary Figure 1. Further details regarding the quality controls for this assay 
can be found in the supplementary data.
Immunofluorescence analysis
Tissue specimens (7 µm) from 207 samples were available for evaluation by immu-
nofluorescence microscopy (Axiovert 200, Zeiss, Göttingen, Germany). After 
fixation with 3% PFA and antigen retrieval (10 min boiling, sodium citrate buffer, 
pH=6.0), slides were incubated with anti-Ki-67 antibody (clone MIB-1, M 7240, 
DAKO) and/or anti-cytokeratin-20 antibody (rabbit monoclonal, 2039-1, Epitomics, 
Burlingame, CA) diluted 1:200, followed by incubation with secondary antibodies 
(Molecular Probes, Darmstadt, Germany; Dianova, Hamburg, Germany), and coun-
terstaining with 4’, 6’-diamidino-2-phenylindole (DAPI, Invitrogen, Darmstadt, Ger-
many). Ki-67 positive nuclei from CK20 positive cells were regarded as bona fide 
tumor cells and were counted in a semi-automated manner using ImageJ freeware 
(http://rsb.info.nih.gov/ij/).
MSI (Microsatellite instability) determination
Tissue from 200 patients of the Munich cohort and all 37 patients of the LUMC 
was available for DNA isolation with the QIAampDNA™Mini Kit (Qiagen, Hilden, 
Germany) according to the manufacturer’s protocol. DNA concentration and qual-
ity was checked with an ND-1000 NanoDrop Spectrophotometer (Thermo Fisher, 
Schwerte, Germany). Subsequently, microsatellite instability was tested with the 
MSI Analysis System, Version 1.2 (Promega, Mannheim, Germany). This assay co-
amplifies five mononucleotide repeat markers; BAT-25, BAT-26, NR-21, NR-24, 
and MONO-27 to determine MSI status. It includes two pentanucleotide repeats, 
Penta C and D, to make sure that normal and tumor samples are derived from the 
same patient. The results of this assay have been previously compared with the 
Bethesda panel markers and proven highly sensitive for MSI determination (26). 
The MSI status was determined for 32 of the 37 LUMC cases, and for 191 of 200 
TUM patients. In 6% of the cases (14 of 237 available DNA samples), MSI status 
could not be determined based on evaluation of the PCR array data by an experi-
enced pathologist due to ambiguous results.
BRAF
The mutational status of the oncogene BRAF (V600E, GTG>GAG substitution in 
exon 15) was assessed by high resolution melting analysis of genomic DNA on a 
Lightcycler 480 II platform (Roche, Mannheim; SYBR Green I /HRM Dye Protocol), 
in accordance to published protocols (23). Briefly, 20 ng of genomic DNA (10 ng/
ȝL) were amplified in total volume of 20 µL with 10 ȝL High Resolution Master Mix, 
2 mM MgCl2, and 1 mM each of oligonucleotide primers, 2ȝL template DNA and 4.8 
ȝL dH2O. Primer sequences were: BRAF Exon 15 For:5’-TGA AGA CCT CAC AGT 
AAA AAT AGG-3’, BRAF Exon 15 Rev: 5’-TCC AGA CAA CTG TTC AAA CTG AT-3’. 














out in 40 cycles (95°C, 15 sec / 61°C, 15 sec / 72°C, 15 sec.), followed by melting 
point analysis with an inital phase: 95°C, 5 sec, and 72 °C, 90 sec, followed by a 
melting profile ranging from 72°C to 95°C in 25 min. As positive control, genomic 
DNA from the BRAF-mutated colon cancer cell line HT29 was used.
Statistical analysis
Statistical analyses were conducted using R Software version 2.11.1 (R Foundation 
for Statistical Computing, Vienna, Austria). In order to derive optimal cut off val-
ues of quantitative CDK measurements for recurrence risk stratification, maximally 
selected log-rank statistics have been used. To consider multiple test issue within 
these analyses, the R-function ‘maxstat.test’ was employed (27). To internally vali-
date the derived cut-off, the entire data set was randomly divided in a training and 
test set (ratio: 70:30). Furthermore, bootstrap re-sampling analysis was conducted 
to estimate distribution of derived cut-off values and 95% confidence intervals 
respectively. Multivariable Cox-regression was performed to assess recurrence risk 
differences between derived sub-groups in simultaneous consideration of poten-
tial confounding factors. Due to the low number of critical events, multivariable 
regression analyses had to be performed consecutively (one by one inclusion of 
potential confounding factors) to avoid over-adjustment. By the use of survival-
ROC analysis, predictive capability of recurrence risk stratification was assessed 
cumulatively over the course of the follow-up. In this term, area under the time 
dependent ROC-curve (concordance index) was reported with 95% bootstrap con-
fidence interval. The Kaplan-Meier Methods was used for survival plotting and log-
rank test for comparison of survival curves. All statistical tests were conducted 
two-sided and a p-value <0.05 was considered significant.
RESULTS
We have determined the specific activity of CDK1 and CDK2 (CDK1SA and CDK2SA) 
in a study population comprised of samples from two independent cohorts of 
stage II colon cancer patients originating from the Leiden University Medical Cen-
tre (LUMC, The Netherlands) and the Klinikum Rechts der Isar, of the Technical 
University in Munich (TUM, Germany). Five samples (1.8%) were excluded due to 
tumor cell content of less than 10 percent. Twelve cases were excluded due to assay 
failure, and in three cases the CDK expression levels were below the detection 
threshold. Of note, all excluded cases were free of tumor recurrence. Altogether, 
the expression and kinase assay (“C2P”, in short for “Cell cycle profiling”) yielded 
results in 96% of patients (254 out of 266; n=217 from TUM, and n=37 from LUMC).
There were no statistically significant differences in clinico-pathological character-
istics between both cohorts (table 1). The specific activity (SA) was calculated and 
indicated as kinase activity in relation to its corresponding mass concentration. The 
CDK activity unit and CDK expression unit were defined as the equivalent of 1 ng 












































































































Abbreviation: pT= tumour stage
between the two study cohorts (Mann-Whitney U test, p=0.35), whereas the aver-
age of CDK2SA was higher in samples from the Netherlands (p=0.012).
Predictive performance and cut-off derivation of CDK specific activity for 
distant recurrence
The distribution of clinical samples was plotted on a scatter diagram according to 
CDK1SA and CDK2SA (figure 1A). Cases with distant metastasis clustered in the 
region with high CDK1 activity, suggesting that mainly CDK1SA could have prog-
nostic power. In order to evaluate the prognostic performance of CDK activity for 
distant metastasis risk, the true positive rates of distant disease recurrence (sensi-
tivity) and corresponding false positive rates (100-specificity) were summarized in 
a time-dependent receiver operating characteristic (ROC) curve. The average area 















Prognostic performance of the specific activities of CDK1 and CDK2. (A) All cases (n=254) spotted 
on a scatter diagram with logarithmic scales according to CDK1 SA and CDK2 SA, respectively. 
Grey triangel: patient with distant metastasis, black dot: no metastasis. (B and C) Time-dependent 
ROC analysis against CDK1 SA (B) or CDK 2SA (C). Thick line: concordance index, thin line: 95% CI. 
Concordance index was 0.69 for CDK1 SA (95% CI: 0.55-0.79, P=0.036), and 0.51 for CDK2 SA (95% 
CI: 0.25-0.66, P=0.57). (D) Derivation of an optimal CDK1 SA cutoff value. The maximum log-rank 








0.55 to 0.79, p =0.024), and 0.51 for CDK2SA, respectively (95%CI: 0.29 to 0.66; 
p=0.57) (figure 1B, C). Combined, these results suggested that CDK1SA, but not 
CDK2SA, is valuable for long-term distant recurrence prediction. Therefore, we 
focused on CDK1SA and derived the statistically best discriminating cut-off value 
for CDK1SA, as indicated by maximum log-rank test. For 254 cases, two local 
maxima of log-rank test statistic were obtained, one for CDK1SA=11 (milli-activity 
unit per expression unit, maU/eU), and one for CDK1SA=18 (maU/eU) (figure 1D). 
In order to test the robustness of the selected cut-off values, a second cut-off 
derivation was performed using the subset of samples with CDK1SA>11 (maU/eU) 
(n=150). In this analysis, the previously proposed cut-off value of 18 (maU/eU) 
neither showed a significant maximum peak, nor was considerably elevated com-
pared to the other candidate cut-off values. This result suggested that the optimal 
cut-off value for CDK1SA was indeed at 11 (maU/eU). The final bootstrap analysis 
confirmed a cut-off value for CDK1 SA of 11 (maU/eU) to be of sufficient discrimi-
nant value for further analysis. In conclusion, patients with CDK1 activity level > 11 
(maU/eU) were classified in the high-risk group (n=104, 40% of the patients), and 
the remaining patients as low-risk (n=150, 60%).
CDK1-based risk prediction for distant metastasis-free survival and cause-
specific survival
Univariable “time to event” analysis showed that patients from the CDK1SA-based 
low risk group had significantly longer distant metastasis-free intervals than patients 
in the high risk group (HR = 6.2; 95%CI: 1.45 to 26.9; p=0.0049) (figure 2A). Impor-
tantly, this finding was retained to be statistically significant after adjusting for the 
multiple log-rank testing which had been performed in order to obtain the optimal 
cut-off value of 11 (maU/eU) (exact conditional Monte-Carlo p-value = 0.029). The 
independence of prognostic ability of CDK1SA-based recurrence risk stratifica-
tion was further evaluated and finally confirmed by multivariable analyses (table 
2). Hazard ratio estimates remained nearly unchanged after consecutive adjust-
ment for the most important clinical-pathological variables which are currently 
used for risk evaluation in stage II colon cancer: T4, poor differentiation, presence 
of obstruction or perforation, lymphatic and vessel invasion, high CEA level, and 
d12 regional lymph nodes examined (24;25)(table 2). Next, a putative confound-
ing influence of mutations in the BRAF oncogene were analyzed. In 217 patients, 
tissue was available for high resolution melting analysis of mutations in exon 15 of 
BRAF. In 32 cases (14.8%), BRAFV600E mutations were detected, 183 patients had 
BRAF wild-type status, and 2 cases were not informative. In Kaplan-Meier analysis, 
the BRAF mutation status was not significantly associated with metastasis-free 
survival (p=0,337), nor with cause-specific survival (p=0,253; not shown), and it 
was excluded as confounding factor for CDK1SA-based risk prediction (table 2).
However, when considering stroma content as adjustment variable, a lack of statis-
tical significance was apparent for the effect of dichotomized CDK1SA. The appar-
ent absence of significance may be explained by the reduced statistical power 















Analysis of distant metastasis-free survival and cause-specific survival. (A) Patients classified in the 
high-risk group (based on CDK1 SA > 11 maUeU-1) had a significantly worse distant metastasis event 
rate as compared with the low-risk group (HR= 6.2, 95% CI: 1.45-26.9, P = 0.0049; exact conditional 
Monte-Carlo P-value = 0.029). (B) Patients classified in the CDK1 SA-based high-risk group had a 
significantly lower cause-specific survival (HR=7.62, 95% CI: 1.80-32.2, P= 0.001).
data. Twenty-five patients (10%) died during the follow-up, among them were all 
20 patients with distant metastases, and only five patients with no evidence for 
distant metastases, but with local tumor recurrence. Due to this strong association 
of distant relapse and death, CDK1SA categorization was found to be a significant 
predictor for cause-specific survival (HR high-risk vs. low-risk group: 7.62; 95%CI: 
1.80-32.2; p=0.001) (figure 2B). This result was thoroughly confirmed in the mul-
tivariable analyses. All adjusted estimates of the hazard ratio showed values of 
>7.75, with lower 95% confidence limits >1.80, and p-values <0.01. However, a non-
significant hazard ratio was estimated after adjustment for stroma content (HR 
high-risk vs. low-risk group: 5.22; 95%CI: 0.65-41.5; p=0.12).
Correlation between CDK specific activity, cell proliferation and 
microsatellite status
Based on the knowledge of the process of tumorigenesis, high CDK1SA levels could 
be a reflection of strongly elevated tumor cell proliferation rates. Therefore, we 
have analyzed tumor cell proliferation with the established proliferation marker 
Ki-67. The Ki-67 labeling index, defined as the percentage of Cytokeratin20-pos-
itive cancer cells with Ki-67-positive nuclei, was determined for n=207 cases. The 
median of the Ki-67 index was 21.4%, but it was not retained by Cox regression 
analysis as significant prognostic factor for distant metastasis (HR = 0.69; 95%CI: 
0.02 to 24.0; p=0.84). Next, a putative correlation between CDKSAs and the Ki-67 
index was examined. However, no significant correlation was found between 









Consecutive (one-by-one) adjustment for confounding factors. 
Pairwise 
comparison

















































































































































Abbrevations: CI = confidence interval; HR = hazard ratio; pT = tumour stage; WT = wild type. a82 
cases (32%) with missing value for stroma content. CDK1SA is not significant (P= 0.180), however; in 
all other test against confounding factors, CDK1 SA achieved significance.
Lastly, a putative correlation between genomic instability and CDK1 activity was 
tested, since CDKs have been shown to be implicated in cellular responses to 
genetic instability. Microsatellite instability (MSI), caused by defects in the cellular 
mismatch repair system, has been suggested for colorectal cancer as a favora-
ble prognostic marker. The microsatellite instability status was determined with 
standard methods for 223 cases, and a high level of instability was detected in 
59 tumors (26.5%, MSI-High), whereas 164 samples showed stable microsatel-
lite repeats (73%, MSS). Cox regression analysis indicated an estimated five-fold 
risk-difference regarding distant metastasis free survival for microsatellite stable 
patients, but the results did not attain significance (HR 5.898; CI95% 0.782-44.481; 
p=0.085). A significant association of microsatellite instability and CDK1SA-based 
risk stratification was apparent, based on the cut-off for CDK1SA of 11 (maU/eU). 















Correlation between CDK SAs and Ki-67 index (percent of Ki-67 positive cells of all CDK20-positive 
tumour cells). Cases were plotted on a scatter diagram according to Ki-67 index against CDK1 SA 
(left), or CDK2 SA (right). Grey circle: tumor with distant metastasis. Ki-67 showed a weak but 
significant positive correlation with CDK2 SA (Spearman’s ȡ = 0.17, P=0.016), but not with CD1 SA 
(Spearman’s ȡ= 0.54).
Figure 4
Association of CDK1 SA-based risk stratification with microsatellite-stable phenotype. Among the 
patients with a stable microsatellite phenotype (MSS), 62% (102 out of 164) were classified in the 
high-risk group based on CDK1 SA. On the other hand, 47.5% (28 out of 59) of the patients with high 
MSI (MSI-H) were classified as high-risk, based on the CDK1 SA threshold (஠2 –test, P=0.0465).
 elevated CDK1  specific activity were observed (chi-square test: p=0.0465, fig-
ure 4). However, a direct comparison of CD1SA between patients with stable or 









This study is the first report demonstrating the specific activity of CDK1 (CKD1SA) 
as prognostic biomarker for stage II colon cancer in a blinded and retrospective 
manner. Two patient cohorts from Germany and the Netherlands were included 
in this study. Essentially, no differences were observed between these cohorts 
regarding clinical parameters or CDK1 activity, indicating that the patients were 
recruited in an unbiased manner. However, the average of CDK2SA was slightly 
but significantly higher in the samples from the Netherlands. This may be due to 
differences in sample embedding and preparation between the study centers, and 
to technical variations between the assay systems for CDK1SA and CDK2SA. Previ-
ously, CDK1SA- and CDK2SA-based risk was shown to be a clinically useful prog-
nostic marker of early breast cancer of Caucasian and Asian cohorts (23-25).
To identify patients with unfavorable prognosis who might benefit from adjuvant 
chemotherapy, several types of staging systems have been developed (4;7;28;29). 
The current staging systems, however, do not provide accurate risk assessment 
for stage II patients (29). Moreover, a number of molecular markers have been 
proposed, such as mutations in KRAS and TP53, loss of heterozygosity of chromo-
some 18, and microsatellite instability (12;30;31). However, none of these candidate 
biomarkers has yet clearly proven to be useful for diagnosis or staging of patients 
with stage II colorectal cancer, except for mutations in the BRAF oncogene, which 
were found to be prognostic for overall survival, particularly in patients with micro-
satellite stable tumors (32;33). Comprehensive approaches using “omics” tech-
nologies have been applied to find biomarkers for colorectal cancer, and we and 
many others have proposed prognostic transcriptome profile sets so far (34-38). 
However, inter-patient and even intra-tumoral heterogeneity, as well as cost fac-
tors have precluded wide-scale clinical application. A promising strategy to cir-
cumvent tumor heterogeneity is to focus on the central hallmarks of cancer, which 
are present in almost all tumors irrespective of the underlying molecular changes. 
Altered cell proliferation and genomic instability are central hallmarks in the case 
of colon cancer (15;39). Therefore, we focused on the enzymatic activities and pro-
tein expression of cyclin dependent kinases (CDKs), the main drivers of cell cycle 
progression. Moreover, CDK regulators have been well documented as prognostic 
indicators in many solid tumors (16-22).
Indeed, CDK1SA was a substantial and constant marker for long-term event predic-
tion of distant metastasis in the present study. A robust cut-off value for CDK1SA 
was derived by choosing a threshold with maximum log-rank statistics (27). 
Importantly, the cut-off value of 11 (maU/eU) was verified by the adjusted multiple 
log-rank test. Multivariate analysis retained CDK1 specific activity as independent 
predictor of distant recurrence. None of the currently accepted clinical risk fac-
tors, e.g., T4 stage, poor differentiation, obstruction or tumor perforation (40), was 
identified as confounding factor (table 2). Moreover, CDK1SA was independent of 
the mutation status in the BRAF oncogene. Therefore, we conclude that CDK1SA-














stage II colon cancer. Two hypotheses, which are not mutually exclusive, may 
explain the increased intratumoral CDK1SA level in patients with worse progno-
sis. First, specific activity of CDK1 may directly reflect higher cancer cell prolifera-
tion. To address this question, we have examined a putative correlation between 
CDK1SA and proliferation. The index of proliferating cancer cells did not signifi-
cantly correlate with CDK1SA. Moreover, the Ki-67 proliferation index itself was 
not significant for prognosis, in accordance with earlier findings (41). Second, CDK1 
activity may be elevated due to chromosomal instability, a factor already asso-
ciated with worse prognosis (40). Indeed, high CDK1SA levels were significantly 
correlated with a stable microsatellite phenotype (chi-square test: p = 0.0465). To 
the best of our knowledge, no reports exist that provide a cause-and-effect link 
between CDK1 activity and microsatellite instability. However, colorectal tumors 
with stable microsatellites are thought to present chromosomal instability (CIN), 
associated with worse prognosis. Thus, microsatellite-stable tumors with high 
CDK1SA levels in our collective are likely to display chromosomal instability. On 
the molecular level, regulation of CDK1 activity is orchestrated by cellular check-
points. Altered expression and activity of the DNA damage and spindle-checkpoint 
proteins are frequently observed in cancer cells, and contribute to chromosomal 
instability (15). Thus, deregulated checkpoint pathways could cause an aberrant 
activation of CDK1. Indeed, over-expression of both cyclinB1 and CDC25, important 
regulators of CDK1 activity, are prognostic markers in colorectal and other can-
cers (18;21;42). In conclusion, CDK1SA-based analysis is a robust and useful assay 
to identify patients with a high risk of distant recurrence, who could benefit from 
adjuvant chemotherapy.
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Background: TNM staging methods fall short identifying stage II colon cancer 
patients at high risk of distant metastasis who might benefit from adjuvant treat-
ment. The addition of combined biomarkers representing important hallmarks of 
cancer, disruption of apoptosis and proliferation, to current staging criteria may 
provide a window for improvement.
Methods: The results of biochemical assays of enzymatic activity of caspase-3 and 
cyclin dependent kinase 1, representing the level of apoptosis and proliferation in 
tumor resection specimens of 217 stage II colon cancer patients, were combined 
into one parameter and correlated to tumor microsatellite status and patient out-
come.
Results: Low levels of the proliferation marker tumor cell CKD1 activity and high 
levels of the apoptosis marker caspase-3 activity were independent predictors 
of better disease free survival (CDK1, hazard ratio 9.6, p=0.029; caspase-3 activ-
ity, HR 0.5, p=0.03). Within the tumor microsatellite stable (MSS) patient cohort, 
based on the combined results of these assays, 87.5% of the stage II patients that 
developed distant metastasis were correctly classified as high-risk.
Conclusion: Combined analysis of the level of proliferation and apoptosis was 
proven to be a reliable parameter to identify high-risk patients within stage II, MSS 









Patient outcome in colon cancer highly depends on disease stage at time of diag-
nosis. This stage is determined using the TNM (Tumor Node Metastasis) criteria (1). 
Traditionally, the TNM stage is used to determine whether a patient is recom-
mended to receive (neo-) adjuvant treatment. Nowadays, a disparity has risen 
between therapeutic decision-making and TNM staging. The statistics on colon 
cancer point out that within the stage II cohort a patient population can be identi-
fied with a high risk of distant metastasis, a risk comparable to patients diagnosed 
with stage III disease (2–4). Therefore, adjuvant chemotherapy is recommended 
for high risk patients with stage II colon cancer (5). Unfortunately, this ‘high-risk’ 
population cannot be identified using the TNM staging criteria alone. The clinical 
decision-making process therefore needs to be ‘updated’ with the addition of bio-
markers to the traditional TNM criteria in order to make the identification of this 
high risk group possible.
Tumor development and progression partly depends on the disruption of the bal-
ance between cell proliferation and apoptosis, which under normal circumstances 
is responsible for tissue homeostasis (6,7). It has recently been shown that clinical 
outcome of colon cancer patients is related to the balance between cell prolifera-
tion and apoptosis at tumor level (manuscript submitted for publication) (8). Com-
bined analysis of these markers might therefore be useful to detect the high-risk 
stage II patient population. In the current study we determined both the level of 
tumor proliferation as well as the level of apoptosis using a biochemical assay. The 
advantages of the use of biochemical assays are their highly accurate performance 
on only a minimal amount of fresh frozen tissue and furthermore their results are 
less influenced by inter-observer variety than for example immunohistochemis-
try (IHC) (9). More importantly, biochemical assays provide information on the 
functional activity of the enzyme versus solely expression levels of the protein, 
determined using IHC. To determine the level of tumor cell proliferation we used 
the Cyclin Dependent Kinase 1 Specific Activity (CDK1 SA) assay and to determine 
the level of apoptosis we used a caspase-3 activity assay. Both have been previ-
ously successfully tested for their applicability on colon cancer tissue. CDK1 SA for 
example has been shown to significantly predict distant metastasis in colon can-
cer patients and was significantly elevated in microsatellite-stable tumors. (10–12). 
The aim of this study was to combine the results of the biochemical analyses of 
apoptosis and proliferation in order to determine both the prognostic quality of 
this combined analysis as well as the discriminative power of these assays in the 


















The study population consisted of 217 stage II colon cancer patients. All patients 
underwent surgical resection of their tumors between 1987 and 2006 at the Klini-
kum rechts der Isar, Technische Universität in München, Germany. None of the 
patients underwent any (neo-) adjuvant treatment. Of all patients, fresh frozen 
samples of their colon tumor specimens were collected. The tumor tissue was 
immediately dissected after surgery by an experienced pathologist and stored at 
-800C. The median follow -up time was 7.9 years. The specimen collected were 
with informed consent, according to the vote of the Ethics committee of the Klini-
kum rechts der Isar (1927/2007).
Cyclin Dependent Kinase 1 specific activity assay
To determine the Cyclin Dependent Kinase 1 specific activity (CDK1 SA) an assay 
called C2P (‘cell-cycle profiling’), which has been described previously, was 
used (12). In brief, from all patients 10-20 sections of 100 µm thickness were cut, 
analyzed for their tumor cell content and subjected to CDK1 SA analysis. CDK1 
SA was calculated as cyclin dependent kinase (CDK) activity units (aU µl-1 lysate) 
divided by its corresponding CDK expression units (eU µl-1 lysate). Further details 
with respect to the CDK1 SA determinations in this specific cohort have been 
described previously (11).
Preparation of lysates and protein quantification
To determine the enzymatic activity of caspase-3 of each tumor sample 10 slides 
of 10 ȝm were cut and put in a 2.0 ml tube with 500 ȝl of lysis buffer (10 mM 
HEPES pH 7, 40 mM ȕ-glycerophospate, 50 mM NaCl, 2 mM MgCl2, 5 mM EGTA). 
Subsequently the samples were homogenized with a Polytron homogenisator (PT 
MR 2100, Kinematica AG, Lucerne, Switzerland) for 10 seconds and subjected to 
four freeze-thaw cycles that included storage in liquid nitrogen until samples were 
frozen followed by storage at 370C until the samples were fully thawed. Until fur-
ther processing, samples were stored at -800C. Quantification of the total amount 
of protein in the lysates was performed using a Bradford assay (13). 10 ȝl of each 
sample was pipetted in a well of a 96 wells plate. Next, 300 ȝl of Coomassie Plus 
Reagent (Coomassie Blue Assay kit, Thermo Scientific, USA) was added to each 
well. The reagents were mixed in a plate shaker for 30 seconds and incubated for 
10 minutes at room temperature. The absorbance levels were measured at 595 nm 
using a Benchmark Microplate Reader (Biorad, UK). Diluted bovine serum albumin 
(BSA, standard provided with Coomassie Blue Assay Kit, Thermo Scientific, USA) 
was used to create a calibration curve at protein concentrations ranging from 2000 
ȝg/ml to 25 ȝg/ml. A control sample containing no BSA was used to serve as a 
blank measurement. The absorbance level of this sample was subtracted from all 
measured absorbance levels to correct for background absorbance. All measure-








Caspase-3 enzymatic activity determination
To determine the activity of the caspase-3 enzyme, a caspase-3-specific fluoro-
metric assay was performed using Ac-DEVD-AFC (Sigma-Aldrich, USA) as sub-
strate. For this assay an AFC calibration curve was prepared by diluting 1 mM of 
AFC (Sigma-Aldrich, USA) in reaction buffer (100 mM HEPES buffer pH 7.25, con-
taining 10% (w/v) sucrose, 0.1% (v/v) Nonidet-P40 and 10 mM dithiothreitol (DTT, 
Sigma –Aldrich, USA) to reach a final AFC concentration ranging from 5000 nM to 
2,5 nM. The emission at 505 nm levels of the calibration curve and tissue samples 
were analyzed in a 96-well microplate using a fluorometer (Victor3V 1420 Multi-
label Counter, Perkin Elmer, USA) at excitation wavelength of 400 nm. Plotting 
the AFC emission levels against their concentrations in nM created the calibration 
curve. As a positive control of caspase-3 activation, a colorectal cancer cell line 
(SW480) was treated with 100 µM Cisplatin. Lysates from the treated cells were 
prepared as described above. Each well to compose the calibration curve con-
tained 100 ȝl AFC standard sample, or for the detection of capase-3 activity 50 ȝl 
tumor sample lysate and 50 ȝl of the reaction buffer. 5 µl (1 mM) of the Ac-DEVD-
AFC (Sigma-Aldrich, USA) substrate solution was added to each well and the plate 
was incubated for 2 hours at 37 0C after which emission levels were measured. The 
emission level of a control sample containing 205 ȝl of reaction buffer only was 
used for background correction. All measurements were performed in duplicate.
Caspase-3 enzymatic activity calculations
The AFC and the Bradford calibration curves both showed a correlation coeffi-
cient of 0.99. For each sample the protein concentration and the activity level of 
caspase-3 were determined by plotting the absorbance and fluorescence meas-
urements in the calibration curves, making it possible to read out the correspond-
ing protein concentration and caspase-3 activity. The enzymatic activity was then 
calculated as a ratio of the total amount of protein in each sample by dividing the 
determined AFC values by the protein concentration of the samples. This yielded 
an activity value expressed in pmol AFC/min/mg protein. The Bradford assay as 
well as the AFC value measurements were performed in duplicate. Samples were 
excluded from analysis when the difference between the two measurements was 
more than two times the standard deviation of the entire group of measurements. 
Additionally, samples that contained too little material for both measurements 
were excluded from analysis.
Microsatellite status determination
Five slides of 10 ȝm of the fresh frozen tumor samples were cut for DNA isolation 
and subsequent determination of the microsatellite status. Of 191 patients tissue was 
available for this assay. DNA isolation was performed with the QIAampDNA™Mini 
Kit (QIAGEN Benelux, Venlo, The Netherlands) according to the manufacture’s pro-
tocol. The DNA concentration and quality was checked with the ND-1000 NanoDrop 
Spectrophotometer (Thermo Scientific, Wilmington, DE, USA). The microsatellite 
















a fluorescence and multiplex PCR-based assay. In this assay 5 mononucleotide 
repeat markers, BAT-25, BAT-26, NR-21, NR-24, and MONO-27, were co-amplified 
to determine the microsatellite status. The results of this assay have been previ-
ously compared with the Bethesda panel markers and proven highly sensitive for 
microsatellite status determination (14). The results were checked and approved by 
an experienced pathologist.
Statistical analysis
The statistical analyses were conducted using the SPSS statistical analysis pack-
age version 17 UK. The One-Way Anova test and the Student’s t-test were used 
to evaluate associations between the clinico-pathological variables, CDK1 SA and 
the caspase-3 activity levels. Survival analysis was performed using the standard 
Kaplan-Meier method to calculate survival probabilities and the log-rank test was 
applied to compare the survival curves. Disease Free Survival was defined as the 
time from date of surgery until disease recurrence (distant recurrence) or tumor-
related death. Cox proportional hazards analysis was used for uni- and multivariate 
analysis. Test sensitivity was defined as the percentage of patients that developed 
a distant recurrence (DR) during follow-up correctly defined as high-risk. Test 
specificity was defined as the percentage of patients that did not develop a DR 
during follow-up correctly defined as low-risk. All statistical tests were two-tailed 
with a 0.05 significance level.
RESULTS
Patient characteristics, caspase-3 activity levels and CDK1 SA analysis
Tumor caspase-3 activity level could be successfully determined in 199 out of 
217 patients. Eighteen patients (8.3%) were excluded from analysis because the 
measurements of the Bradford assay or the AFC value did not meet the qual-
ity control standards mentioned in the material and methods section. The char-
acteristics of the successfully measured patients are summarized in table 1 and 
did not statistically significantly differ from the entire 217 patients included in this 
study. The mean caspase-3 activity level was 46.4 pmol AFC/min/mg protein with 
a range between 0 and 404.5 pmol AFC/min/mg protein. In concordance with pre-
viously published data, the dispersion of our results was skewed (15) Therefore, the 
median level of activity (24.4 pmol AFC/min/mg protein) was used as the cut-off 
value for group division into above-median caspase-3 activity (high) and below-
median caspase-3 activity (low). The clinicopathological characteristics listed in 
table 1 were also analyzed for their association with the level of caspase-3 activity 
using this cut-off value. None of these showed a significant relation with the level of 
caspase-3 activity except for tumor microsatellite status. The tumor microsatellite 
stability status could be determined in 181 out of the 199 patients (91%), in the other 
cases to little tumor material was available for analysis. The percentage of patients 









baseline characteristics of the stage II colon cancer patient population related to the caspase-3 
activity assay


































































































Abbreviations: Cm, centimeters; MSS, Micro Satellite Stable; MSI, Micro Satellite Instable; CDK1 SA, 
Cyclin-Dependent Kinase 1 Specific Activity.
This table shows the association of clinico-pathological characteristics with caspase-3 activity of 
the 199 primary stage II colon cancer patients. Caspase-3 activity was measured in pmol AFC/min/
mg protein, CDK1 SA was measured in milli-activity unit per expression unit, maU eU-1. The clinico-

















low caspase-3 patient population compared to the high caspase-3 group (91.2% vs. 
53.3%, P-value <0.001).
CDK1 SA measurements were available for all but 1 patient, in this case to little 
tumor material was available for analysis. The cut off level of high and low CDK1 
SA was set at 11 (milli-activity unit per expression unit, maU eU-1), based on a previ-
ously published study in which these activity level has been determined to be the 
optimal cut off level using bootstrap analysis (11). CDK1 SA was not significantly 
related to caspase-3 activity levels. In concordance with the previous published 
results CDK1 SA was not significantly related in direct comparison to the tumor 
microsatellite status (11).
The prognostic value of caspase-3 activity and CDK1 SA for disease free 
survival
The level of caspase-3 activity in tumor showed a significant relation to the patients’ 
disease free survival (DFS). Patients with high levels of activity had a mean DFS 
time of 14.2 years compared to 13.3 years in the low activity level group (p-value: 
0.012). The same was observed for the CDK1 SA. Patients with CDK1 SA below the 
cut off value had a mean DFS time of 14.8 years compared to a mean DFS time of 
13 years in the group with CDK1 SA above the cut off value (p-value: 0.001, figure 1). 
When the survival analysis was stratified based on tumor microsatellite status this 
relation was only present in the MSS patient population. In this cohort, again high 
caspase-3 activity levels (p-value: 0.029) and low CDK1 SA levels (p-value: 0.005) 
were significantly related to a better DFS; this was not the case in the MSI popula-
tion.
Table 2 shows the results of the Cox proportional univariate analysis for DFS. Both 
the caspase-3 activity level and the CDK1 SA were statistically significant prognos-
tic indicators of DFS in univariate analyses. To determine the independent prog-
nostic value of both caspase-3 activity level and CDK1 SA, multivariate analysis was 
performed taking into account known prognostic factors in colon cancer such as 
tumor microsatellite stability status. Both caspase-3 activity and CDK1 SA remained 
statistically significant, prognostic parameters in multivariate analysis, with a HR of 
0.513 with a p-value of 0.03 and a HR of 9.6 with a p-value of 0.029, respectively. 
Additional multivariate analysis was performed to investigate the additional effect 
of microsatellite status through the implementation of an interaction term. This 
analysis showed no statistical significance. Therefore, the effects of CDK1 SA and 
caspase-3 activity on patient outcome are not influenced by the tumor microsatel-
lite status.
The combined analysis of tumor proliferation and apoptosis level to 
identify high-risk stage II colon cancer patients
The goal of this study was to prove that the combined analysis of the level of 
tumor apoptosis and proliferation improves our ability to identify high-risk stage 
II colon cancer patients. To study this hypothesis we combined the results of both 






































p-value: 0.012 p-value: 0.001
High caspase-3 activity
A B
Low caspase-3 activity Low-CDK 1 SA
High-CDK 1 SA
Figure 1
Abbreviations: DFS, disease-free survival; CDK1 SA, cyclin-dependent kinase 1 specific activity.
Kaplan Meier curves for DFS in 199 stage II colon cancer patients according to level of (A) caspase-3 
activity: high level of tumor caspase-3 activity is significantly related to a better DFS cancer patients; 
and (B) CDK1 SA: low level of tumor CDK1 SA is significantly related to a better DFS. 
group, consisting of patients with tumors showing high level of apoptosis as well 
as  proliferation; a double-negative patient group, showing low level of both apop-
tosis and proliferation; and two groups of patients of which one the tumor samples 
showed high level of proliferation and low level of apoptosis and one vice versa. We 
performed the same statistical analysis with this combination variable as previously 
described for both the assays separately. These results pointed out that patients 
who showed low levels of apoptosis but high levels of proliferation in their tumor 
samples had the worst outcome perspectives regarding DFS (p <0.001) compared 
to all the other groups (figure 2). We performed the same analysis stratified for 
tumor microsatellite status (figure 2). From this analysis we concluded that our 
combination variable can be used to significantly determine outcome in the tumor 
MSS stage II patient cohort. We classified the low-caspase-3 activity and high-
CDK1 SA population consisting of 53 (40%) patients of the entire MSS population 
as high-risk population, the remaining 78 (60%) as the low-risk population.
In 2004 the American Society of Clinical Oncology (ASCO) listed a number of cri-
teria that clinicians can use to identify the high-risk stage II colon cancer patients 
who might benefit from adjuvant chemotherapy (5). Although these criteria are 
only considered to be recommendations, some countries, like the Netherlands and 
Germany have adopted them in their national guidelines of the treatment of colon 

















The Cox univariate analysis for disease-free survival.



































































































Abbreviation: N, total number of patients included in the analysis; HR, Hazard Ratio; P, p-value; MSS, 
Micro Satellite Stable; MSI, Micro Satellite Instable; CDK1SA, Cyclin Dependent Kinase 1 Specific 
Activity.
Cox univariate analysis for disease free survival. The significant p-values are marked bold. Caspase-3 
activity was measured in pmol/AFC/min/mg protein, CDK1 SA was measured in milli-activity unit per 





























A Total population B MSI cohort
C MSS cohort
DFS in years DFS in years
DFS in years
p-value: 0.001 p-value: 0.721
p-value: 0.003
Low caspase-3 and low-CDK1 SA
High caspase-3 and low-CDK1 SA
High caspase-3 and high-CDK1 SA
Low caspase-3 and high-CDK1 SA
Figure 2
Abbreviation; DFS, disease free survival; CDK1 SA, cyclin dependent kinase 1 specific activity; MSI, 
microsatellite instability; MSS, microsatellite stability.
Kaplan Meier curves for DFS in years for the combined caspase-3 & CDK1 SA parameter in (A) the 
total study population, and separately analyzed stratified for tumor microsatellite status in (B) for 
















the criteria mentioned in the ASCO recommendations: T-stage and the  number 
of lymph nodes resected. Based on these two variables we were able to classify 
109 of the 131 MSS stage II colon cancer patients analyzed as low-risk (83%) and 
the remaining 22 as high-risk (17%). Of these 131 colon cancer patients, 16 patients 
actually developed a distant recurrence (DR) during follow-up. Based on our 
combined variable of caspase-3 activity and CDK1 SA levels we identified 14 out 
of these 16 patients correctly as high-risk, hence only two patients (12.5% of the 
high-risk patients) were incorrectly classified as low-risk. Using the ASCO recom-
mendations, 11 out of these 16 patients were correctly classified, and 5 (31% of the 
high-risk patients) patients were incorrectly classified as low-risk. Based on these 
numbers the sensitivity of our combined variable was 88% with a specificity of 
66%. Application of two the ASCO recommendations showed a lower sensitivity of 
68%, but at a higher specificity of 85%.
DISCUSSION
This study underlines the clinical importance of analyzing both tumor apoptosis 
and proliferation for the identification of a patient cohort at high risk of distant 
metastasis within a stage II colon cancer population. We showed that a variable, 
based on the combined measurements of the level of tumor apoptosis measured 
with a biochemical caspase-3 activity assay and the level of tumor proliferation 
measured with a CDK1 SA assay, has substantial discriminating power to inden-
tify high risk stage II MSS colon cancer patients that might benefit from adjuvant 
therapy. Our variable performed equally to a subset of ASCO criteria designed to 
identify this patient selection at risk of distant metastasis in our MSS stage II colon 
cancer patient population (5).
Several countries, including the Netherlands, in their national guidelines, have 
adapted the ASCO criteria. Recent data from the Dutch Surgical Colorectal Audit 
(DSCA) pointed out that in the Netherlands only 18% of the stage II patients indi-
cated as high-risk based on these recommendations actually received adjuvant 
treatment (16). From these data it can be concluded that the recommendations are 
not yet standard of care in the Netherlands, even though they are mentioned in the 
national guidelines. Furthermore, the criteria listed by the ASCO are all clinical and/
or pathological parameters, no biomarkers were recommended for clinical use. It is 
our opinion that to better identify high-risk stage II colon patients the implemen-
tation of both clinical and pathological parameters as well as biomarkers should 
be applied. In other fields of medical care, such as in cardiovascular medicine, a 
positive effect on high-risk patient identification by combining biomarkers with 
established clinico-pathological parameters has already been proven (17). Until 
now both the ASCO’s Tumor Markers Expert Panel and its European counterpart; 
The European Group on Tumor Markers, based on extensive reviews of the avail-
able literature, have not found any single biomarker to be of sufficient prognostic 








clinical outcome of colon cancer patients greatly depends on the balance between 
cell proliferation and apoptosis at tumor level determined with IHC (manuscript 
submitted for publication). Both disruption of the pathway of apoptosis and the 
pathway of proliferation are important hallmarks of the highly regulated process of 
tumorigenesis (7,21). This current study validates the result of our previous study, 
only now using biochemical assays, proving the clinical significance of a combined 
parameter reflecting both tumor apoptosis and proliferation levels on patient out-
come. Because we were able to validate the prognostic value of our parameter in 
the independent cohort in this current study and because our criteria showed to 
perform equally to a subset of the already clinically approved and applied ASCO 
criteria, future studies in independent cohorts will hopefully confirm that the use 
of our parameter together with the ASCO criteria will provide a synergistic effect 
in high-risk patient identification.
Interestingly, our parameter performed the best in high-risk patient identification 
in the MSS patient population. Microsatellite instability is predominantly found in 
right-sided tumors. These tumors display a phenotype that has been found to cause 
a substantial immune reaction resulting in higher levels of apoptosis and, moreo-
ver, tumor microsatellite instability has been significantly related to better patient 
outcome (22–24). Furthermore, a lack of benefit in DFS and OS has been shown 
by, amongst others, Ribic et al. with fluorouracil-based adjuvant chemotherapy in 
MSI patients (25,26). We feel that the results of these studies justify the applica-
tion of our parameter in only a MSS stage II colon cancer patient cohort. Because 
they point out that the role of MSI status as a predictive marker for chemotherapy 
efficacy needs prospective validation and administration of chemotherapy in MSI 
Stage II CRC patients is controversially.Therefore it will be mainly within the MSS 
cohort that high risk patient that might benefit from adjuvant therapy.
In conclusion, current staging criteria have shown to be inadequate to determine 
a patient’s need for adjuvant therapy especially those with a high risk of DR in 
stage II colon cancer. To improve these criteria, they should be re-evaluated which 
will implicate the addition of new biomarkers. This study indicates that the combi-
nation of the tumor apoptotic status, determined with a caspase-3 activity assay, 
and the determination of the tumor proliferation level, determined with a CDK1 SA 
assay, in especially MSS patients is a valuable tool in predicting distant recurrence 
in stage II colon cancer patients. Future validation of these assays for clinical appli-
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This review elucidates current strategies of active immunotherapy for colorectal 
cancer patients with a focus on T-cell mediated immunotherapy. Poor progno-
sis of especially stage 3 and 4 colorectal cancer patients emphasizes the need 
for advanced therapeutic intervention. Here we refer to clinical trials using either 
tumor cell-derived vaccines or tumor antigen vaccines with a special interest on 
safety, induced immune responses, clinical benefit and efforts to improve the clini-









Colorectal adenocarcinoma is the third most common cancer and accounts for a 
significant number of cancer deaths worldwide (1-3). The lifetime risk for colorec-
tal cancer is about 5-6%, with a peak incidence in the 7th decade. Surgery is the 
treatment of choice when the disease is only confined to the bowel wall. How-
ever, 30–40% of patients have loco-regionally advanced or metastatic disease 
which cannot be cured by surgery alone. Adjuvant chemotherapy is indicated for 
stage III colon cancer (4-6). There is evidence to suggest that patients with a high 
risk group of stage II colon cancer may benefit from adjuvant chemotherapy as 
well (4-6). Patients with operable rectal cancer receive short-course preoperative 
radiotherapy (7,8). More than half of the patients that are initially believed to be 
cured by surgery and possibly adjuvant therapy develop recurrences and die of the 
disease (9). This prompts for more advanced treatment options and much effort 
has been put in exploiting the activation of the patient’s immune system as a thera-
peutic modality by the enhancement of tumor-immunity.
IMMUNOTHERAPY OF CANCER
The tumor immune surveillance hypothesis postulated that the immune system 
identifies cancerous and/or precancerous cells and eliminates them before they 
can cause harm (10). In humans the majority of the evidence that supports the 
immune surveillance hypothesis comes from the observed increased relative risk 
ratios for various types of cancers with no apparent viral origin in immunosup-
pressed transplant recipients (11). Furthermore, patients on chronic immunosup-
pression with a colorectal tumor have significantly worse long-term oncologic 
outcomes after surgery (12). Moreover, the positive association between the num-
ber of tumor infiltrating lymphocytes and prognosis of colorectal cancer patients 
supports a role for the immune system in controlling colorectal cancer (13). These 
data support the development of strategies to use the immune system as anti-
cancer therapeutic to prevent the growth of tumor recurrence and prolong sur-
vival of cancer patients. For a long time T-cell based immunotherapy of cancer 
patients was associated with limited clinical success. Recent studies have revealed 
the dawn of a new era in which the activation of tumor-specific T-cells starts to 
make a difference. Sipuleucel-T is the first therapeutic cancer vaccine to demon-
strate effectiveness in Phase III clinical trials by prolonging the life of advanced or 
late stage metastatic, asymptomatic hormone refractory prostate cancer patients 
(HRPC) (14,15). The vaccine was approved by the U.S. Food and Drug Administra-
tion to treat patients with HRPC (16). Treatment with Ipilimumab, a monoclonal 
antibody that targets the immune regulatory molecule CTLA-4 represents the first 
modality that had a significant impact on the overall survival of patients with meta-
static melanoma (17). These results are the first positive demonstration that block-















Also adoptive T-cell therapy (ACT) has been found to be effective in the treatment 
for metastatic melanoma patients (18-20). In a recent series of three consecutive 
clinical trials in these patients, the infusion of autologous tumor infiltrating lym-
phocytes (TIL) yielded objective response rates between 49% and 72% (18-20). 
Last but not least, vaccination with a synthetic long-peptide (SLP) vaccine against 
the HPV-16 oncoproteins E6 and E7 resulted in the complete regression of human 
papillomavirus-16-positive, grade 3 vulvar intraepithelial neoplasias in 47% of the 
patients (21). Complete responses in this study were correlated with the strength of 
HPV-16-specific immunity (21). These encouraging results in patients with different 
types of carcinomas positively stimulate research on immunotherapy of colorectal 
cancer patients. This review provides an overview of clinical vaccination studies 
performed in patients treated for colorectal cancer and speculates on the develop-
ment of therapeutic and prophylactic vaccination for colorectal cancer patients.
THERAPEUTIC VACCINATION FOR COLORECTAL CANCER
Both spontaneously- and therapy-induced cell-mediated tumor-specific immune 
responses need to be robust in order to attack and eliminate tumor cells. This calls 
for close collaboration between cells of the innate immune system and cells of the 
adaptive immune system (22). The cells of the adaptive immune system consist of 
B-cells and T-cells. Tumor-infiltrating B-cells sustain and enhance T-cell responses 
by producing antibodies (Abs), stimulatory cytokines, and chemokines, as well as 
serve as local antigen presenting cells (APCs) (23). Furthermore, they are involved 
in organizing the formation of tertiary lymphoid structures to sustain long-term 
immunity (23). T-cells recognize antigens that are presented in the context of MHC 
class I and II molecules at the surface of tumor cells. Immunotherapy should initiate 
responses against those antigens that uniquely target tumor cells. An important 
consideration is whether to use vaccines based on defined antigens or tumor cell 
derivatives.
INDUCTION OF ANTITUMOR IMMUNITY BY TUMOR CELL-DERIVED 
VACCINES
Tumor associated antigens (TAA) are poorly characterized and many remain to 
be identified. It is believed that the best source of antigens is the tumor cell itself. 
A possible benefit of tumor cell-derived vaccines is that, although targets for the 
adaptive immune system are unidentified, these preparations induce responses 
against multiple targets, possibly minimizing the chance for immune escape. 
A potential disadvantage of tumor cell-derived vaccines is that relevant TAA might 
be under-expressed in the tumor cell and thus results in weak immune responses 
compared to the injection with identified antigens. Furthermore, without the 








immune monitoring with these vaccines are limited, thus prohibiting further clinical 
development based on immune parameters (24). Both autologous and allogeneic 
tumor cell-derived samples have been used in vaccination studies.
Reinjection of irradiated autologous tumor cells
Vaccine preparations based on autologous tumor tissue often consist of autologous 
single tumor cell suspensions. They are prepared from parts of the resected tumor 
and cryopreserved until use. Before reinjection, autologous tumor cell-derived vac-
cines are irradiated to prevent growth and combined with an immune stimulating 
agent such as BCG (25-29), Ulster strain of the Newcastle disease virus (NDV) (30-
32), heat shock proteins (33) or IL-2 transfected fibroblasts (34) (table  1) These 
vaccines rely on boosting tumor-specific T-cells via tumor cell surface-expressed 
HLA-tumor peptide complexes. Furthermore, tumor antigens released by dying 
tumor cells may be presented to T cells by professional APCs. Professional APCs 
(e.g. DC) express very high levels of co-stimulatory molecules which is required to 
maximize T-cell activation (35). An advantage of using autologous tumor cell prep-
arations is that all antigens that are presented to the immune system are also rele-
vant for the recognition of the tumor. However, the preparation of such tailor-made 
vaccines is time consuming, relatively costly and, therefore, clinically difficult to 
apply outside a clinical trial setting. The use of these types of vaccines has revealed 
no serious toxic events (table 1). As TAA in this approach are unknown no extensive 
immune monitoring was performed. One study reported a T-cell response that was 
either a de novo induced or boosted in 15 of 29 patients (33). Other studies used 
the delayed cutaneous hypersensitivity skin reaction as an indirect parameter to 
measure vaccine specific immunity (table 1). In two studies a positive correlation 
was found with survival (28,31). Of the eight clinical phase II (27,31,32) and phase III 
(28,25,26,29,30,31) studies in different patient cohorts, six determined the effect 
on prognosis. Three studies reported that tumor cell reinjection combined with 
BCG had an effect on survival in subgroups (only stage II patients (25,26) or only 
patients with colon cancer (29)). Furthermore, one randomized phase III trial 
where NDV-infected autologous tumor cells were injected reported a significant 
effect on survival when compared to non-vaccinated patients (table 1) (31). Other 
phase II and randomized phase III trials using NDV-infected autologous tumor cells, 
described a positive effect on survival of vaccinated patients, when compared to 
historical controls or in subgroups of only colon cancer patients (table 1) (31,32). 
Despite these results with autologous tumor cell-derived vaccines no new clinical 
trials have been initiated. This is possibly due to the lack of pharmaceutical sup-





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Dendritic cells loaded with an allogeneic tumor cell vaccine
Another approach is to use directly ex vivo antigen-pulsed DCs for vaccination. 
Support for this strategy comes from animal studies. Here it was demonstrated 
that such DC administered to tumor bearing hosts were able to elicit effective 
antitumor T-cell immunity. DCs can be easily generated from the blood of patients 
and, therefore, this approach was translated to clinical trials designed to study 
their capacity to prime tumor-specific CD8+ T-cells and T-helper cells and clinical 
efficacy. The advantage of allogeneic tumor cells to pulse DCs is that the allogeneic 
tumor cell component can become an off-the-shelf product. A potential disadvan-
tage is that the immune system will be aroused against tumor antigens that are 
not present in the patient’s tumor, and as such are irrelevant. In a number of trials 
DCs were pulsed with an allogeneic melanoma cell lysate, which amongst others 
is rich in the cancer/testis antigen MAGE (36,37), the expression of which has not 
been found in normal tissues except for the testis. Approximately 40% of all colo-
rectal carcinomas expressed at least one of MAGE A-1 to -6 antigens (38-41). No 
severe adverse events were found in these clinical trials but the clinical effect has 
been limited to the description of cases (table 1) (36,37). In addition, the induction 
of anti-tumor immunity was not studied in great detail and mainly relied on the 
description of delayed cutaneous hypersensitivity skin tests. A large study focus-
ing on survival is lacking.
TUMOR ANTIGENS STUDIED IN CLINICAL TRIALS
Defined antigens to be used as vaccine candidates ideally should be overexpressed 
in the context of HLA at the cell surface of tumor cells and not (or at very low) 
levels by other cells of the human body. All antigens used in vaccination studies 
for colorectal cancer comprise TAA and consequently are likely to be expressed 
by normal cells (42-44). Different TAA such as: p53, CEA, MUC1, Sialyl-Tn, 5T4, 
SART3, MAGE have been applied in clinical trials to vaccinate colorectal cancer 
patients (table 2) (42-46). The use of antigens potentially expressed by normal 
cells bears the risk of immune tolerance. Indeed, tolerance to many TAA has been 
found. For instance, animal models indicated that the p53-specific CD8+ T-cell but 
not the CD4+ T-cell repertoire is severely restricted by self-tolerance and might 
only consist of lower affinity p53-specific CD8+ T-cells (47,48). Data from our recent 
clinical vaccination trial with the p53-SLP vaccine confirmed these results (49). In 
contrast a blunted CD4+ T-cell repertoire was found for the T-cell response against 
the carcinoembryonic antigen (CEA) in animal models (50). Also studies in a MUC1-
transgenic mouse model indicated that low antibody and CTL responses to MUC1 
peptides are due to CD4+ T-cell tolerance (51-54). These results indicate that tol-
erance forms a potential hurdle for immunotherapies of cancer when using TAA. 
A possible option to bypass tolerance and to induce both CD4+ and CD8+ tumor 









Different types of tumor-associated antigens with examples of antigens used to vaccinate colorectal 
cancer patients
Type Description Tumor associated antigen
Differentiation antigens expressed by the tumor and the normal 




Shared or cancer testis 
antigens
expressed by tumor cells and not by 
normal tissues, with the exception of 
spermatogonia, which do not express 





Over expressed antigens antigens not or in low amounts 
expressed in normal tissues, but mas-








Unique antigens Mutation or genetic instability uniquely 
expressed by tumor cells
Frameshift mutated products
RAS
Abbrevation: CTL: Cytotoxic T lymphocyte. Data from (42;139).
against different TAA able to induce complementary reactivity of non-tolerized 
CD4+ and CD8+ T-cells.
Different strategies have been used to immunize patients against the fore-men-
tioned TAAs. Four vaccination strategies have been popular and tested in mainly 
phase I and II trials i.e.: peptide vaccination, dendritic cell vaccination, polynucleo-
tide vaccines and recombinant viruses.
Peptides
An elegant approach is the use of synthetic peptides that represent parts of the 
TAA and are in general injected intradermally or subcutaneously. Two types of 
peptide strategies are currently used for vaccination purposes: minimal peptide 
vaccines (55) and synthetic long peptides vaccines (56). Minimal peptide vaccines 
comprise the minimal cytotoxic T-cell peptide–epitope sequence that can bind 
directly to its presenting HLA class I molecule. Notably, each peptide can only 
bind to one specified HLA class I subtype and as such vaccination is limited to 
those patients expressing that specific type of HLA molecule. Direct injection of 
such peptide vaccines into patients have met with limited clinical success, prob-
ably because the induced CD8+ T-cell responses do not possess strong effector 
functions, the response is transient because of the lack of T-cell help. In some 
vaccination strategies, these minimal peptide vaccines may induce immunologi-
cal tolerance rather than immunity (55). Table 3 summarizes a large diversity of 















clinical  trials were derived from different antigens: CEA (57), survivin (58), SART3 
(59), and a personalized mixture of antigens (60-62) (table 3). These minimal pep-
tide vaccines were all well tolerated with mainly grade I/II adverse events at the 
injection site (table 3). In most studies the peptide vaccines induced or boosted 
antigen-specific T-cell or IgG responses in the majority of vaccinated patients 
(table 3). Unfortunately, detailed insights into the phenotype and function of these 
T-cells was missing. Although phase I and II studies are not designed to describe 
therapeutical effects, reduction of tumor load was described in nearly all studies. 
One study described a positive relation between the presence of vaccine-induced 
IgG and overall survival (60), whereas others mentioned reduction of tumor mass 
or a decrease in the level of serum tumor markers in individual patients (table 3).
To gain the induction of strong T-cell responses the concept of overlapping syn-
thetic long peptides (SLP) was introduced. These long peptides, containing a mix 
of T-helper epitopes and cytotoxic T-cell epitopes do not bind directly to MHC 
class I at the cell surface but are taken up by professional APCs such as DCs which 
process and present the appropriate epitopes in MHC class I and II molecules at 
the cell surface in the right context thereby activating both CD8+ and CD4+ T-cells 
and in the end a more effective immune response (56). Notably, the use of pools 
of overlapping peptides corresponding to the complete amino acid sequence(s) 
of one or more different antigens allows for the application of vaccines in groups 
of patients irrespective of their HLA type. The SLP vaccines have successfully 
been used to induce strong and broad CD4+ and CD8+ T-cell immunity in animals 
and humans (56,63). Long peptides vaccines used in phase I or II vaccination tri-
als to vaccinate colorectal cancer patients represented the TAA: p53 (49), ȕHCG 
(64), MUC-1 (65) and mutation specific Ras (66) (table 3). Only limited toxicity has 
been found in these trials. Two of these four studies determined vaccine-induced 
immunity. One study, using a mutation specific Ras peptide, was able to estab-
lish mutated Ras-specific CD4+ T-cell and CD8+ T-cell responses (66). Our study 
on p53-SLP vaccination revealed long lasting vaccine-specific responses in 9 of 
10 colorectal cancer patients as determined by IFN-Ȗ enzyme linked immunos-
pot, proliferation and cytokine bead arrays (49). Furthermore, p53-specific T-cells 
isolated from the vaccination site were characterized as CD4+ T-cells producing 
both T-helper type 1and 2 cytokines on stimulation with p53 peptide and p53 pro-
tein  (49). However, multiparameter flow-cytometry revealed that only a minor 
population of the p53-specific CD4+ T-cells was optimally polarized, suggesting 
that the vaccine strategy used was not optimal for the induction of p53-specific 
Th1 cells. These results emphasize the importance of immune monitoring to fur-
ther optimize vaccine strategies and to better understand clinical responses after 
vaccination (49). Only one study, using a ȕHCG long peptide vaccine found that 
patients with high anti-ȕhCG antibodies levels exhibited a significant longer sur-
vival compared to patients who developed low anti-ȕhCG antibody levels (64). 
Unfortunately, no efficacy study was performed to determine the true effect of 
vaccination on survival. The immunogenicity of peptide vaccines may be further 
increased by using adjuvants such as: incomplete Freund adjuvant, cytokines, and/



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The injection of autologous DCs pulsed with MHC class I restricted peptides derived 
from CEA (67-70), Her2/NEU (67), MAGE2 (67), MAGE3 (67,71), or DCs expressing 
antigen via recombinant techniques such as viral vectors (72) or mRNA encod-
ing the CEA antigen (73) may form an alternative approach (table 4). In contrast 
to the use of defined HLA class I-restricted peptide-epitopes the latter approach 
has the advantage to include patients irrespective of their HLA type. A potential 
disadvantage is the possibility that the viral vector contains more immunogenic 
epitopes that compete for binding and presentation with the epitopes derived 
from the antigen of interest, thereby weakening the induction of tumor specific 
immunity. A  series of phase I/II trials in colorectal cancer patients showed that 
DCs vaccines are safe and able to arouse a T-cell response (table 4). Compre-
hensive immune monitoring revealed that dendritic cell vaccines induce peptide-
specific IFNȖ-producing T-cells with variable efficiency. It is difficult to compare 
the outcomes of peptide vaccines with peptide-pulsed DCs vaccines as mostly the 
assays have not been harmonized and no gold standard exists. One study found 
that objective clinical responses correlated with the expansion of tetramer+CD8+ 
T-cells (70). The other studies described only cases (67,69,72,73,71,70). An inter-
esting study reported the application of a multiple target vaccine (67) in order to 
prevent immune escape. Unfortunately, only immune reactivity against CEA was 
tested in this study limiting the interpretation of this trial (67).
Viral vector vaccines
Since the discovery that viral infection results in presentation of viral peptides in 
the context of MHC class I and II on infected cells, viruses have been optimized as 
vectors for the delivery of TAA. Vectors often used to express recombinant proteins 
in colorectal patients are: canarypox virus (ALVAC) and Modified Vaccinia Ankara 
(MVA) virus. Sometimes constructs to co-express co-stimulatory molecules such 
as B7.1 were used (74-76). In general, these vaccines are not toxic (table 5) and 
have been used to induce immunity against CEA (74-79), EpCAM/KSA (80), p53 
(81,82), and 5T4 (83,84,85,86) (Table 5). The use of these vaccines not only yielded 
antibody and T-cell responses against tumor antigens but frequently also against 
viral components. In most cases the immune response to the tumor antigens was a 
bit disappointing. The foreign viral components may have formed a more attractive 
target for the immune system. Indeed, whereas we detected only low p53-specific 
T-cell reactivity in patients vaccinated with ALVAC-p53, a strong T-cell response 
against the viral vector was found (82). In contrast, the response to p53 was much 
stronger and broader when patients were vaccinated with p53 overlapping long 
peptides (49). Interestingly, the MVA-5T4 vaccine did induce strong 5T4-specifc 
immune responses. The group of patients with stronger 5T4-specific proliferative 
responses showed significantly longer survival (85,86). Unfortunately so far only 
phase I and II studies have been performed. Therefore mainly descriptive effects 































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































One of the most unique features of the immune system consists of its capacity to 
specifically search and destroy targets. As such, many have discussed if tumor cells 
represent one of the regular targets of the immune system and in addition if the 
patient’s own immune system can be used to specifically destroy tumor cells once 
tumor cells escaped immune surveillance (10). Subsequently, many have tried to 
reinforce the immune system to cure cancer patients. In this review we provided 
an overview of currently tested vaccines to treat colorectal cancer patients. The 
few trials focused on clinical efficacy comprised phase III trials using irradiated 
tumor samples which suggested some clinical benefit in selected subpopulations 
(25,29) but overall were rather disappointing. However, most of the trials have 
been designed to test the safety and immunogenicity of vaccines but have yet not 
resulted in the design and execution of phase III trials. Although in most trials no 
serious vaccine related adverse events were noted, lack of clinical results suggests 
that the vaccine-induced T-cell responses against these antigens are at this point 
not robust enough or of sufficient quality to confidently progress to efficacy trials.
In general, a stronger focus should be put on how to induce the strongest and best 
qualified leukocyte population by vaccination. Vaccines should be combined with 
adjuvants to induce a vaccine specific Th1 polarized response and suppress a Th2 
response. At the moment many candidate adjuvants, including monophosphoryl 
Lipid A, poly I:C, CpG and different cytokines are available. Also chemotherapeu-
tics and monoclonal antibodies comprise strong immune modulating agents that 
can be used to polarize a response after vaccination. Various mechanisms may 
explain the reported synergistic effects of chemotherapy and immunotherapy. 
Direct effects of chemotherapy on tumor or host environment, such as induction 
of tumor cell death, elimination of regulatory T cells, and/or enhancement of tumor 
cell sensitivity to lysis by CTL may account for enhancement of immunotherapy 
by chemotherapy. On the other hand, immunotherapy may directly modulate the 
tumor’s sensitivity to chemotherapy (87). Indeed, results have suggested that MVA-
5T4 vaccination can be combined with chemotherapy (84). Recently, the CTLA-4 
blocking antibody ipilimumab has been successfully used in the treatment of mela-
noma patients (17). Also other monoclonal antibodies such as anti-PD-1 antibodies 
will become available in the near future. As single agent, anti-PD-1 antibodies may 
occasionally provide clinical benefit (88) Based on their mechanisms of action it is 
highly likely that these antibodies will synergize with strong vaccines as they will 
block the negative feed-back on vaccine-induced tumor-specific T cells.
The most recent vaccine developments suggest that some of the current vaccine 
strategies do harbor the capacity to induce strong immune responses in cancer 
patients even to self-antigens. In particular, we and others have found that the 
use of long overlapping peptides allow the activation of strong and broad T-cell 
immunity to HPV, p53, NY-ESO and HER2/neu (63,89,49,90-94). While these vac-















 activation of tumor-specific T-cell reactivity is no longer an issue of concern. How-
ever, other relevant questions remain:
± What are the tumor antigens recognized by tumor-infiltrating T-cells, and 
which antigens would be most appropriate in colorectal cancer?
± Does vaccination only enhance effector T-cells or also suppressive T-cells?
± Do vaccine-induced tumor-specific leukocytes migrate to the tumor and 
mediate an antitumor effect?
± Which cancer patients are most likely to benefit from immunotherapy?
Frame-shift mutated gene product-derived peptides, a class of tumor-
specific antigens
Despite many years of work, the number of antigens recognized by TILs of colo-
rectal cancer identified is limited (95-98). Consequently, vaccines so far have been 
developed on the basis of proteins that are selectively expressed by tumor cells 
but for which immunity can be blunted, such as p53 where the CD8 T-cell compo-
nent suffers from central tolerance, or may lead to autoimmunity such as has been 
observed with CEA (48,50). The exception comprises microsatellite instable (MSI-
H) tumors that, due to numerous of frameshift mutations in microsatellites express 
neo-antigens. MSI-H is a molecular feature of tumors associated with the familial 
Lynch or hereditary non-polyposis colorectal cancer (HNPCC) syndrome, account-
ing for approximately 5% of all colorectal cancer cases (99-101) and for approxi-
mately 15% of all sporadic colorectal, gastric and endometrial cancers, as well as at 
lower frequencies for various other sporadic cancers (102-106). MSI-H colorectal 
tumors are predominantly localized in the proximal colon, comprising 50% of all 
proximal colon tumors (107,108). Since frameshift mutated products (FSPs) are 
foreign to the immune system, they represent a unique group of tumor-specific 
antigens. No tolerance and consequently strong T-cell responses are expected 
against these FSPs. Unfortunately, relatively little is known on the immunogenic 
behavior of such FSPs (98). A few studies have been performed to predict the 
immunogenic behavior of a selection of frame-shift mutated genes which are fre-
quently detected in MSI-H cancers (98,109,110). We developed a methodology for 
predicting their immunogenic behavior that is based on accumulation and MHC 
class I presentation (109). Our data indicated that, out of the 15 FSPs examined in 
our study, 4 (TGFȕR2-1, MARCKS-1, MARCKS-2 and CDX2-2) are of primary inter-
est (109). Four additional antigens (TAF1B-1, PCNXL2-2, TCF7L2-2 and BaxĮ+1) are 
of moderate interest for further tumor immunological research (109). The data 
of others suggested that FSP-specific T-cells may be present in the circulation of 
patients with MSI-H colorectal cancer, healthy HNPCC syndrome mutation carri-
ers, but not in patients with microsatellite stable (MSS) colorectal cancer or in 
healthy donors (110,111). In general, most FSPs consist of a relatively small number 
of amino acids downstream of the frame-shift mutation, suggesting that the FSPs 
may contain a sequence that can only be presented by a limited number of HLA 
class I or HLA class II molecules. In order to treat patients, knowledge on which 








be obtained. Although MSI-H tumors comprise only about 15% of all colorectal 
tumors, patients with a MSI-H tumor are very interesting vaccination candidates 
because: 1) strong effector responses are expected after vaccination using non-
self-antigens; 2) colorectal cancer is one of the major cancers in the western world; 
and 3) many families with Lynch or HNPCC syndrome at risk for a MSI-H tumor 
have been identified. The latter group may be amenable for prophylactic vaccina-
tion to prevent the outgrowth of MSI-H tumors. Hence, a rapid identification of the 
immunogenic non-self-segment of the frame-shift products is required. Notably, 
the amino acid length of the frame-shift products make them perfect candidates 
for overlapping synthetic long peptide-based vaccines that have been shown to 
be highly immunogenic in rodents and human beings as we discussed above (56).
Does vaccination only enhance effector T-cells or also suppressive T-cells?
In contrast to animal models, the history of constant interactions between tumor 
and immune system shapes both tumor and the immune system of an individual 
patient in a way that is difficult to mimic in animal tumor models. It is of utmost 
importance that vaccines only boost the reactivity of immune cells that mediate an 
antitumor effect and not that of immune cells that support tumor growth. There-
fore, to gain a thorough understanding of the immunological events occurring in 
patients in vaccination trials it is in our opinion crucial to comprehensively perform 
immune monitoring during vaccination trials. The results from immune monitoring 
make it possible to understand possible clinical effects, to guide the optimization 
of vaccination strategies and may even encourage investigators to move the prod-
uct forward into the clinic (24). Unfortunately, most immunotherapeutic vaccine 
trials mostly report on one particular aspect of the desired immune response (e.g. 
HLA-multimer+ cells, IFN-Ȗ-producing cells). They do not include more detailed 
analyses of the total vaccine-modulated immune response. Colorectal cancers are 
infiltrated by both CD4+ and CD8+ Foxp3+ Tregs, and the number of Foxp3+ Tregs 
negatively correlates with disease stage and survival in colorectal cancer (112-114). 
Notably, the analyses of the antigens recognized by colorectal cancer infiltrat-
ing Tregs revealed that they recognized colorectal cancer-associated antigens, in 
particular Mucin, Her-2/neu, and CEA (96). Hence, therapeutic vaccination with 
these antigens may not only boost CD4+ and CD8+ effector T-cells but also the Treg 
population. Vaccine-induced expansion of such antigen-specific Tregs has been 
observed previously in a mouse tumor model (115) and also in humans (63). More 
specifically, in this study the magnitude of the vaccine-enhanced antigen-specific 
Treg response was related to clinical failure of an otherwise successful therapeutic 
vaccine for premalignant disease (116). In a trial conducted by our group, in which 
colorectal cancer patients were vaccinated with overlapping p53 long peptides, 
strong p53-specific CD4+ T-cell responses were found but this did not coincide with 
the expansion of p53-specific CD4+Foxp3+ T-cells (49). This fits with the observa-
tion that the spontaneous T-cell response to p53 in colorectal cancer patients is 
not under control of Tregs (96). In human beings several approaches have been 















been detected when patients with hepatocellular cancer were treated with low 
cyclophosphamide (118), as well as in metastatic melanoma patients treated with 
the anti-CD25 antibody Daclizumab (119), or after using denileukin diftitox (120). 
Whereas, the use of Daclizumab did not enhance the efficacy of the peptide-pulsed 
DC vaccine (119), mulitiple injections of deniluekin diftitox did result in enhanced 
CEA-specific T-cell responses (120).
Migration of tumor-specific T-cells
The success of immune responses partly depends on the ability of effector cells 
to infiltrate the cancer microenvironment and finally contact and attack tumor 
cells. As most TAA are intracellular proteins and results from observational studies 
show that especially presence of intra-epithelial activated CD8+ T-cells has a posi-
tive impact on prognosis (13), vaccine strategies should focus on the induction of 
tumor-specific CD8+ T-cell responses. The function of cytotoxic T-cells depends 
on a network of collaborating leukocytes. Consequently vaccines should create 
a CD8+ T-cell friendly and supportive cancer microenvironment. Data from other 
studies in colorectal cancer indicate that especially tumor-specific CD4+ Th1 cells 
are associated with a supportive cancer microenvironment that is beneficial to 
the prognosis of cancer patients (121-123). It has been well documented that CD4+ 
T-cells not only license the priming of tumor-specific CD8+ T-cells but are important 
to sustain their fitness (56). Moreover, tumor-specific CD4+ Th1 cells are needed for 
the production of IFN-Ȗ in order to modulate the local tumor microenvironment in 
such a way that it will produce chemokines that attract CD8+ T-cells (124,125). In 
addition, the IL-2 produced by these CD4+ Th1 cells enhances local CD8+ T-cell pro-
liferation and cytolytic function (125). Indeed chemokine expression as well as that 
of endothelial adhesion molecules and extracellular matrix has been associated 
with the migration of leukocytes into colorectal carcinoma (126-129). Vaccines can 
induce tumor-specific Th1 cells but they may make up only a minor population of all 
tumor-specific T-cells that are induced by therapeutic vaccines. In our series about 
60% of the patients vaccinated with the p53 SLP vaccine mounted p53-specific 
CD4+ T-cells that were able to produce IFN-Ȗ as measured by IFN-Ȗ ELISPOT (49). 
Assessment of all p53-activated CD4+ T-cells, by gating on the CD4+CD154+ T-cell 
population by multiparameter flow cytometry, however, revealed that the IFN-Ȗ-
producing population of T-cells was only in a minority of cases the major subset 
among the vaccine-induced p53-specific T-cells (49) suggesting that new trials 
should focus on improving the percentage of p53-SLP vaccine-induced Th1 polar-
ized T-cells in order to benefit from the local effect of tumor-specific Th1 cells.
Optimization of vaccination studies results in clinical success
Although many studies determined the induced immune response after immuni-
zation, no gold standard has been set to define clinical response after vaccina-
tion (130). Activation of the cellular arm of the immune system is seen as the first 
biological event after administration of immunotherapy, consequently determina-








been developed for immune monitoring: enzyme-linked immunosorbent spot 
(ELISA), carboxyfluorescein succinimidyl ester-based proliferative assays, HLA 
peptide multimer staining and flow cytometry-based tests. Unfortunately sub-
stantial variability in results among laboratories prohibits data reproducibility and 
prevents meaningful comparison among studies. Therefore initiatives have been 
put up to standardize immune monitoring and harmonize cellular immune assays. 
Harmonization will establish the use T-cell-based assays as a reproducible gold 
standard for immunotherapy and reliable parameter to determine the correlation 
between induced T-cell responses and clinical events. Under the auspices of the 
CIMT Immunoguiding Program (CIP), a working group founded under the aegis 
of the Association for Cancer Immunotherapy (CIMT) and the Cancer Immuno-
therapy Consortium under the auspices of the Cancer Research Institute (CRI) two 
large immune monitoring programs were initiated to provide a quality assurance 
process for laboratories conducting immune monitoring and harmonize assay per-
formance (131-133).
An important question that remains is which cancer patients are best candidates 
to study clinical endpoints once safety and immunogenicity of a therapeutic vac-
cine strategy have been established. So far most trials have included end-stage 
patients only. Although regression of tumor mass can be very convincing and 
objectively measured, vaccination of end-stage patients may present with several 
drawbacks that negatively influence the immunotherapeutic effect. Major draw-
backs are the suppressed immune status, the general short survival period that 
may obscure clinical effects of therapy at later time points (134), a large immuno-
suppressive tumor mass, variety of treatments before vaccination, and co-mor-
bidity. Therefore clinical endpoints might be best studied in an adjuvant rather 
than an end-stage setting. These patients, who have no measurable tumor mass 
and a relatively normal functioning immune system are expected to respond 
optimally to immunization. Classically, the clinical effects of therapeutic vaccines 
have been determined shortly after vaccination by Response Evaluation Criteria 
In Solid Tumors (RECIST) (130,135,136). These criteria depend on tumor shrinkage 
and were initially optimized for chemotherapeutical agents (130,135,136). Immuno-
therapeutics often demonstrate delayed clinical responses resulting in a delayed 
separation of Kaplan-Meier curves. To compensate delayed separation in statis-
tical models altered statistical models describing hazard ratios as a function of 
time and recognizing differences before and after separation of curves may allow 
improved planning of phase III trials (130). Especially for phase III trials if thera-
peutic vaccines are used in an adjuvant setting and consequently patients lack 
presence of tumor mass. Furthermore, the differences in immune-induced clinical 
response patterns when compared to those observed after treatment with cyto-
toxic agents (130), have led to the use of new immune-related response criteria 

















For many years vaccine strategies have failed to induce strong and broad immune 
responses in patients with cancer. New vaccine strategies and platforms have 
resulted in vaccines that are more powerful but still require optimization. In addi-
tion, vaccine strategies in colorectal cancer still suffer from a lack of antigens that 
may be used for vaccination. Whereas for other types of tumors the reactivity of 
tumor-infiltrating T-cells validate the choice of antigen used in the vaccines for that 
type of cancer, this is still limited in colorectal cancer and calls for more in-depth 
studies on the specificity of T-cells infiltrating the tumor or present in metastatic 
lymph nodes. In view of the increasing role of CD4+ T-cell help to the induction, sus-
tainment and migration of CD8+ T-cells, it is advisable to screen not only for CD8+ 
T-cell responses but also for tumor-specific CD4+ T cells. The absence of clearly 
defined antigens applicable to a majority of colorectal cancer patients may have 
provided the rationale to use tumor cell-derived vaccines to be tested in phase III 
trials. These have all failed to induce a statistical significant positive clinical reac-
tion. The failure to show clinical efficacy may have been the result of delayed clinical 
reactivity also seen with other immunotherapeutic approaches but is more likely 
to reflect poor immunogenicity. Due to the absence of defined clinically important 
antigens it will be hard to perform studies showing that immunogenicity of these 
types of vaccines can be improved. Unfortunately, defined tumor antigen-based 
vaccines have not been tested in a phase III study. Their design, however, will not 
only provide the opportunity to fully optimize their activity under all sorts of condi-
tions, but also allows studying their effects locally within the tumor. Still such vac-
cines may be unsuccessful due to all sorts of reasons that play a role in colorectal 
cancer, including the fact that colorectal cancer can evolve via several different 
routes. To obtain proof-of-concept, the immunotherapy of colorectal cancer may 
want to concentrate on the treatment of tumors with microsatellite instability as 
they are known to be heavily infiltrated by T cells and express tumor-specific anti-
gens that are derived from frameshift-mutated gene products.
FIVE-YEAR VIEW
There is a clear role for tumor-specific T-cell immunity in the final clinical outcome 
of colorectal cancer. Hence, a continued effort will be put in the development of 
vaccines and vaccine strategies against colorectal cancer. Despite that some of the 
current vaccines are able to induce strong antigen-specific immune responses in 
the absence of serious adverse events, there is hardly any evidence generated to 
show the clinical impact of these vaccines in patients with colorectal cancer. The 
current successes in the treatment of cancer by activation of the host’s immune 
system has spirited studies aiming to improve the clinical impact of colorectal 
cancer vaccines. It is not likely that colorectal cancer vaccines are able to induce 








Key issues in the development of anti-cancer-vaccines for colorectal cancer patients:
± Vaccines used in clinical trials to treat colorectal cancer patients are safe and immunogenic.
± The vaccines used lack clinical effect or have not been tested for efficacy.
± T-cell based immunotherapy has been shown to mediate clinical effects in other cancer types.
± To obtain clinical results in colorectal cancer vaccine strategies may require to: 
± Select truly tumor-specific antigens;
± Enhance the number of effector T cells but not that of suppressive T cells; 
± Create a T cell friendly and supportive cancer microenvironment;
± Combine vaccination with other immune stimulating treatment modalities;
± Vaccinate patients in the adjuvant setting and not end-stage patients;
± Harmonize immune monitoring to allow comparison of trial data and to boost the 
development of working strategies.
± Persons with MSI-H colon cancer or at risk for MSI-H tumors comprise a unique opportunity 
for respectively therapeutic or prophylactic vaccination using non-self frameshift-mutated 
peptides.
modalities that target regulatory mechanisms in order to improve the local micro-
environment. The current wealth of preclinical and clinical information predicts 
a future strategy in which therapeutic vaccines, blockers of immunosuppressive 
mechanisms and conventional therapies are applied jointly to overcome immuno-
logical tolerance and promote tumor regression. It will not be trivial to synchronize 
all the different treatment modalities but help may come from the generation of 
immunological data sets analysing the supposed mechanism of action as well as 
that of non-desired immune reactions expected to occur by the treatment modali-
ties. As most trials in colorectal cancer are currently performed by small biotech-
nology companies or even academic institutes, we will see that they will harmonize 
their immune monitoring efforts in order to fully profit from the results generated 
by vaccination strategies that use different additional treatment modalities. We 
anticipate and endorse that most of the financial power will flow into phase I/II 
trials synchronizing a multimodality treatment to enforce local antitumor reactiv-
ity. This means that the move from phase I/II trials to phase III trials, which are a 
prerequisite to establish efficacy of T-cell mediated immunotherapy for colorectal 
cancer patients is not likely to happen soon, but may follow a few years from now.
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Purpose: We previously established safety and immunogenicity of a p53 synthetic 
long peptides (p53-SLP®) vaccine. In the current trial we investigated whether 
combination of Interferon-alpha (IFN-Į) with p53-SLP® is both safe and able to 
improve the induced p53-specific IFN-Ȗ response.
Experimental design: Eleven colorectal cancer patients successfully treated for 
metastatic disease were enrolled in this study. Of these, nine patients completed 
follow up after two injections with p53-SLP® together with IFN-Į. Safety and 
p53-specific immune responses were determined before and after vaccination. 
Furthermore, cryopreserved PBMCs were compared head-to-head to cryopre-
served PBMCs obtained in our previous trial with p53-SLP® only.
Results: Toxicity of p53-SLP® vaccination in combination with IFN-Į was limited to 
grade 1 or 2, with predominantly small ongoing swellings at the vaccination site. All 
patients harbored p53-specific T cells after vaccination and most patients showed 
p53-specific antibodies. Compared to the previous trial, addition of IFN-Į signifi-
cantly improved the frequency of p53-specific T cells in IFN-Ȗ ELISPOT. Moreover, 
in this trial, p53-specific T cells were detectable in blood samples of all patients 
in a direct ex vivo multiparameter flowcytometric assay, opposed to only 2 out of 
10 patients vaccinated with p53-SLP® only. Finally, patients in this trial displayed 
a broader p53-specific immunoglobulin-G response, indicating an overall better 
p53-specific T-helper response.
Conclusions: Our study shows that p53-SLP® vaccination combined with IFN-Į 
injection is safe and capable of inducing p53-specific immunity. When compared 
to a similar trial with p53-SLP® vaccination alone the combination was found to 









The modest to poor prognosis of colorectal cancer patients treated with curative 
intent, calls for additional treatment modalities such as immunotherapy (1).
p53 is one of the most frequently used tumor-associated antigens in tumor directed 
vaccination studies (2). Due to a mutation, p53 is inactivated and over-expressed 
in 34-45% of colorectal tumors, while wild-type p53 is expressed at extremely low 
levels (3). This provides an appropriate immunological window for T cells, being 
targeted to p53, to discriminate between tumor cells and normal cells (4).
A clinical-grade p53 synthetic long peptides (p53-SLP®) vaccine was developed 
that was tested in two parallel phase I/II studies in colorectal and ovarian cancer 
patients (5-7). Results from these first trials revealed that in the vast majority of 
vaccinated cancer patients mainly p53-specific CD4+ T cells were induced (6,7).
The presence of tumor-specific CD4+ T cells in the cancer microenvironment is a 
prerequisite for support, proliferation, recruitment and cytolytic function of tumor-
specific CD8+ T cells, greatly accelerated by the production of IFN-Ȗ and IL-2 (8-10). 
Patients with metastatic colorectal cancer vaccinated against the tumor antigen 
5T4 were found to have more clinical benefits when 5T4-specific IFN-Ȗ ELISPOT 
responses were induced (11). Also, in women with human papillomavirus (HPV) 
positive vulvar intraepithelial neoplasia, complete responses after vaccination 
against HPV were positively associated with the induction of IFN-Ȗ-producing 
and proliferative T-cell responses (12). Together, these data suggest that clinical 
responses after vaccination depend on the induction of strong and broad vac-
cine-specific type 1 T-cell responses. Results from the first two trials with p53-
SLP® showed that vaccine-induced type 1 T-helper (Th1) cells produced only low 
amounts of the key cytokines (i.e. IFN-Ȗ and IL-2), indicating that tumor-induced 
p53-specific Th-responses are present but not properly polarized (6,7). Therefore, 
in order to benefit from the tumor-specific Th cells at the tumor site, the p53-SLP® 
should be combined with immune modulating adjuvants that specifically induce 
Th1-cell polarization. A possible candidate adjuvant to achieve this is Interferon-
alpha (IFN-Į).
IFN-Į is used to treat patients suffering from chronic viral hepatitis infection and 
different malignancies (13). IFN-Į plays a major role in the differentiation of the 
Th1 subset, the generation of CTL and the promotion of proliferation and survival 
of T cells (14,15). Moreover, several studies have shown that type I IFNs promote 
the differentiation of monocytes into dendritic cells (DC) and enhance DC activ-
ity (16-21). In a murine melanoma model, it was shown that addition of IFN-Į to a 
gp100 peptide, suppressed melanoma growth and increased the accumulation and 
proliferation of gp100-specific, IFN-Ȗ-secreting CD8+ T cells (22). Moreover, adop-
tive transfer of tumor-reactive T cells and daily injections of IFN-Į in metastatic 
melanoma patients can lead to successful treatment of metastatic melanoma (23). 
In humans, peptide vaccination has been combined with IFN-Į injections show-
ing that the combination was safe, resulted in a consistent enhancement of vac-


















precursors (24). We now report the results of a phase I/II trial addressing safety 
and immunogenicity in which successfully treated metastatic colorectal patients 
were subcutaneously vaccinated with p53-SLP® in combination with subcutane-
ous administration of IFN-Į. In addition, we analyzed whether addition of IFN-Į 
close to the vaccine site not only induced a stronger p53-specific but also a better 
polarized Th1 response by testing and comparing cryopreserved peripheral blood 
mononuclear cells (PBMCs) and serum samples of the current trial head-to-head to 
samples obtained in our previous clinical trial, in which a similar group of colorectal 
cancer patients were vaccinated with the p53-SLP® vaccine only (6).
PATIENTS, MATERIALS AND METHODS
Patients, vaccination scheme and safety and tolerability monitoring
Colorectal cancer patients who were successfully treated with metastasectomy, 
chemotherapy and/or Radiofrequency Ablation (RFA) for disease metastasis to 
the liver and/or the lung were accrued during their follow up visits at the surgical 
oncology out-patient clinic into this phase I/II trial. Primary endpoint of this study 
was safety and immunogenicity of the p53-SLP® in combination with administra-
tion of IFN-Į. The secondary endpoint was to assess whether this combination 
is able to induce an overall significantly stronger p53-specific Th1 response than 
observed in the group of patients vaccinated in our previous trial (6). Patient eligi-
bility criteria for in- and exclusion and the study design, including the vaccination 
schedule (twice vaccinated with a three week interval), were identical to those used 
in the previously performed clinical trial with p53-SLP® (6), with the exception that 
in the current study one hour after each vaccination pegylated interferon-alpha-2b 
(Pegintron, 1 µg/kg body weight, Schering-Plough, the Netherlands) was injected 
within 10 centimeters proximity to the vaccination site. Furthermore, patients were 
discharged within one hour after they received their Pegintron injection. The study 
design was approved by the Central Committee on Research Involving Human 
Subjects in The Hague, the Netherlands (NL24089.000.08) and by the medical 
ethical committee of the Leiden University Medical Center. All patients gave their 
written informed consent before they were enrolled in the study.
Patients were asked to monitor and report any adverse event (AE) including fever 
(temperature measured at home either orally or anally above 38OC). Prompted 
and spontaneous AEs, injection site reactions, clinical assessments, and clinical 
laboratory variables were monitored during all visits as reported previously (25). 
Injection site reactions were defined as pain, redness, itch and calor on a scale of 
0-3 (0 being no reaction, 1 as mild, 2 as moderate and 3 as a severe reaction). Local 
swelling was measured bi-directionally in cm. Before each vaccination the medi-
cal history was taken and blood was drawn (both for safety and immunological 










Patient characteristics of patients enrolled
Patient
Number














p21 M 44 1 Rectum Liver,LR PR/RTx/CTx/Rlu/
CTxLu
Alive (14) 2
p22* F 57 4 Sigmoid 
colon
Liver PR/CTx/Rli Withdrew 
consent
X
p23 M 60 4 Rectum Lung PR/RTx/CTx/Rlu/
CTxlu/RFA
Alive (2) 3
p24 F 61 3 Rectum Liver PR/RTx/Rli/CTx/
RFA
Alive (12) 2
p25 F 50 4 Sigmoid 
colon
Liver PR/Rli/CTx/RFA Alive (12) X
p26 M 52 4 Rectum Liver PR/Rli/CTx Alive (2) 3
p27 M 60 4 Cecum Liver PR/Rli/CTx/CTxli/
RFA
Death (5) 1
p28* M 64 4 Rectum Liver PR/RTx/CTx Withdrew 
consent
X
p29 M 65 4 Rectum Liver PR/RTx/CTxli/
RFA/Rli
Alive (7) 1
p30 F 64 3 Ascending 
Colon
Liver PR/CTx/Rli Alive (4) 2
Abbrevations: TNM: Tumor Node Metastasis Stage at time of diagnosis primary tumor. F; female. 
M; male. Lr: local recurrence. RTx; neo-adjuvant radiotherapy, Pr; primary resection. CTx; (neo) 
adjuvant chemotherapy. CTxlu; isolated lung perfusion, CTxLi: isolated liver perfusion, Rlu; resection 
lung lesion. Rli; resection liver lesion. RFA: radiofrequency ablation. NED; no evidence of disease 
(months between second vaccination and disease recurrence or last follow up date). P53 status 
immunohistochemistry (IHC). 1: expression of p53 in <25% of the tumor cells; 2: expression of p53 in 
t25% but <75% of the tumor cells; 3: expression of p53 in t75% of the tumor cells; X: no material was 
available for IHC. *Patient number 22 withdrew consent after the first vaccination due to adverse 
event (table 2). Patient number 28 withdrew consent before the first vaccination.
Vaccine
The clinical-grade peptides (9 peptides of 20-30 amino acids long with an overlap 
of 5-14 amino acids) were synthesized at the Department of Clinical Pharmacy and 
Toxicology, Leiden University Medical Center (LUMC), the Netherlands, together 
representing the part of the p53 protein from amino acid positions 70 to 235. In 
comparison to our previous trial one long peptide (i.e. the peptide with amino acid 
sequence 224-248) was not included in the current vaccine mixture, because yields 
of the synthesis and purification of this peptide were very low. At the day of vac-



















The expression of p53 by colorectal tumor cells was determined in the available 
paraffin-embedded metastatic tissue of the vaccinated patients by standard two-
step indirect immunohistochemical staining as described previously (6). The per-
centage of tumor cells expressing p53 (nuclear expression), together with internal 
control, was estimated and categorized into three groups: (1) expression of p53 in 
<25% of the tumor cells; (2) expression of p53 in t25% but <75% of the tumor cells; 
(3) expression of p53 in t75% of the tumor cells.
P53-peptide ELISA for IgG antibodies
Serum samples (pre-vaccination and 3 weeks after the second vaccination) of 
the colorectal cancer patients from both trials were subjected to a p53-peptide 
ELISA for detection of p53 peptide-specific immunoglobulin G (IgG). A 96-wells 
plate (Costar 3590) was coated overnight at 4oC with the individual p53 peptides 
(30-mers, 14 amino acids overlap; 50µl of 1µg/ml diluted in 0.1M carbonate/bicar-
bonate coating buffer; Merck, Darmstadt, Germany). Then, the plate was washed 
6 times with phosphate buffered saline (PBS; Fresenius Kabi Bad Homburg, Ger-
many) +0.05% Tween (Merck) and blocked for 1 hour at room temperature (RT) in 
100µl/well PBS+0.05% Tween+0.1% bovine serum albumin (BSA; Sigma Aldrich, 
St Louis, MO, USA), which is assigned as blocking buffer. After 6 washings with 
PBS+0.05% Tween, the serum samples diluted in blocking buffer (1:100) were 
added to triplicate wells (50 µl/well) and incubated at RT for 2 hours. The plate 
was washed again and 50 µl/well of goat anti-human IgG-Horseradish peroxidase 
(HRP; Southern Biotechnology, Birmingham, AL, USA) (diluted 1:3000 in blocking 
buffer) was added and incubated for 1 hour at RT. Finally, after the 6 washings 
tetramethyl-benzidine liquid substrate (50 µl/well TMB, Sigma Aldrich) was added 
for the colorimetric enzymatic reaction. This reaction was stopped by adding 50 
ȝl/well of 2M H2SO4 (Merck) and the plate was read in an ELISA reader at 450 nm. 
A cut-off value was calculated to define a positive response. For this the aver-
age OD-value plus 2xSD of the triplicate wells for all 12 peptides per plate in a 
pre- or post-vaccination serum sample was calculated. All OD-values above this 
cut-off value were discarded and again the average+2xSD was calculated with the 
remaining OD-values. This process was repeated until all OD-values were below 
the last calculated cut-off value. At least 2 of the 3 OD-values per triplicate pep-
tide test needs to be above this cut-off value, then a peptide was considered to 
yield a positive response, i.e. is recognized by specific IgG in the serum. A 2-fold 
increase of the post-vaccination serum sample over that of the pre-vaccination 
serum sample was considered a vaccine-induced positive response and calculated 
as fold induction. The average number of vaccine-induced positive responses for 
the individual peptides was determined in the group of patients from both clinical 
trials. Subsequently, the number of positive peptide reactions per patient and an 
overall response rate (the number of positive peptides divided by the total number 








We acknowledge the concept of the Minimal Information About T-cell Assays 
(MIATA) reporting framework for human T-cell assays (26,27).
Cell samples
Hundred mL of heparine blood was drawn prior to vaccination and 3 weeks after 
the second vaccination. PBMCs were isolated using Ficoll density gradient cen-
trifugation within 2 hours, washed with PBS, resuspended in cold Fetal Calf Serum 
(FCS; PAA Laboratories, Pasching, Austria) and cooled on ice for 15 minutes. After 
drop-wise addition in a 1:1 ratio of freezing medium (80% FCS and 20% DMSO 
(Sigma Aldrich)), the PBMCs were cryopreserved at 10 million per ml per vial using 
an automated controlled rate freezer (Cryosolutions, ’s Hertogenbosch, The Neth-
erlands), and stored in equal aliquots in a vapor phase liquid nitrogen vessel until 
use. The handling and storage of the PBMCs were done according to the stand-
ard operation procedures (SOPs) of the department of Oncology at the LUMC by 
trained personnel.
Antigens
Overlapping peptides (30-mers with 14 amino acids overlap) covering the entire 
p53 protein were synthesized at the department of Clinical Pharmacy and Toxi-
cology, LUMC, with >95% purity (28), dissolved in DMSO at 50 mg/mL and fur-
ther diluted in PBS to obtain a concentration 0.5 mg/mL (in PBS/1% DSMO). The 
clinical-grade peptides of the vaccine were used in the immune monitoring assays. 
PHA (HA16; Murex BioTech,Kent, UK) and memory response mix (25,29) was taken 
along as a positive control.
T-cell assays and data acquisition
The PBMCs were tested for p53-specificity by a set of complementary T-cell 
immune monitoring assays including: IFN-Ȗ ELISPOT, lymphocyte stimulation 
test (LST) and cytometric bead array (CBA), all as previously described (6). Fresh 
PBMCs and T cells cultured out of the vaccination site biopsy were also subjected 
to the directly ex vivo intracellular cytokine staining (ICS) and analyzed as previ-
ously described (6). In this study the cells were stained for the following markers: 
CD3, CD4, CD8, CD154, CD137, IL-2 and IFN-Ȗ (6,30). For a fair comparison with the 
results of our previous trial with metastasized colorectal patients vaccinated with 
p53-SLP® only, cryopreserved PBMCs from both trials were thawed and subjected 
to our novel ICS assay (25) under the same conditions. As higher concentrations 
of the peptides (i.e. 50 µg/mL) were required in this new ICS assay the non-clinical 
grade peptides covering the complete p53 protein were used.
Data analysis and interpretation
A positive response is predefined per assay and described previously (6). For all 
T-cell assays, a vaccine-induced response was defined as at least a 3-fold increase 
in the response after vaccination when compared to the results before vaccination. 


















The Fisher’s exact test or the Mann-Whitney test were used to evaluate differences 
in patient characteristics between patients included in the current and the previous 
trial with the p53-SLP® vaccine. The Mann-Whitney test was also used to evaluate 
the difference in number of IFN-Ȗ-producing T cells, the level of IFN-Ȗ produc-
tion and to compare the difference in antibody responses between the two study 
cohorts.
Laboratory environment
The immunomonitoring assays were performed in the laboratory of the depart-
ment of Clinical Oncology (LUMC) that operates under research conditions, follow-
ing SOPs and using trained staff. This laboratory has participated in all proficiency 
panels of the CIMT Immunoguiding Program (CIP) (http://www.cimt.eu/work-
groups/cip/), as well as in IFN-Ȗ ELISPOT panels of the Cancer Immunotherapy 
Consortium (31,32), to validate its SOPs.
RESULTS
Patient characteristics
Eleven colorectal cancer patients were enrolled in this study, 9 of whom completed 
all follow-up visits. The clinicopathological characteristics are displayed in table 1. 
None of these patients showed evidence of any macroscopic disease at enrollment. 
Six out of 9 patients were male. The average age of the 9 patients vaccinated twice, 
was 58 years. Over-expression of p53 in the tumor (i.e. t25% of the tumor cells 
express p53) was found in 6 patients, while normal p53 expression (i.e. in <25% of 
the tumor cells) was observed in 2 patients (p27, p29). Of 3 patients, the p53 status 
was not determined because no tumor material was available (p25) or because 
they prematurely withdrew consent (p22, p28).
Safety of the vaccine
The AEs of all vaccinated patients are summarized in table 2. All patients reported 
swelling confined to the vaccination site. In the majority of the cases the induration 
occurred after both vaccinations and was still present at the final check-up visit 
around 28 weeks after the first vaccination. The average size of these swellings at 
the first vaccination site was 3.3 cm and at the second site 3.5 cm. Four patients 
reported fever post vaccination, but it never lasted longer than 1 day. One patient 
also suffered from flu-like symptoms after both vaccinations for one day. Only two 
patients reported pain at the vaccination sites. None of the patients reported any 
pain, swelling or other changes of the skin at the IFN-Į injection site. Only patient 
p22 experienced an AE exceeding grade I toxicity based on the Common Terminol-
ogy Criteria (CTC) for AE version 4.0. This patient already experienced pain before 
vaccination in her left arm. After first vaccination, she experienced local swelling 
classified as an AE grade 1 and pain throughout her entire left arm, classified as an 









Adverse events of patients enrolled
Patient AE description Relation Action CTC Type Duration
p20 Swelling at site 1











p21 Swelling at site 1
Swelling at site 2
Pain at both site 1,2






















p22 Swelling at site 1











p23 Swelling at site 1











p24 Swelling at site 1
Fever after vaccination 1
















p25 Swelling at site 1











p26 Swelling at site 1
Fever after vaccination 1
















p27 Swelling at site 1
Fever after vaccination 1
















p29 Swelling at site 1#











P30 Swelling site 1
Swelling at site 2
















Table 2 reports all adverse events (AE) recorded for each patient included in this trial during the 
entire follow up period. AE were detected either at site 1 (the site of the first vaccination) or at site 2 
(the site of the second vaccination). No AEs were reported with respect to the injection site of either 
the first or the second IFN-Į administration. The heading AE provides a description of all the AE 
reported on in each patient. For each EA it is stated whether there was a plausible relation of the 
AE to the vaccination and whether the AE required any actions of the trial coordinator. All AEs were 
graded according to the Common Terminology Criteria for Adverse Events v4.0 as published by the 
EORTC (www.eortc.org). Grade I implicates mild AE defined as asymptomatic or mild symptoms; 
clinical or diagnostic observations only; intervention not indicated. Grade II implicates moderate 
AE defined as minimal, local or noninvasive intervention indicated; limiting age-appropriate 
instrumental activities of daily living. Grade III or IV AEs were not observed during this trial. The 
heading Type reports on how the AE was diagnosed; this was either at the injection site (Type I), as 
a systemic response (Type 2), in the laboratory (Type 3) or otherwise such as pain which cannot be 
objectified (Type 4). Finally the duration of the AE was listed. The description “Ongoing” implicates 
that the AE was still present at the final follow up visit. Patient number 28 was not mentioned in this 
table because consent was withdrawn before vaccination 1 and therefore no AE were recorded.
# The swelling did not occur until 1.5 weeks after the first vaccination. In all other cases the swelling 
post vaccination occurred directly or within 1 hour after vaccination. * Because of the pain in the arm 
after the first vaccination p22 withdrew consent to participate in the trial. The patient stated that this 
exact pain had also been present before the vaccination but because of the swelling and the fear of 


















We have previously vaccinated 10 patients with the p53-SLP® vaccine but with-
out the administration of IFN-Į (6). Clinicopathological parameters of both trial 
cohorts were similar (table 3). In the current trial all patients developed ongoing 
swelling at either one or both peptide vaccination sites visible at the final check-
up visit (28 weeks after first vaccination), which contrasts with the previous trial 
in which only one patient showed inflammation at the p53-SLP® injection site. In 
conclusion, addition of IFN-Į to the p53-SLP® resulted in prolonged and increased 
inflammation at the vaccination site, suggesting that addition of IFN-Į promotes 
inflammation at p53-expressing sites after injection of p53-SLP®.
p53-SLP® and IFN-Į injection elicit both proliferative and IFN-Ȗ producing 
p53-specific T cells
Using PBMCs isolated from blood samples taken before and after the second vac-
cination, three complementary T-cell assays (LST, CBA and IFN-Ȗ ELISPOT) were 
performed to monitor the immunogenicity of p53-SLP® combined with IFN-Į injec-
tion. After the two vaccinations, 4 (p25, p26, p29, p30) out of 9 patients showed 
vaccine-induced proliferative responses as determined by LST. All 4  patients 
responded against peptide pool 5, whereas for patients p25 and p26 also responses 
against peptide pool 3 and in the case of p29, against peptide pool 4 were detected 
(figure 1A). Based on our cutoff criteria, PBMCs of patient p21 displayed a prolifera-
tive response against p53 peptide pools 1 and 6 at baseline that disappeared after 
vaccination. Patient p27 showed a positive proliferative response against peptide 
pool 6 after vaccination. However, this response was not induced by vaccination 
as it may have already been present at baseline, although just below the cut-off. 
Except for patients p20 and p24, a proliferative response against the recall anti-
gens in the memory response mix was detected both at baseline and after vaccina-
tion (data not shown).
Supernatants isolated at day 6 from the cultures of all PBMC samples tested in the 
LST were used for the analysis of antigen-specific production of cytokines (IFN-Ȗ, 
TNF-Į, IL-2, IL-4, IL-5, and IL-10) by CBA. After vaccination, 6 out of 9 patients (p20, 
p23, p24, 25, p26, p30) showed detectable induction of IFN-Ȗ (median 55, aver-
age 134; range, 26 – 618 pg/mL). IFN-Ȗ production was induced by the vaccine as 
shown upon stimulation of PBMCs with peptide pool 1 (p26), pool 2 (p24), pool 3 
(p20, p24, p25, p26), pool 4 (p24, p30) and/or pool 5 (p20, p23, p25, p26) (fig-
ure 1B). One patient (p21) showed IFN-Ȗ production against peptide pool 5 follow-
ing vaccination, however, also displayed production of this cytokine already prior 
to the vaccinations. Moreover, the IFN-Ȗ production at baseline was mainly found 
after stimulation with p53 peptide pools 1 or 6 in patients p21 and p25 (median 
251, average 220; range, 23 – 505 pg/mL) (figure 1B). Vaccine-induced produc-
tion of TNF-Į, albeit at very low amounts, was detected in PBMCs of patients p25, 
p26, and p27 (median 48, average 75; range, 22 – 175 pg/mL). IL-5 production was 
found in patients p20, p24, p25, p26 (median 33, average 40; range, 22 – 74 pg/
mL) and IL-10 in patient p20, p24, p25 and p26 (median 28, average 30; range, 21 









Results of three complementary T-cell assays with either freshly isolated PBMCs: (A) LST and 
(B) INF-ܵ in CBA, or cryopreserved PBMCs: (C) INF- ܵ ELISPOT results are depicted for each 
individual patient (n=9) before vaccination (prevaccination; left) and 3 weeks after vaccination 
(postvaccination; right); each peptide pool is represented by a symbol. (A) Proliferative responses 
upon stimulation with the indicated peptide pools of p53 are depicted as stimulation index (SI); 
a SI  3 (indicated line) was defined as a positive reponse. (B) Concentration of INF- ܵ (pg/ml) as 
measured by CBA in the supernatants isolated at day 6 from the proliferation assay; production of 
 20 pg/ ml (indicated line) was defined as a positive respons. (C) INF- ܵ ELISPOT results; number of 
T cells per 105 PBMCs specifically producing a spot of the cytokine INF- ܵ after stimulation with the 
indicated p53 peptide pools are shown; antigen-specific T-cell frequencies were considered to be 
positive when specific T-cell frequencies were  10 of 105 PBMCS (indicated line)
was consumed by the cells during the 6 days of culture. In none of the cultures, IL-4 
could be detected.
The IFN-Ȗ ELISPOT assay was used to determine the number of IFN-Ȗ produc-
ing p53-specific T cells. In all patients, p53-SLP® vaccination combined with IFN-Į 
injection induced p53-specific T-cell responses (figure 1C). Up to 162 specific spots 
per 105 PBMC against at least one of the vaccine-representing p53 peptide pools 
were found. Out of 9 patients, 6 patients (p20, p21, p23, p24, p25, p26) displayed 
an IFN-Ȗ-associated T-cell response to at least 3 or 4 peptide pools that repre-
sented the vaccine (Figure 1C). In patients p20 and p21, IFN-Ȗ-producing T cells 
were detected in the baseline samples mainly against peptide pools 1 and/or 6 
that represented peptides outside the vaccine pool of peptides. These responses 
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Ex vivo measurement of the percentage 
of p53-specific activated T cells, and their 
production of IFN-Ȗ and IL-2, as determined by 
multiparameter flow cytometry. Freshly isolated 
PBMC of patients before the first and three 
weeks after second vaccination were directly 
ex vivo intracellularly stained after an overnight 
stimulation with medium or peptide pools p53.2 
to p53.5. A, depicts ICS results from patient p20 
pre- and post-vaccination. Freshly isolated PBMCs were directly ex vivo stained after incubation in 
medium or stimulation with p53 peptide pools. Depicted are the IL-2 and/or IFN-Ȗ-producing cells in 
the CD3+CD4+ (upper) or CD3+CD8+ (lower) T-cell population. The numbers in the quadrants indicate 
the percentage (%) of positive cells within this population. B, displays percentages (%) of p53 
specific CD4+ T-cells stained positively with the activation markers CD154 and/or CD137; results are 
given for before (left side) and after vaccination (right side). C and D, display the percentages IFN-Ȗ+ 
and IL-2+ activated CD4+ T-cells, respectively split up for the activation markers CD137 and/or CD154, 








T-cell response to the positive control (memory response mix; data not shown). 
In contrast to patients with p53-negative tumors determined by immunohisto-
chemstry (p27, p29), higher vaccine-induced cytokine levels were found in patients 
that exhibited p53-positive tumors, as determined by CBA and IFN-Ȗ ELISPOT. In 
conclusion, the three immune monitoring assays showed that injection of IFN-Į 
in close proximity of the p53-SLP® vaccine induced p53-specific IFN-Ȗ-producing 
T cells in all cases.
Intracellular cytokine staining (ICS) detects p53-specific activated T-cells 
capable of producing IFN-Ȗ/IL-2
To phenotype and enumerate p53-specific T cells, freshly isolated PBMCs from 
blood samples drawn before the first and after the second vaccination were 
directly ex vivo stimulated overnight with p53 peptide pools, followed by analysis 
of the expression of the T-cell markers: CD3, CD4 and CD8; in combination with 
the T-cell activation markers: CD137 and CD154; and cytokines: IFN-Ȗ and IL-2 by 
multiparametric flow cytometry (figure 2A). In 8 of the 9 vaccinated patients an 
increase in the percentage of p53-specific CD4+ T cells expressing CD137 and/or 
CD154 was found after vaccination (figure 2B). In general, the production of the 
cytokines IFN-Ȗ (figure 2C) and/or IL-2 (figure 2D) in these activated cells was also 
boosted after vaccination. Notably, the CD4+ T cells of patient p24 displayed CD137 
and CD154 expression before vaccination, suggesting that this patient already had 
a pre-existing response to p53, however, only after vaccination these activated 
T cells produced IFN-Ȗ and IL-2 (figures 2B, 2C, 2D). In 1 out of the 9 tested patients 
(p20) activated CD8+ T cells, which also produced IFN-Ȗ, were detected in the 
freshly isolated PBMCs obtained after two vaccinations (figure 2A).
T cells cultured from skin biopsies harbor p53-specific reactivity
From 6 out of 9 skin biopsies taken from the second vaccination site sufficient 
T cells could be cultured to perform multiparametric flow cytometry using the same 
markers as described above for PBMCs. The CD4+ T cells from 5 out of these 6 skin 
biopsy cultures (p25, p26, p27, p29, p30) displayed elevated expression levels (at 
least twice the non-stimulated sample) of the activation marker(s) upon stimula-
tion with p53-SLP® vaccine-specific peptides (figure 3A); a median frequency of 
21% CD137+ and/or CD154+CD4+ T cells could be observed in the p53-peptide stimu-
lated samples versus 2.2% in the non-stimulated T-cell culture control. The vast 
majority of these activated CD4+ T cells produced IFN-Ȗ and/or IL-2 (figures 3B and 
3C). Moreover, in biopsies from 3 patients (p25, p26 and p30) both p53-specific 
IFN-Ȗ producing CD4+ and CD8+ T cells were found (figure 3D).
Addition of IFN-Į to p53-SLP® results in increase of IFN-Ȗ producing p53-
specific CD4+ T cells
The characteristics of the two patient cohorts vaccinated in the current and our 
previous trial are generally similar (table 3), thereby allowing us to compare the 



















Measurement of the percentage of p53-specific activated T cells cultured from skin biopsies of the 
p53-SLP® injection site, which produce IFN-Ȗ and, or IL-2, as determined by multiparameter flow 
cytometry. These cultured T cells were incubated in medium or stimulated with peptide pools p53.2 
to p53.5. A, displays percentages (%) of CD4+ T cells stained positively with the activation markers 
CD154 and/or CD137. B and C, respectively display the percentages IFN-Ȗ+ and IL-2+ activated CD4+ 
T-cells split up for the activation markers CD137 and/or CD154. D, depicts the ratio of IFN-Ȗ+CD8+ 
T-cells of p53 peptides versus medium stimulated T cells. The line indicated a 2-fold increase; > 
2-fold increase is defined as a positive response.
modalities in terms of their immunogenicity, with the limitation that the two vac-
cine modalities were not directly compared in the same trial.
To enable comparison of the results with those from the first trial, available cryo-
preserved PBMCs from patients in the first clinical trial (i.e. p01, p02, p03, p04, 
p07, p10, p11), vaccinated with p53-SLP® only, and cryopreserved PBMC samples 
from the patients in the current trial were thawed and subsequently head-to-head 
tested in a direct ex-vivo ICS assay, optimized for detecting both antigen-spe-
cific CD4+ and CD8+ T-cell responses in one single cryopreserved PBMC sample 
using long overlapping peptides as antigens (25) (figures 4A-D). In PBMCs from 
patients receiving p53-SLP® in combination with IFN-Į not only significantly more 
CD154+CD4+ were found (p=0.002), but also a significantly higher frequency of 
these activated CD4+ T-cells produced IFN-Ȗ (p= 0.008), when compared to the 
activated CD4+ T cells isolated from patients that received the p53-SLP® vaccine 
only. Importantly, in 4 out of 9 patients (p20, p25, p27 and p29), who received p53-
SLP® and IFN-Į, also low numbers of IFN-Ȗ-producing CD8+ T-cells were found, 
while patients vaccinated with p53-SLP® only, showed no p53-specific CD8+ T-cell 














Sex (%male) 8 (80%) 6 (68%)















































CEA (screening, average) 3,7 2.2
Abbreviations: TNM: Tumor Node Metastasis Stage at time of diagnosis primary tumor. p53 status 
IHC. 1: expression of p53 in <25% of the tumor cells; 2: expression of p53 in t25% but <75% of the 
tumor cells; 3: expression of p53 in t75% of the tumor cells. * in patients vaccinated with p53-
SLP® and IFN-Į there was insufficient tissue present for IHC in 3 patients. CEA: Carcinoembryonic 
Antigen.
of liquid nitrogen, reacted similarly over a period of at least 4 years indicating that 
the influence of cryopreservation time is unlikely (data not shown).
ELISPOT plates from the previous trial were reanalyzed using the same ELISPOT 
reader conditions as the current trial to obtain a fair comparison. Addition of 
IFN-Į to the p53-SLP® clearly results in a broader response per vaccinated patient 
(figure 5A). Patients that were injected with both p53-SLP® and IFN-Į showed a 
significantly higher median frequency of IFN-Ȗ producing T cells after vaccina-
tion (p=0.018) compared to patients that received the p53-SLP® only vaccine (fig-
ure 5B). These data recapitulate the results obtained in the direct ex-vivo ICS assay 
conducted on cryopreserved PBMCs.
Comparison of the IgG responses to p53 in serum of p53-SLP® vaccinated 
patients with and without IFN-Į
In order to analyze whether vaccination also resulted in the induction of a p53 
peptide-specific antibody response we developed a p53 peptide-specific ELISA 



















Results from patients injected with p53-SLP® and IFN-Į compared to the results from colorectal 
cancer patients injected with p53-SLP® only. A, The bar plot shows a graphical comparison of 
the percentages of activated CD4+ T-cells (CD137+CD154- in black, CD137-CD154+ in gray and 
CD137+CD154+ in white) between the two vaccination studies. B and C, display the percentages IFN-Ȗ+ 
and IL2+ activated CD4+ T-cells respectively split up for the activation markers CD137 and/or CD154. 
D, depicts the ratio of IFN-Ȗ+CD8+ T-cells of p53 peptides versus medium stimulated PBMC. The line 
indicated a 2-fold increase; > 2-fold increase is defined as a positive response.
after the second vaccination. These analyses were performed simultaneously on 
the sera obtained from patients participating in the current trial and our previous 
vaccination study. In the current trial p53-specific IgG antibody responses were 
detected in 7 out of the 8 patients of whom both serum samples (pre- and post-
vaccination) were available. In one patient (p29) no antibody response to p53 was 
detected. On average, the number of p53 peptides to which IgG antibodies were 
detected in these 8 patients was 2.3 (range 0-5), with an obvious peak in the rec-
ognition of those peptides that were present in the vaccine (peptides 9-15; fig-
ure 6). In sera of 3 out of the 9 tested patients from our previous colorectal cancer 
trial p53-specific IgG responses were detected. Here on average the number of 
peptides recognized was 0.4 (range 0-2). Patients in the current trial recognized 
significantly more peptides than those from the first trial (p=0.02). The results of 
the ELISA therefore indicate a broader p53-specific IgG response by the addition 








p53-SLP ®      p53-SLP ® & IFN-α
         Peptide pools       Peptide pools
1 2 3 4 5 6 1 2 3 4 5 6
V V V V V V V V
P01 <1 <1 <1 29 45 3 <1 13 137 <1 40 <1 P20
P02 <1 <1 5 59 71 <1 <1 4 32 12 91 7 P21
P03 2 10 <1 <1 <1 <1 <1 5 31 25 70 12 P23 <10
P04 5 17 15 29 2 18 2 139 162 140 106 14 P24 10-50
P05 <1 <1 <1 <1 9 <1 <1 <1 89 20 33 <1 P25 50-100
P07 <1 <1 <1 <1 <1 <1 2 10 109 12 67 4 P26 >100
P08 <1 2 17 143 81 4 <1 <1 12 <1 <1 <1 P27
P09 <1 5 26 69 62 4 <1 <1 <1 19 41 <1 P29
P10 <1 <1 <1 <1 <1 <1 <1 <1 10 2 55 2 P30
P11 <1 <1 <1 59 72 14
Median NA 13.5 17 59 71 16 NA 13 60.5 19.5 61 13
Positive (%) 0 20 30 60 50 20 0 33 89 67 89 22
A
Figure 5
The heat map of (A) reflects the IFN-Ȗ ELISPOT results from both trials. The number of positive 
spots per 105 PBMC is given for every patient. Every value is colored in relation to the number of 
positive spots per 105 PBMC. White corresponds with a count of < 10 positive spots 105 PBMC, light 
grey t 10 - < 50, dark grey t 50 - < 100 and black t 100 spots per 105 PBMC On the bottom of the 
heat map the median and the percentage positive responses is given per peptide pool. Peptide pools 
represented by the vaccine are indicated by a ‘V’. (results of patients vaccinated with only p53-SLP® 
(left side) and vaccinated with p53-SLP® and IFN-Į (right side). (B) The median of all specific spots 
as determined IFN-Ȗ ELISPOT in the two trials before and three weeks after the second vaccination 
are compared by reanalyzing the ELISPOT plates of the first trial (p53-SLP® only) with the same 
settings of the reader as the current trial (p53-SLP® and IFN-Į). Not only the number of specific 
spots in both cohorts was significantly higher after vaccination compared to pre-vaccination, 
this increase in specific spots was significantly better in the patients that also received the IFN-Į 







































The grid table in this figure represents the number of peptides that were recognized by the 
individual patients based on their specific IgG antibody responses. The peptides are listed on the 
x-axis, the individual patients on the y-axis. Peptides are numbered and indicated by the first and 
last amino acids used of the p53 protein. Patients 1-10 represent the study cohort of the first trial 
who received solely p53-SLP® injections, patients 20-30 represent the study cohort of the second 
trial in which patients received both p53-SLP® and IFN-Į injections. Negative responses are white 
(< 2); positive responses are displayed in light grey: t 2 and < 5, dark grey t 2 and < 5-fold and 
black t 10-fold increase of p53-specific IgG response after vaccination. There is an obvious peak, 
mainly present in the second cohort, in the recognition of peptides that were actually covered by the 
vaccine.
DISCUSSION
Results from previous studies suggest that colorectal cancer vaccines should aim 
at inducing strong type 1-associated immunity to obtain a clinical response (11,33-
35). Although in patients, vaccination with the p53-SLP® resulted in the induction 
of p53-specific CD4+ T-cell immunity, the production of Th1-associated cytokines 
such as IFN-Ȗ and IL-2 was probably too low to become truly effective (6). Com-
bining vaccines with immune modulating adjuvants should allow polarization of 
the vaccine-induced immune response. Here we show that the clinical grade p53-
SLP® vaccine combined with IFN-Į induced p53-specific Type 1-polarized CD4+ 
and CD8+ T-cell responses in all and 6 of 9 colorectal cancer patients, respectively.
We have previously shown that the p53-SLP® vaccine was safe (6,7). The addition 
of IFN-Į in the current trial also resulted in no serious AEs. However, in contrast to 
vaccination with p53-SLP® only (6), this time all vaccinated patients showed long 
lasting local swelling and inflammation of at least one of the peptide but not the 
IFN-Į injection sites. As the groups of vaccinated patients were highly comparable 
(table 3), this suggests that addition of IFN-Į potentiates inflammation at the vac-
cination sites where p53 antigen is present, thereby improving the antigen presen-








The vaccine-induced p53-specific antibody and cellular response of patients vac-
cinated with the combination p53-SLP® and IFN-Į were compared with those of 
patients vaccinated with p53-SLP® only. They were analyzed in a head-to-head 
comparison of cryopreserved PBMC samples by ICS and serum samples in the 
peptide ELISA assay. Although, these materials were obtained in two independ-
ent trials, they were similarly isolated from successfully treated colorectal cancer 
patients with highly comparable disease state and preserved under the same con-
ditions. Within these limitations, our results indicate that addition of IFN-Į to p53-
SLP® induces an immune response against a broader range of peptide pools and 
also a higher frequency of vaccine-specific activated IFN-Ȗ producing T cells. Addi-
tion of IFN- Į to p53-SLP® also increased the amount of p53-specific IgG antibod-
ies, indicating the underlying improved Th cell induction.
In the current trial, one of the peptides was excluded from the original p53-SLP® 
vaccine composition, due to low yield of purified material of this particular long 
peptide (6). The peptide not included was the last 13 amino acid overlapping pep-
tide from the C-terminal section of the p53 sequence used in the previous vac-
cination trial (6). Our data comparing p53-specific T-cell responsiveness was not 
focused on the measurement of responses to individual peptides, therefore, it is 
difficult to estimate how the exclusion of this specific peptide altered the immu-
nogenicity of the vaccine. However, in the current trial the responsiveness after 
vaccination was significantly increased compared to the previous trial, despite the 
lack of this one peptide.
In the literature, it has been suggested that the p53-specific CD8+ T-cell repertoire 
is severely restricted due to self-tolerance (36,37). Consequently, p53-specific vac-
cination will result mainly in the induction of p53-specific high affinity CD4+ T-cells 
and low affinity CD8+ T cells. Our results indicated that addition of IFN-Į might 
have increased the number of p53-specific CD8+ T cells as we were able to detect 
them in 6 out of 9 patients from the present trial and in none of the patients from 
the previous trial. The 6 patients with p53-specific CD8+ T cells included the follow-
ing 4 patients: one patient (p20) who showed a response when PBMC were freshly 
tested and the others (p25, p26 and p30) displayed p53-specific CD8+ T cells in the 
cells cultured from the biopsy of the vaccine site. Most CD8+ T-cells responses were 
found in cryopreserved PBMCs (p20, p25, p27 and p29). The reason why we were 
better able to detect p53-specific CD8+ T cells in the cryopreserved samples lies in 
the fact that the ICS assay used for analyzing thawed PBMC is optimized to detect 
antigen-specific CD8+ T cells by using 10-fold higher concentrations of the long 
peptides as antigens. It also differs from the assay used to analyze the fresh PBMC 
samples by the addition of TLR3 agonist poly I:C to activate the peptide-loaded 
antigen presenting cells (25).
Together, we have found that combining p53-SLP® with IFN-Į injection results 
in enhanced inflammation, p53-specific type 1-polarized CD4+ and CD8+ T-cell 
responses. We have not studied the effect on DC activity, therefore we can only 
speculate on the exact function of IFN-Į. However, from literature it is clear that 


















T cells (39). A recent study also found a reduction in regulatory T cells following 
high-dose IFN-Į (40).
We can conclude that the addition of IFN-Į clearly induces both a qualitatively and 
quantitatively better p53-specific T-cell response compared to p53-SLP® vaccina-
tion alone. These data provide support to the notion of combining cancer vaccines 
with immune modulating agents such as IFN-Į to augment and polarize the vac-
cine-induced immune response. However, the minimal requirements of a vaccine-
induced immune response in order to obtain a clinical response are undefined. 
Therefore it is tempting to perform an efficacy study with p53-SLP® combined with 
IFN-Į to determine whether the strength and quality of the response are good 
enough to prevent recurrence or metastasis in stage II and stage III colorectal can-
cer patients, who have not yet developed any kind of distant metastasis at the time 
of vaccination.
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CHAPTER 8
FoxP3- and CD8-positive 
infiltrating immune cells 
together determine 
clinical outcome in 
colorectal cancer
E. Zeestraten, A. Van Hoesel, F. Speetjens, A. Menon, 
H. Putter, C. van de Velde, P. Kuppen




















Immune cells are known to affect clinical outcome in colorectal cancer. Subsets of 
immune cells can both support and inhibit immunological interaction with tumor 
cells. We examined the clinical impact of T cells that are supposed to be respon-
sible for the down regulation of a T cell response: regulatory T cells or Tregs. The 
study population (n=76) consisted of a random population of colorectal cancer 
patients who did not receive any (neo-) adjuvant therapy, with a median follow-up 
time of 7.3 years (range 0.1-23.1 years). Expression of FoxP3 was used as an immu-
nohistochemical marker to identify Tregs. We considered FoxP3+ cells present in 
tumor stroma and tumor epithelium separately, and related results to clinical out-
come and to data on CD8+ immune cell infiltration that we previously obtained in 
the same patient cohort. All samples showed presence of Foxp3+ cells and in the 
majority of the patients (85.5%) these cells were also present in the tumor epithe-
lial compartment. A relative high level of Foxp3+ cells in the tumor epithelium was 
significantly related to down regulation of HLA Class I expression (p-value 0.03). 
There was a trend, but no significant relation, towards a longer overall survival 
(p-value; 0.084) and disease-free survival (p-value; 0.073) when high levels of 
Foxp3+ cells were present in the tumor epithelium. More importantly, the ratio 
of CD8+/Foxp3+ cells did show a significant correlation with distant-recurrence-
free survival. This was the case for both Foxp3+ cells specifically located in the 
tumor epithelium (p-value 0.024) as well as in the stroma compartment (p-value 
0.018). Unfortunately due to the small sample size the ratios did not retain their 
statistical significance in multivariate analysis. These results provide further evi-
dence that local interactions in the cancer microenvironment between tumor cells 
and immune cells are not only determined by tumor cell-related factors like HLA 









The process of tumor development in colorectal cancer (CRC) is one of the most 
studied and best characterized models of tumorigenesis in the world today. At 
least six features can be identified that hallmark tumor growth and development. 
(1;2) Three of which are related to the immune system. Tumor cells may acquire 
the ability to thrive in a inflamed micro-environment, to evade immune recognition 
and, to suppress immune reactivity. (3)The adaptive immune system and its key 
players, especially cytotoxic T Lymphocytes (CTL), play an important role in con-
trolling tumor growth and metastasis. Naito et al. were the first to demonstrate that 
infiltrating CTL are a prognostic factor in CRC. (4) Due to their genetic instability, 
tumor cells may arise with a phenotype that makes them less sensitive to immune 
surveillance, thus escaping CTL recognition. This phenotype includes down regula-
tion or complete loss of one or more HLA class I alleles. This enables tumor cells 
to minimize their presentation of tumor-associated antigens (TAA) and, therefore, 
diminish their chance of recognition and subsequently destruction by CTL. (5-8)
Another mechanism to evade immunosurveillance is to suppress immune reactiv-
ity by attraction of immunosuppressive regulatory T cells (Tregs) into the tumor 
micro-environment. Both, down regulation of HLA class I, and presence of Tregs, 
have been shown to be of clinical relevance in various types of solid tumors. (9-12) 
CRC-related studies that describe HLA class I expression in relation to clinical prog-
nosis have, however, rendered contrasting results. Some studies were not able to 
determine any significant relation between HLA class I expression and survival, 
while others did. (13-16) When a significant relation could be established, a total 
lack of HLA class I expression always resulted in more favorable prognosis. This is 
probably due to the fact that HLA Class I negative metastatic cells in the circula-
tion will be targets for destruction by Natural Killer (NK) cells that are abundantly 
present in the circulation but not in solid tumors. (17;18) Partial expression, how-
ever, was related to either a better or worse prognosis compared to high expres-
sion (15;16) Similar, there are a variety of studies describing the presence of Tregs 
in tumor tissue in relation to clinical outcome. In case of ovarian cancer, three stud-
ies were able to establish that high Treg infiltration was associated with a poor 
prognosis. (10;19;20) In colorectal cancer, however, 4 studies describing the pres-
ence of Tregs in cancer tissues have rendered contrasting results. Loddenkemper 
et al. performed an analysis on 40 colorectal tumor samples and could not estab-
lish a significant relation between the presence of Foxp3+ Tregs or the ratio CD8+/
Tregs with outcome.(21) In contrary, a recently published study by Suzuki et al., a 
predictive value of the intra-tumoral ratio of CD8+ T cells and Foxp3+ Tregs could 
be established.(22) A third study by Salama et al. using a Tissue Micro Array of 
967 stage II and III CRC patients was able to significantly correlate the presence of 
Tregs to clinical outcome parameters. (23) High Foxp3+ Treg density in the normal 
mucosa of patients was associated with a worse prognosis, while a high density in 
the tumor tissue was associated with improved survival. Finally, a study of Deng et 



















lymph nodes to disease.(24) The latter four publications as well as the studies on 
the significance of HLA Class I expression in colorectal cancer all have in common 
that they were performed on mixed study populations containing both adjuvant 
and non-adjuvant treated, metastatic and non-metastatic patients and patients 
of which tumor microsatellite status was often not determined. Besides, the pres-
ence of Foxp3+ Tregs was expressed in several ways; either as their presence in the 
tumor epithelium, in the tumor stroma or as a ratio with CD8+ cells. All these vari-
ations in study methods make it difficult to recapitulate the results of these studies 
into one overall conclusion. Therefore, the importance of HLA class I expression 
and Foxp3+ Treg infiltration in relation to the presence of CD8+ CTLs still remains 
to be determined in CRC patients. The purpose of this study was to analyze the 
presence of Foxp3+ Tregs and relate the data to the data on infiltrating immune 
cells and HLA expression that we have previously obtained in a random cohort 
of patients, without adjuvant treatment.(7) The data on Foxp3+ Tregs were also 
correlated with clinico-pathologic variables such as TNM (Tumor Node Metastasis) 
classification, tumor differentiation grade and the tumors microsatellite stability 
status (MSS/MSI), as well as with outcome parameters such as overall survival (OS) 
and disease free survival (DFS).
PATIENTS AND METHODS
Patients
Between January 1980 and December 1992, 266 consecutive patients underwent 
curative resection with post-operative follow up for a colorectal adenocarcinoma 
at the Leiden University Medical Center. Within this cohort, previously described 
by Tollenaar et al. and Menon et al., 76 patients were identified who did not receive 
any (neo-) adjuvant therapy and of whom data was available on CD8+ lympho-
cyte infiltration, tumor microsatellite stability status and HLA Class I expres-
sion. (7;15;25) CD8+ infiltration was scored as the number of CD8+ leukocytes per 
tumor area (leukocytes/mm2 tumor epithelium). The average leukocyte infiltration 
of 25 fields per tumor section was calculated and defined as the intraepithelial 
leukocyte infiltration. In addition, leukocytes in the tumor stroma and at the tumor 
margin were assessed semi quantitatively into ‘none–poor’ or ‘moderate – marked’ 
leukocyte infiltration. The tumor microsatellite status was determined with MLH1-
based immunohistochemistry. MLH1 expression was categorized as absent if the 
majority of the tumor cells lacked nuclear MLH1 expression; this suggests a micros-
atellite instable (MSI) tumor phenotype. If nuclear MLH1 expression was present in 
the majority of the tumor cells samples were indicated to be microsatellite stable 
(MSS).
HLA Class I expression was determined previously by immunohistochemistry 
using the monoclonal antibodies HCA2 and HC10 according to the defined stand-
ard method of the International HLA and Immunogenetics Workshop (IHIW) 








5-25%   positivity, 25-50% positivity, 50-75% positivity and 75-100% positivity). In 
66 out of the 76 (87%) tumors, both HCA2 and HC10 staining could be quantified 
and, therefore, were available for evaluation of total HLA Class I expression. Three 
groups were identified according to a standardized method and defined as (1) HLA 
class I loss (staining of both HCA2 and HC10 was less than 5% of the tumor cells; 
(2) HLA class I reduced expression (staining of either HCA2 or HC10 was less than 
50% of the tumor cells); and (3) HLA class I expression (staining of both HCA2 and 
HC10 was more than 50% of the tumor cells).(8)
Tumors were staged according to the TNM criteria.(26) Known tumor characteris-
tics included differentiation grade, Jass lymphocyte infiltration score, DNA micro-
satellite status, and presence of mucinous characteristics. Median follow-up was 
7.3 years (range 0.1 -23.1 years). Patient and tumor- characteristics are shown in 
table 1.
Immunohistochemistry
A Foxp3 / laminin immunohistochemical double staining of tumor sections was 
performed to evaluate the presence of Foxp3+ regulatory T cells in both the epi-
thelial and stromal compartment of the primary tumors. FFPE (formalin-fixed 
paraffin-embedded) tissue sections of 5 µm thickness were prepared on amino-
propylethoxysilane (APES)-coated slides and dried at 37°C. Tissue sections were 
deparaffinized in xylene, submerged in 0.3% hydrogen-peroxidase methanol to 
block endogenous peroxidase, and rehydrated in a graded ethanol series. For anti-
gen-retrieval, tissues were soaked in 0.01 M citrate buffer (pH 6) at 100°C for 10 
minutes. After rinsing in PBS, tissues were incubated overnight with anti-FOXP3 
(1:300, ABCAM AB20034). On the second day, Biotin-labeled Rabbit-anti-Mouse 
secondary antibody (30 minutes, 1:200, DAKO) followed by Streptavidin-Biotin-
complex (30 minutes, 1:100, DAKO) was used for signal amplification. After 5 min-
utes of soaking in a 0.05M Tris-HCl solution, tissues were developed for 10 minutes 
with 3,3-di-amino-benzidine tetrahydrochloride (DAB) for visualization. Next, tis-
sues were transferred to a 0.01% trypsin solution and soaked at 37°C for 10 minutes. 
Rabbit polyclonal anti-laminin (1:50, Sigma L9393) was applied to the sections for 
overnight incubation. Subsequently, tissues were incubated with Biotin-labeled 
Swine-anti-Rabbit (1:400, DAKO) for 30 minutes, followed by Streptavidin-Biotin-
complex (1:100, DAKO) for 30 minutes. A blue signal was achieved by developing 
the tissue sections for 12 minutes in a 4-chloro-1-naphtol solution. Methyl green 
was used for nuclear counterstaining. Finally, all tissue sections were dehydrated 
and mounted in Kaiser’s glycerol. FFPE sections of tonsil and normal colon tissues 
were included as positive controls for the Foxp3 and laminin staining and as nega-
tive controls by replacing incubations with either the primary antibody or second-











































































































Abbreviations. Yrs: years. TNM: Tissue Node Metastasis. MSS: Micro Satellite Stable. MSI: Micro 
Satellite Instable. HLA: Human Leukocyte Antigen.
This table shows the clinico-pathological characteristics of all of the 79 primary colorectal cancer 








Evaluation of the Immunohistochemistry
The number of Foxp3+ cells in primary colorectal tumor tissues was microscopically 
evaluated by two independent observers (ECMZ and AQvH). Microscopic evalua-
tion was done without previous knowledge of patient characteristics or disease 
outcome. The laminin-staining served as demarcation to distinguish the epithelial 
from stromal tumor compartments and other tissue. For counting, an ocular grid 
was used at 100x magnification. First the total amount of Foxp3+ cells (tot-Foxp3+) 
was counted in 5 randomly chosen, separate grid fields (surface-area of 3mm2) 
in each tumor. This approach enabled to determine the number of positive cells 
per mm2 tumor tissue. The tot-Foxp3+ count was further subdivided according 
to location of the Foxp3+ cells: Foxp3+ cells located actually in the tumor epithe-
lium, which means there was direct contact with the tumor cells and the Foxp3+ 
cells, were counted as tumor-Foxp3+ cells (t-Foxp3+), and Foxp3+ cells located in 
the tumor stroma as stromal-Foxp3+ cells (s-Foxp3+). Inter-observer conformity 
was calculated using the intraclass correlation test. Intraclass correlation coeffi-
cients for single measures were 0.93, 0.82 and 0.93 (p<0.001) for the tot-Foxp3+, 
the t-Foxp3+ and the s-Foxp3+ cell counts respectively. Observer counts were 
averaged and used to calculate the final t-Foxp3+ and s-Foxp3+ counts and the 
t-Foxp3+/tot-Foxp3+ ratio for each tumor sample. Previously determined number 
of CD8+ cells present in the tumor epithelium (t-CD8+) were used to calculate the 
t-CD8+/ t- or s-Foxp3+.(7)
Statistical Analysis
Statistical analyses were performed with SPSS software version 16.0 (SPSS Inc, 
Chicago, IL). To test whether the mean levels of Foxp3+ cells differed between the 
tumor and the stroma compartments the Wilcoxon Signed ranks test was applied. 
The Chi-squared test was used to evaluate associations between the presence 
of t-Foxp3+ cells, s-Foxp3+ cells and the t-Foxp3+/tot-Foxp3+ ratio and various 
clinico-pathologic parameters, and HLA Class I expression and the presence of 
CD8+ cells. For the survival analysis, date of surgery was used as the entry date for 
analysis. The Kaplan-Meier method was used for overall survival (OS), disease-free 
survival (DFS), distant-recurrence-free survival (DRFS) and local-recurrence-free 
Survival (LRFS) and the log-rank test for comparison of the survival curves. OS, 
DFS, DRFS and LRFS were defined as follows; date of any event of interest minus 
entry date. Hazard ratios were calculated the Cox proportional hazards analysis 
for uni- and multivariable analysis. Only parameters that were of statistical sig-
nificance in the univariate analysis were analyzed in the multivariate model. Sig-
nificance of hazard ratios was tested with the Wald’s test. All statistical tests were 





















The laminin IHC double staining demarcated the tumor epithelium from the stro-
mal compartment within the tumors. (figure 1) Therefore, the exact location and 
number of the Foxp3+ cells within the tumor tissue could be determined. For all 
76 cases, Foxp3 infiltration data were obtained. Foxp3+ cells were found to be 
present in the stromal compartment of all tumors. In the majority of the patients 
(85.5%) Foxp3+ cells were also present in the tumor epithelium. The mean number 
of Foxp3+ cells in the tumor epithelium (t-Foxp3+) was 0,25/mm2 with a range of 
0-1.73, and in the tumor stroma (s-Foxp3+) 5.84/mm2, ranging from 0,43-20,87. 
This was a significant difference (p-value <0.000). Because the counts of both 
locations of FoxP3+ cells were skewed to the right of the range, the median was 
used for further analysis as a cut-off point for the presence of Foxp3+ cells. The 
median was 0.133/mm2 for t-Foxp3 and 4.818/mm2 for s-Foxp3 respectively.
The numbers of CD8+ cells were previously determined in the same patient cohort. 
As described in the study by Menon et al., the cut-off used for the number of CD8+ 
cells in the tumor epithelium (t-CD8+), was at the 75 percentile (65 cells/mm2)
Figure 1
A representative image of the Foxp3 and laminin double staining. In which the laminin clearly 
demarcates the tumor stroma from the tumor epithelium. In this image typical examples of epithelial 








(7). The presence of CD8+ cells at the tumor margin (m-CD8+) or tumor stroma 
(s-CD8+) was scored qualitatively as either no or poor infiltration, moderate, and 
marked infiltration. The scores in the entire study population did not statistically 
significantly differ from those of the patients used in this subset analysis.
Association of presence and location of Foxp3+ cells with clinico-
pathological parameters, HLA class I expression, and presence of CD8+ 
cells.
Neither the presence of t-Foxp3+ or s-Foxp3+ showed a significant correlation to 
any of the standard clinico-pathological parameters (table 2). Their presence was 
also not related to HLA class I expression status of the tumor. The ratio of t-Foxp3+/
tot-Foxp3+ did show a statistically significant relationship with HLA class I expres-
sion. When HLA class I expression was low, no expression or reduced expression 
within the tumor, the ratio of t-Foxp3/tot-Foxp3 was higher at a p-value of 0.03 
(table 2). Patients with reduced HLA class I expression were therefore more likely 
to have relatively higher numbers of Foxp3+ cells in the tumor epithelium com-
pared to the number of s-Foxp3.
In concordance with the data previously shown by Menon et al., the number of 
t-CD8+ cells significantly correlated with tumor stage and was inversely correlated 
with HLA status. (7)
The presence of t-Foxp3+ cells or the ratio of t-Foxp3+/ tot-Foxp3+ cells did not 
show any statistical significant relationship with the presence of CD8+ cells at any 
location in the tumor. In contrast, the presence of s-Foxp3+ cells did show a signifi-
cant relation to the presence of CD8+ cells at the tumor margin. When more CD8+ 
cells were present in the tumor margin the number of Foxp3 + cells in the stroma 
also increased statistically significantly (p-value: 0.043, table 3).
Association of the t-CD8+/Foxp3+ ratio with clinico-pathological 
parameters and HLA Class I expression
To determine whether the number of Foxp3+ cells combined with the number of 
CD8+ cells was related to clinico-pathological parameters or HLA Class I expression, 
their ratio was calculated. This was performed for both t-Foxp3+ and s-Foxp3+ cell 
counts. Absolute data on CD8+ cells was only available for the t-CD8+ counts. The 
ratio t- CD8+/ t-Fox3+ or t-CD8+/s-Foxp3+ could be determined for 63 cases. The 
median t-CD8+/ t-Foxp3+ ratio was 73, median t-CD8+/ s-Foxp3+ ratio was 4.03. 
Due to the distribution of the data the median was used as a cut-off point. Nei-
ther of these ratios was related to clinico-pathological parameters or HLA class I 














































































































































Abbreviation: TNM: Tissue Node Metastasis. MSS: Micro Satellite Stable. MSI: Micro Satellite Instable. 
HLA: Human Leukocyte Antigen.
Table two shows the relation of either the presence of Foxp3 + cells in the tumor stroma (s-Foxp3+), 
in the tumor epithelia, (t-Foxp3+) and the ratio t-Foxp3+/ total amount of Foxp3 + (t-Foxp3+/tot-
Foxp3+ present to clinico-pathological parameters and HLA expression. Presence is expressed as 
the percentage of patients that showed levels of s-Foxp3+ and t-Foxp3+ or a ratio above the cut-off 

























































Table three shows the relation of the presence of Foxp3 + cells in the tumor stroma (s-Foxp3+), in 
the tumor epithelium, (t-Foxp3+) and the ratio t-Foxp3+/ total amount of Foxp3+ cells (t-Foxp3+/
tot-Foxp3+) present to the presence of CD8+ cells in either the tumor epithelium (t-CD8+), the tumor 
stroma (s-CD8+) or the tumor margin (m-CD8+). The determination and qualification of the presence 
of CD8+ cells has been previously described. (7)
Association of Foxp3+ cells and the CD8+/Foxp3+ with clinical prognosis
The presence of t-Foxp3+ cells or s-Fop3+ cells was not related to tumor recurrence 
(p-values of 0.598 and 0.446 respectively). Patients with high t-Foxp3+ cell counts 
compared to patients with low t-Foxp3+ counts showed a trend towards both a 
longer Overall Survival (OS) time (122 months vs. 96,7 months, p=0.084) and a 
longer Disease Free Survival (DFS) time (109 months vs. 83 months, p=0.073). 
(figure 2&3). Previously, Menon et al. have shown that t-CD8+ cells was an inde-
pendent prognostic factor of a longer disease-free survival. (7)Also the ratio of the 
number of t-CD8+ cells and number of t -Foxp3+ cells (t-CD8+/t-Foxp3+) showed 
a trend towards a longer OS time. A ratio above the median, indicating a rela-
tive larger number of t-CD8+ cells compared to t-Foxp3+ cells, was related to a 
longer OS time of 130 months compared to 87 months at a ratio below the median 
(p-value; 0.053). The same trend was seen for DFS, however this was again not 
significant at a p-value of 0.081 (figure 2&3). The t-CD8/s-Foxp3+ ratio was never 
related to OS or DFS. Interestingly, both the t-CD8+/t-Foxp3+ and t-CD8+/s-Foxp3+ 
ratio were significantly related to Distant Recurrence Free Survival (DRFS). Both 
ratios showed a longer DRFS time for patients when above median: 214 months vs. 
142 months for the t-CD8+/s-Foxp3+ ratio at a p- value of 0.018, and 226 vs. 158 
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Kaplan Meier graphs for Foxp3 levels in the tumor epithelium (t-Foxp3+) (A) and as a ratio with 



































Disease Free Survival in Months
Number of t-Foxp3+ cells t-CD8+/t-Foxp3+ ratio
Disease Free Survival in Months
A B
p-value: 0.073 p-value: 0.081
Figure 3
Kaplan Meier graphs for Foxp3 levels in the tumor epithelium (t-Foxp3+) (A) as a ratio with CD8+ in 











































Distant Reccurence Free Survival in months Distant Reccurence Free Survival in months
t-CD8+/s-Foxp3+ ratio
A B
p-value: 0.018 p-value: 0.024
Figure 4
Kaplan Meier graphs for the t-CD8/t-Foxp3 levels (A) and the t- CD8/s-Foxp3+ (B) relation to Distant 
recurrence Free Survival
Univariate and multivariate Analysis
Uni – and multivariate analysis was performed to calculate hazard ratios, to iden-
tify whether the t-CD8+/t-Foxp3+ and t-CD8+/s-Foxp3 ratios were independent 
of prognostic significance for DRFS. Analysis included known risk factors such as 
age, TNM stage, tumor microsatellite status, etc. For the DRFS, advanced TNM 
stage as well as the t-CD8+/t-Foxp3+ and s-Foxp+ ratios were statistically signifi-
cant predictors in the univariate analysis. The hazard ratios for TNM stage II and 
III were 4,294 (CI95% 0,717-25,713) and 8,125 (CI95% 1,847-36,533) respectively 
at a p-value of 0.003. The hazard ratios of t-CD8+/t-Foxp3+ -and s-Foxp3+ cells 
were 0.190 (p-value 0.034) and 0.294 (p-value 0.034). However neither of these 
parameters was able to retain their value as an independent significant predictor 
of DRFS in multivariate analysis (data not shown). Also for OS analysis, univariate 
and multivariate analysis were executed with the same parameters. In univariate 
analysis only mucinous differentiation showed a statistically significant relation to 
OS. (HR 0.504; CI95% 0.288-0.882; p-value 0.016) This effect did not remain in the 




















The ability of tumor cells to thrive in a chronically inflamed microenvironment is 
only one of three important immune system-related hallmarks of tumor growth 
and development. Two other features also play a major role in the process of tumo-
rigenesis. First, tumors are able to develop certain features that make it possible 
for them to evade immune recognition.(27) Among others, these features com-
prise down regulating or even complete loss of HLA class I expression. This way, for 
the most part they lose the capability to become recognized and attacked by the 
immune system. Tumor cells may also be poorly immunogenic because of insuf-
ficient presence of TAA presentation or co-activating signals. Secondly, tumor cells 
may evade immune reactivity by restraining an anti-tumor immune response. (5-8) 
The latter currently gets a lot of attention in tumor immunology as it has become 
clear that tumor cells may attract immunosuppressive cells such as Foxp3+ regula-
tory T cells (Tregs). Tregs inhibit the development of autoimmune responses, but 
also are capable of impeding antitumor immune responses. (28;29) In this study 
we were able to identify and quantify both these features in colorectal tumor 
samples. In addition we found that both features were seemingly interconnected. 
The mechanism by which Foxp3+ Tregs become attracted to the tumor micro-
environment remains yet to be discovered. Two hypotheses can be postulated. 
Either tumor cells actively attract these cells or the overall inflammatory character 
induced by tumor growth also induces the influx of Tregs into the tumor microen-
vironment. Our results showed that down regulation of HLA class I was associated 
with a relative higher level of epithelial Foxp3+ cells as compared to the number of 
Foxp3+ cells in the tumor stromal compartment. This seems to be contradicting, 
but may be a reflection of an earlier anti-tumor immune reaction. Possibly, tumor 
reactive CTL caused selective outgrow of HLA loss tumor variances. The immune 
cells involved, such as the Tregs and CD8+ cells, apparently remain present as illus-
trated by our results.
Our data also illustrate the importance of the interplay between various types of 
immune cells in the tumor microenvironment in determining clinical outcome as 
neither the presence of Foxp3+ cells nor CD8+ cells was statistically significantly 
prognostic. Combined, however, the ratio of these cells significantly predicted clin-
ical outcome with respect to distant recurrence of disease, suggesting a functional 
mutual relationship. Previous data published on the effect of Foxp3+ cells in CRC 
patients is rather inconclusive with respect to their prognostic relevance (21-24) 
One of the reasons for lack of consistency in the results may be variation in study 
population size as the larger studies by Salama et al. and Suzuki et al. both showed 
a relationship between Foxp3+ cell presence in tumors and clinical prognosis, 
while studies on smaller populations did not.(22;23) The data presented here, even 
though derived from a relative small patient cohort, indicates that a more compre-
hensive approach is probably of greater importance than large patient numbers. 








to interact, but also tumor characteristics that may interfere, will better show the 
involvement and clinical relevance of the immune system in colorectal cancer. A 
comparable approach was chosen by Loddenkemper et al. and Suzuki et al., but in 
our study this approach was extended by the incorporation of more data regarding 
key elements of the process of tumor development. (21;22) Tumor microsatellite 
status, and other tumor characteristics that were previously shown to be of clinical 
importance, including HLA class I status, were included in our analysis. The major 
advantage of this comprehensive ‘mapping’ approach at the level of immune regu-
lation in colorectal cancer is the clinical applicability of the data, as the information 
might be used to determine treatment allocation, like suggested before. For exam-
ple, a study by De Kruijf et al. showed that the presence of Foxp3+ cells alone in 
breast cancer patients had no prognostic value.(9) However, when combined with 
level of HLA expression the data showed a prognostic effect in adjuvant treated 
patients. It was postulated that counteraction of Tregs by chemotherapy allowed 
CTL to affect tumor metastases development, but only when HLA expression 
was intact. (9) Further research conducted in stage III and IV adjuvantly treated 
patients will determine whether such an effect is also present in CRC patients.
In conclusion, we were able to determine a prognostic effect on disease recurrence 
free survival of the presence of Foxp3+ cells, in either the tumor stromal compart-
ment or the tumor epithelium, but only when combined with data on CD8+ cells. 
This indicates the importance of a comprehensive approach that shows the inter-
play between members of the immune system in CRC patients. We hypothesize 
that studying even more cell types and molecules involved, such as NK ligands, 
co-stimulating molecules, and activating or suppressing cytokines, will lead to a 
better understanding of the tumor-immune system interaction. This will eventually 
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CHAPTER 9
Combined analysis of 
HLA Class I, HLA-E 
and HLA-G predicts 
prognosis in colon 
cancer patients
E. Zeestraten, M. Reimers, S. Saadatmand, I. Goossens-Beumer, 
JW. Dekker, GJ. Liefers, PJ van den Elsen, C. van de Velde, P. Kuppen

















Background: Evasion of immune surveillance and suppression of the immune sys-
tem are important hallmarks of tumor development in colon cancer. The goal of this 
study was to establish a tumor profile based on biomarkers that reflect a tumors’ 
immune susceptibility status and to determine their relation to patient outcome.
Methods: The study population consisted of 285 Stage I-IV colon cancer patients of 
which a tissue micro array (TMA) was available. Sections were immuno-histochem-
ically stained for presence of Foxp3+ cells and tumor expression of HLA Class  I 
(HLA-A, -B, -C) and non-classical HLA-E and HLA-G. All markers were combined 
for further analyses, resulting in three tumor immune phenotypes: strong immune 
system tumor recognition, intermediate immune system tumor recognition, and 
poor immune system tumor recognition.
Results: Loss of HLA class I expression was significantly related to a better OS 
(p-value 0.005) and DFS (p-value 0.008). Patients with tumors that showed nei-
ther HLA class I nor HLA-E or -G expression (phenotype a) had a significant better 
OS and DFS (p-value <0.001 and 0.001, respectively) compared to phenotype b 
(OS HR 4.7, 95% CI 1.2-19.0, p=0.001) or c (OS HR 8.2, 95% CI 2.0-34.2, p=0.0001). 
Furthermore, the tumor immune phenotype was an independent predictor for OS 
and DFS (p-value 0.009 and 0.013 respectively).
Conclusions: Tumors showing absence of HLA class I, HLA-E and HLA-G expres-
sion were related to a better OS and DFS. By combining the expression status of 
several immune-related biomarkers, three tumor immune phenotypes were cre-
ated that related to patient outcome. These immune phenotypes represented sig-









Historically, the immune system has been attributed an important role in controlling 
tumor growth and metastasis (1–4). Evasion of immune surveillance and suppres-
sion of the immune system are two important traits cancer cells have to acquire 
during the process of tumorigenesis (5). Research of the last century has indicated 
that the influence of the immune system on tumor cells, both in the tumor micro-
environment as well as during the process of tumor metastasis, also contributes to 
tumor progression (6). The cancer immune-editing hypothesis describes both the 
host-protective as well as the tumor-promoting actions the immune system might 
have on developing tumors, shaping tumor immunogenicity. (7–13). Tumors are 
thought to be ‘edited’ through a Darwinian selection process into poorly immu-
nogenic tumor cell variants invisible to the immune system and able to grow pro-
gressively. Immune-editing might therefore have substantial effects on patient’s 
prognosis.
Several mechanisms taking place at the tumor cell level contribute to this process. 
The first mechanism is downregulation of human leukocyte antigen (HLA) class I 
expression. Downregulation of HLA class I minimizes the level of tumor-associated 
antigen (TAA) expression by tumor cells and therefore their recognition and sub-
sequently destruction by cytotoxic T-cells (CTL) (5,14–16). The second mechanism 
is the ability of tumor cells to regulate the expression of non-classical HLA class I 
molecules (HLA-E and HLA-G) on the cell surface. Expression of these markers has 
been found to inhibit Natural Killer (NK) cell recognition in the blood stream and 
therefore results in further tumor cell escape from immune surveillance (17–20). 
HLA-E is regularly expressed in various healthy tissues and correlated with HLA 
class I expression (21). In contrast, HLA-G is rarely found in healthy tissues, but 
is frequently observed in tumors (19). Thirdly, tumor cell immune reactivity can 
become suppressed by the attraction of immunosuppressive regulatory T cells 
(Tregs) into the tumor micro-environment (22,23). Tregs are able to modulate the 
anti-tumor immune response as they suppress the activity of CTL through direct 
cell-to-cell contact or via the release of cytokines like transforming growth factor ȕ 
(24–26). Tregs and CTLs therefore show opposing actions in tumor immunity (27).
Previously, both the downregulation of HLA class I, presence of Tregs and HLA-E 
and -G expression have been shown to be of clinical relevance in several types of 
cancers (28–31). In colorectal cancer (CRC), various studies have described the 
impact of the level of HLA class I tumor expression or the presence of Foxp3+ 
Tregs cells on patients with varying results (32–39). In general, loss of HLA class I 
tumor expression seemed to result in a better prognosis (39,40). The presence 
of high levels of Foxp3+ cells in CRC patients was related to a worse prognosis 
in some studies, although this relation could not always be established in CRC 
patients (33,34,37,38,41). Studies on the prognostic value of HLA-E and HLA-G 

















Previous studies have shown a complex interaction between different immune 
markers, highlighting the need for combined marker analysis (29,41,46). The pur-
pose of this study was to investigate the prognostic value of the immune-related 
biomarkers HLA Class I, HLA-E and -G and Foxp3+, to establish distinct patterns 
that reflect a tumor’s immune-escape mechanism by combining these markers, 
and to relate these patterns to clinical outcome.
MATERIALS AND METHODS
Study population
The patient population comprised a consecutive series of 470 colorectal cancer 
patients all treated with surgery for their primary tumor in the Leiden University 
Medical Center (LUMC) between 1991 and 2001. Of these patients tumor mate-
rial, clinico-pathological data and information on the follow-up was collected in 
retrospect. This research was approved by the Medical Ethical Committee of the 
LUMC. Mucinous differentiation was defined as fully (>50%), partly (0-50%) or no 
mucinous differentiation. Tumor Node Metastasis (TNM) was defined by the Union 
for International Cancer Control (UICC) (47). Tumor differentiation was defined as 
good, moderate or poor, as described in the pathology report. Patients with rectal 
cancer, patients with a history of cancer other than basal cell carcinoma or cervical 
carcinoma in situ, patients with more than one colon tumor at the same time, and 
patients that received radio- or chemotherapy treatment prior to resection were 
excluded from the analysis (n=185 in total). The study cohort therefore consisted of 
285 colon cancer patients.
Antibodies
The mouse monoclonal antibodies HCA2 and HC10 were used, which recognize 
the heavy chains of HLA Class I, and were kindly provided by Prof. Dr. J. Neefjes. 
The reactivity spectrum of HCA2 comprises all HLA-A chains (except HLA-A24), 
as well as some HLA-B, HLA-C, HLA-E, HLA-F, and HLA-G chains. HC10 reacts 
with HLA-B and HLA-C heavy chains and some HLA-A (HLA-A10, HLA-A28, HLA-
A29, HLA-A30, HLA-A31, HLA-A32, HLA-A33) (46). The mouse antibodies against 
human Foxp3 (ab20034 clone 236A/E7; Abcam) were used for Treg identifica-
tion. The reactivity spectrum of Foxp3 is composed of regulatory T cells and may 
include small numbers of CD8+ cells but is generally considered to be the best 
single marker for Treg identification (48,49). For HLA-E and HLA-G identification 
mouse monoclonal antibodies against HLA-E (ab2216 clone MEM-E/02: AbCam, 
UK) and HLA-G (4H84: Exbio, Czech Republic) were used. MEM-E/02 recognizes 
denatured HLA-E (50,51), while 4H84 recognizes denatured HLA-G molecules and 








TMA production and immunohistochemistry
The histo-pathological characteristics of the tumor material from all patients 
included were determined by qualified pathologists according to current stand-
ards. Of the formalin-fixed paraffin-embedded (FFPE) tumor blocks of the pri-
mary tumors, sections were cut for haematoxylin and eosin staining. Based on 
microscopic inspection of the slides, histo-pathologically representative bulk 
tumor regions from each tumor block were identified and punched for preparation 
of tumor tissue microarray (TMA) blocks. From each donor block, three 0.6 mm 
diameter tissue cores were punched from the identified tumor areas and trans-
ferred into a receiver paraffin block using a custom-made precision instrument. 
Immuno-histochemical staining (IHC) for Foxp3+ cells, non-classical HLA-E and 
HLA-G, and classical HLA class I tumor expression was performed on 4 µm sec-
tions, which were cut from each receiver block and mounted on glass.
The sections were deparaffinized and rehydrated. Endogenous peroxidase was 
blocked for 20 minutes in 0.3% hydrogen peroxide in PBS. For antigen retrieval, 
slides were boiled in 0.01 M EDTA buffer (pH 8) for 10 minutes at maximum power 
in a microwave oven. Sections were incubated overnight with anti-Foxp3+, -HLA-E 
or -HLA-G antibodies at pre-determined optimal dilution. After 30 minutes of incu-
bation with Envision anti-mouse (K4001; DAKO Cytomation, Glostrup, Denmark), 
sections were visualized using diaminobenzidine solution (DAB+). Tissue sections 
were counterstained with haematoxylin, dehydrated and finally mounted in pertex. 
The IHC for HCA2 and HC10 was performed using the Autostainer Link 48 (DAKO). 
For antigen retrieval Envision TM Target Retrieval Solution (DAKO), pH low, was 
used. The sections were incubated for 18 hours with either HCA2 or HC10 antibod-
ies at pre-determined optimal dilution, followed by incubation with Envision FLEX/
HRP (DAKO). Sections were visualized using DAB+ liquid solution (DAKO). Finally 
these slides were counterstained with haematoxylin as well, dehydrated and finally 
mounted in pertex. All slides were stained simultaneously to avoid interassay varia-
tion. For each patient, normal epithelium, stromal cells, or lymphoid cells served as 
internal positive control for HLA class I antibody reactivity.  Placenta tissue slides 
served as positive control for HLA-E and HLA-G staining. Slides from human tonsil 
tissue served as positive control for Foxp3+ staining. Negative controls were tissue 
slides that did undergo the whole immunohistochemical staining without primary 
antibody.
Evaluation of immunohistochemistry
Microscopic analysis of HCA2, HC10, HLA-E and HLA-G expression and presence of 
Foxp3 + cells was performed by two independent observers in a blinded manner 
(M.S.R.: 100% of the cohort, E.C.M.Z. 30% of the cohort). The Cohen’s Kappa was 
> 0.75 for all stainings indicating substantial agreement between the two observ-
ers. The scores of the three 0.6 mm punches were averaged. For HCA2 and HC10 
the percentage of tumor cells with membranous staining was assessed. HLA class I 
expression status was determined according to the standard set by the Inter-
















 percentages were divided into two categories; 0-5% of the tumor cells show 
expression and 5-100% show expression. If <5% of the tumor cells showed expres-
sion for each of the two markers, this was determined to represent loss of HLA 
class I expression; if expression in <5% of the tumor cells of one of the two mark-
ers as HLA class 1 downregulation; and if expression in more than 5% of the tumor 
cells for each of the two markers this was denoted as HLA class I expression. For 
HLA-E and HLA-G, intensity of tumor staining (absent, weak, moderate or strong 
intensity) was determined. For HLA-E, absent and weak staining together versus 
moderate and strong staining together were used for the final analysis. For HLA-
G, absent tumor staining was analyzed versus weak, moderate and strong tumor 
staining together, because HLA-G is normally not expressed on healthy tissues in 
comparison to HLA-E (19,21). Quantification of the number of Foxp3+ cells was 
microscopically assessed in the entire tumor punches of the TMA and the absolute 
number of positive cells was used for the analysis.
Determination of microsatellite stability status
DNA was extracted from 2mm tumor-cores. Paraffin was dissolved in xylene, tissue 
was rehydrated in ethanol (100%/70%) and dried for 10 minutes at 37°C. Nucle-
ospin 96 Tissue kit (Machery-Nagel, Düren, Germany) was used for DNA extraction 
according to the manufacturer’s protocol.
MSS-status was tested using the MSI Analysis System Version 1.2 (Promega, Man-
nheim, Germany) and interpreted by an experienced pathologist, as described pre-
viously (55).
Statistical Analysis
Statistical analyses were performed using the statistical package SPSS (ver-
sion 17.0 for Windows; SPSS Inc.). The Student’s T-test and the Chi-squared test 
were used to evaluate associations between tumor expressions of HLA class I, and 
non-classical HLA-E and HLA-G and tumor infiltration of Foxp3+ cells and various 
clinico-pathological variables. Overall Survival (OS) was defined as time of sur-
gery until death and Disease Free Survival (DFS) as time of surgery until death 
or relapse of disease, whichever came first. The Kaplan-Meier method was used 
for calculation of survival probabilities and the Log-rank test for comparison of 
survival curves between these three phenotypes. Cox regression was used for uni-
variate and multivariate analysis for OS and DFS. Significant variables (p<0.05) in 









HLA class I expression
Microscopic quantification of HLA class I expression was performed on 242 patients 
as, due to staining artifacts and loss of material during the staining procedure, 
the IHC results of 43 cases could not be analyzed. Representative images of HLA 
class 1 staining and frequencies of HLA class I expression in the different groups 
are shown in figure 1 and 2. Patient characteristics and data on HLA class I expres-
sion are shown in table 1. Since HCA2 also reacts with some HLA-G chains (46), we 
examined the relationship between HCA-2 reactivity and HLA-G expression and 
found no correlation (p=0.348).
Patients whose tumors showed loss of HLA class I had a significantly better Overall 
Survival (OS) and Disease Free Survival (DFS) (logrank p-value 0.005 and 0.008) 
compared to patients with tumors with HLA class I downregulation or expression 
(figure 3). The Hazard Ratios (HRs) for OS and DFS for HLA class I tumor expres-
sion are shown in Table IIa and IIb
Foxp3+ cells
The number of Foxp3+ cells could be evaluated in 245 patients, because, due 
to staining artifacts and loss of material during the staining procedure, the IHC 
results of 40 cases could not be analyzed. The mean number of positive cells per 
tumor punch was 19 with a median of 12.0. In 4.1% (n=10) of the patients no Foxp3+ 
cells were present. Representative images of Foxp3+ staining are shown in figure 
1. Patients with expression of HLA class I showed borderline significantly higher 
levels of Foxp3+ cells in their tumor punches compared to HLA class I downregu-
lation or loss: mean in expression group 21 vs. a mean of 12 and 14 positive cells 
in the downregulation group and loss of HLA class I group respectively; p-value 
0.07. Patients with stage 1 tumors showed significantly higher levels of Foxp3+ 
cells compared to patients with stage 2, stage 3 and stage 4 tumors: mean level of 
Foxp3+ cells in stage 1 tumors was 38 compared to 13, 17 and 20 for the stage 2, 
3 and 4 tumors, p-value <0.001. For further analysis Foxp3+ was categorized as 
below vs. above median based on the median due to the skewness in the spread 
of the data. Frequencies are shown in figure 2. The presence of Foxp3+ cells in the 
tumor micro-environment was not related to OS (logrank p-value 0.114) or DFS 
(logrank p-value 0.155).
HLA-E and HLA-G
Representative images for HLA-E and HLA-G and frequencies in the different 
groups are shown in figure 1 and 2. HLA-E and HLA-G were not related to OS and 
DFS (logrank p-values for OS 0.809 and 0.239 respectively, logrank p-values for 
DFS 0.876 and 0.117 respectively). None of the clinico-pathological characteris-


















Representative images of HLA class 1, HLA-E, HLA-G and Foxp3+ staining.
Representative images of immuno-histochemical stainings for HLA Class I expression (HCA2 and 
HC10), HLA-E and HLA-G expression and presence of FOXP3+ on the left side with magnifications 
on the right side, performed according to standard protocols (details in Material and Methods).
(A) HCA2-positive tumor (B) HC10-positive tumor (C) HLA-E-positive tumor (D) HLA-G- positive 
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Frequencies of HLA class I tumor expression, Foxp3+ tumor infiltration and HLA-E and –G tumor 
expression. Pie-charts indicating the frequencies of all stainings including missings due to staining 
artifacts and loss during the staining procedure. Details about group composition and scoring 
methods are written in Material and Methods (A) Frequency of HLA class I tumor expression; 
missing 43/285 (15.1%), loss of HLA class 1 11/242 (4.5%), Downregulation of HLA class 1 38/242 
(15.7%), Expression of HLA Class 1 193/242 (79.8%) (B) Frequency of Foxp3+ tumor cell infiltration; 
Foxp3+ below median 134/245 (54.7%) Foxp3+ above median 111/245 (45.3%) Missing 40/285 
(14.0%). (C) Frequency of HLA-E tumor expression. Negative HLA-E expression 59/244 (24.2%) 
Positive HLA-E expression 185/244 (75.8%) Missing 41/285 (14.4%) (D) Frequency of HLA-G tumor 












































































































































































































Abbreviations. MSS; microsatellite stability, MSI; Microsatellite instability.
Note: HLA-EG is a combination of HLA-E and HLA-G (explained in the material and methods 
section). 
This table shows the patient characteristics of the entire colon cancer cohort (n=285) and stratified 







































Loss of HLA class I
Expression of HLA class I
Downregulation of HLA class I
A B
p-value: 0.005 p-value: 0.008






































11 10 6 2 0
37 15 6 1 0 37 15 6 1 0
183 104 60 19 0 183 94 54 17 0
Figure 3
Survival curves stratified for HLA class I tumor expression in colon cancer 
A) Kaplan Meier curve for OS in the study population of 285 colon cancer patients stratified for HLA 
class I tumor expression status. B) Kaplan Meier curve for DFS in the study population of 285 CRC 
















A combined variable of HLA-E and HLA-G scores was created (cEG). Expression 
was considered positive when both HLA-E and HLA-G were expressed (cEG+) and 
negative when either HLA-E or HLA-G was not expressed (cEG-). The group with 
tumors with both absences of HLA-E and HLA-G was too small to analyze sepa-
rately. Positive cEG was found in 14.7% (42 of 244) of tumors. Patient character-
istics and data on the combined variable HLA-E and -G expression can be found 
in table 1. None of the clinico-pathological variables shown in table 1 were signifi-
cantly related to tumor expression of cEG. cEG was not significantly related to OS 
(logrank p-value 0.245) and DFS (logrank p-value 0.100).
Multivariate analysis for single immune markers
Both for OS and DFS a univariate analysis was performed for the following param-
eters: sex, age, TNM stage, HLA class I expression status, mucinous differentiation, 
tumor grade, adjuvant therapy and microsatellite status. In the univariate analysis 
for OS, age (p-value <0.001), TNM status (p-value <0.001) and HLA class I expres-
sion status (p-value 0.011) were significant predictors of survival. The same was 
true for the univariate analysis for DFS with a p-value of <0.001 for age and TNM 
status and a p-value of 0.02 for HLA class I expression. Therefore all three were 
included in the multivariate analysis. In this analysis age and TNM stage remained 
significant for both OS and DFS (OS and DFS p-values all <0.001): HLA class I was 
a borderline independent significant predictor for OS (p-value 0.08) (table IIa and 
IIb).
Analysis of tumor immune phenotypes
Except for HLA class I, none of the tumor immune markers showed a significant 
correlation with patients’ clinical outcome. The interaction between tumor cells and 
immune cells, however, is complex and multifaceted. Therefore, we hypothesized 
that analysis of combined tumor immune markers; describing a tumor’s immune 
phenotype may better reflect outcome of the interaction between tumor cells and 
the immune system. We combined all of the data into one combined variable. The 
Kaplan Meier curves performed with this combined variable indeed revealed 3 dis-
tinct patterns in relation to patient outcome (figure 4 and 5). The entire population 
could be divided in 3 phenotypes:
a) Strong immune system tumor recognition: Patients with tumors that showed 
loss of HLA class I expression, presence of Foxp3+ cells in the tumor micro-
environment, and negative cEG expression (n=11).
b) Intermediate immune system tumor recognition: Patients with tumors 
that showed downregulation of HLA Class I expression and negative cEG 
expression, but were found to have Foxp3+ cells in the tumor micro-
environment or patients with tumors that showed normal HLA class I 
expression irrespective of cEG expression and the presence of Foxp3+ cells 
(n=184).
c) Poor immune system tumor recognition: Patients with tumors showing normal 
or downregulated HLA class I and no presence of Foxp3+ cells irrespective of 









Univariate and multivariate analyses of Overall Survival (OS) in the different immune markers and in 
the tumor immune phenotypes
Univariate analysis Multivariate analysis*

























































*Corrected for sex, age, TNM stage, HLA class I expression status, mucinous differentiation, tumor 
grade, adjuvant therapy and microsatellite status. Only significant variables in univariate analysis are 
corrected in multivariate analysis. Note: HLA-EG is a combination of HLA-E and HLA-G (as explained 
in the results section).
These three phenotypes showed significant differences for OS (logrank p-value 
<0.001) and DFS (logrank p-value 0.001). The HRs of the three phenotypes for OS 
and DFS are shown in table IIa and IIb.
Multivariate analysis for tumor immune phenotypes
Again, both for OS and DFS a univariate analysis was performed for the following 
parameters: sex, age, TNM stage, tumor immune phenotype, mucinous differentia-
tion, tumor grade, adjuvant therapy, and microsatellite status. In univariate analy-
sis, next to age and TNM status, the tumor immune phenotype was a significant 
predictor for OS (p-value 0.001) and DFS (p-value 0.002). Therefore all three these 
parameters were included in multivariate analysis. The tumor immune phenotype 
was an independent significant predictor for both OS (p-value 0.009) and DFS 

















Univariate and multivariate analyses of Disease Free Survival (DFS) in the different immune markers 
and in the tumor immune phenotypes
Univariate analysis Multivariate analysis*

























































*Corrected for sex, age, TNM stage, HLA class I expression status, mucinous differentiation, tumor 
grade, adjuvant therapy and microsatellite status. Only significant variables in univariate analysis are 
corrected in multivariate analysis. Note: HLA-EG is a combination of HLA-E and HLA-G (as explained 






































Overall Survival in months from surgery Disease Free Survival in months from surgery
HLA loss, cEG-, Treg+
HLA loss, cEG-, Treg-
HLA expression, cEG+, Treg+
HLA downregulation, cEG-, Treg+
HLA expression, cEG-, Treg-
HLA expression, cEG-, Treg+
HLA downregulation, cEG+, Treg-
HLA expression, cEG+, Treg-
HLA downregulation, cEG-, Treg-
HLA downregulation, cEG+, Treg+
A B
p-value: 0.019 p-value: 0.043
Figure 4
Survival curves stratified for combined tumor expression of HLA class I, HLA-E, HLA-G and Foxp3+ 
in colon cancer. A) Kaplan Meier curve for OS in the study population of 285 colon cancer patients 
stratified for all the different combinations between tumor expression of HLA class I, combined 
expression of HLA-E and HLA-G (cEG) and the presence of Foxp3+ cells (Tregs) based on which 
3 distinct patters could be distinguished as shown in figure 4 B) Kaplan Meier curve for DFS in the 
study population of 285 colon cancer patients stratified for all the different combinations between 
tumor expression of HLA class I, combined expression of HLA-E and HLA-G (cEG) and the presence 















































Overall Survival in months from surgery Disease Free Survival in months from surgery
A B









































11 10 6 2 0
175 102 59 19 0 174 94 54 17 0
44 17 7 1 0 44 15 6 1 0
Figure 5
Survival curves stratified for immunehenotypes in colon cancer. 
A) Kaplan Meier curve for OS in the study population of 285 colon cancer patients stratified for all 
the different combinations between tumor expression of HLA class I, combined expression of HLA-E 
and HLA-G (cEG) and the presence of Foxp3+ cells (Tregs) based on which 3 immune phenotypes 
could be distinguished. See results section for explanation of the phenotypes. B) Kaplan Meier 
curve for DFS in the study population of 285 colon cancer patients stratified for all the different 
combinations between tumor expression of HLA class I, combined expression of HLA-E and HLA-G 
(cEG) and the presence of Foxp3+ cells (Tregs) based on which 3 immune phenotypes could be 









Tumor-immune interactions may be important for the prognosis of cancer patients 
(17). In this study, we showed that by combining the immune-related markers HLA 
class I, HLA-E, HLA-G and Foxp3+, we were able to determine three distinct pat-
terns in survival, which might represent how immune surveillance controls tumor 
growth and metastasis.
The first marker of tumor-immunogenicity used was the level of HLA class I expres-
sion of cancer cells. Our results are comparable with the results of other studies 
that were able to determine a prognostic effect of the HLA class I status in colon 
cancer (35,39). Watson et al. showed that tumors with downregulation of HLA 
class I had a worse survival comparable with our results (39). In contrast, Menon et 
al. showed a survival benefit in patients with downregulated HLA-A tumors (35). 
However, when HLA-A and HLA-B/C were combined, statistical significance was 
lost. Furthermore, patients with expression of HLA class I were related to a better 
survival in the study by Watson et al., whereas our study and the study by Menon 
et al. showed an improved survival in patients with loss of HLA class I expres-
sion. Possible explanations for these differences might be a different definition for 
HLA class I expression, differences in staining techniques and scoring, a different 
patient cohort and microsatellite instability (MSI), which is associated with loss of 
HLA class I and a better prognosis (56,57). In our study, 33% of the tumors with 
loss of HLA class I showed the MSI phenotype, in comparison to 14% and 13% for 
HLA class I downregulation and expression. Results from Menon et al. also showed 
that 50% of the tumors with loss of HLA class I had the MSI phenotype. In contrast, 
Watson et al. did not mention MSI.
As hypothesized, loss of HLA class I expression in tumor cells could also be related 
to a better patient survival because such cells, once they metastasize to the blood-
stream, are eliminated by NK cell attacks (35,39,58). Tumors with loss of HLA class I 
have also shown to have significantly higher NK cell infiltration (15). More interest-
ingly, the tumors showing loss of HLA class I in our cohort were also the ones that 
showed to be negative for HLA-E and -G expression (phenotype a). Absence of the 
HLA-E and -G expression makes them even more susceptible to NK cell elimina-
tion (17–20). Furthermore, this is also confirmed by CRC tumors with loss of HLA 
class I expression who do not metastasize to the liver (59).
The presence of the third marker Foxp3+ is thought to represent the inhibition of 
host-protective antitumor responses. When stimulated, they inhibit the function 
of CTL (6). Although the exact mechanism by which these cells are drawn into the 
tumor micro-environment remains unexplained, their immunosuppressive effect 
has been proven with a high density of tumor-infiltrating Foxp3+ cells found to be 
associated with an unfavorable prognosis in a wide range of human carcinomas, 
including breast and lung cancer (60,61). However, in colon cancer different results 
are reported as well (37,38). One possible explanation for these opposite results 
might be a different micro-environment of colon cancer, which is colonized with 
















cytokines causing tumor-enhancing effects. Instead of the specificity of infiltrating 
T-cells for tumor-antigens, T-cells in colon cancer could be more specific for the 
microflora and suppress inflammation and immune responses from bacterial inva-
sion, resulting in an anti-tumorigenic effect, which could explain the better prog-
nosis of patients with tumors with a strong Foxp3+ infiltration (62). We were not 
able to demonstrate differences in disease outcome for Foxp3+ tumor infiltration 
supporting this latter hypothesis, but we did see differences in Foxp3+ infiltration 
if we combined them with HLA class I expression and with HLA-E and -G expres-
sion, especially in patients who have retained their HLA class I expression. Patients 
with normal HLA class I expression and absence of Foxp3+ cell infiltration showed 
a worse patient outcome. We hypothesize that the tumors of these patients have 
had a minimal CTL attack because the HLA class I expression in preserved. Since 
CTL and Foxp3+ cells show opposing actions (27) and CTLs are possible scarce in 
these tumors, Foxp3+ cell infiltration might not be necessary. These tumors could 
therefore progress aggressively as immune surveillance is poor. In contrary, tumors 
with HLA class I expression, which were able to attract Foxp3+ cells, showed a 
slightly better prognosis. In this case, Foxp3+ cell infiltration might indicate CTL 
activity resulting in suppression of the tumor growth.
Therefore, in our opinion, the clinical relevance of the studies by Watson et al. 
and several others does not provide an optimal perspective on prognosis (35,39), 
because expression of a single immune marker is not sufficient for the selection of 
high-risk colon cancer patients or treatment allocation. As shown by our results 
and previous studies, immune markers are related to each other (29,46,63,64).
When all markers were combined, patients showing the worst prognosis were 
patients with HLA class I downregulation, negative or positive cEG expression and 
absence of Foxp3+ cells denoted as phenotype c. We hypothesize that these poor 
immune system recognized tumors were able to elicit only a minimal CTL attack 
because they partly preserved HLA class I expression and subsequently attracted 
little to no Foxp3+ cells in their tumor micro-environment. Furthermore, these 
tumors showed a positive expression of HLA-E and -G, further escaping immune 
surveillance through inhibition of NK cell recognition (17–20). These tumor cells can 
therefore quickly progress to the bloodstream and might eventually metastasize.
It is important to realize that what we are evaluating is just a ‘snapshot’ of the 
ongoing process of cancer immuno-editing in the patient’s primary tumor at time 
of resection. Still, from a clinical point of view, at the patient’s bedside this is usually 
the only data available based on which clinical decision making has to take place 
and these data can actually be of clinical value to, for example, the allocation of 
adjuvant therapy as opposed by De Kruijf et al. in breast cancer and other studies 
(29,65,66).
Our study does have a few limitations. Not all combinations between HLA class I, 
HLA-E and -G and Foxp3+ were present in our cohort. There was no representation 
of tumors with loss of HLA class I, which were HLA-E and -G positive. Therefore 
we were not able to investigate the prognosis of these tumors, but we hypoth-








NK cell attack. Although there is a physiological correlation between HLA-E and 
HLA class I molecules, this has been found to be disturbed in tumors, suggesting 
further escape from immune recognition through upregulation of HLA-E (21,46). 
To truly investigate these tumors, our study has to be validated in a bigger cohort. 
Second, the antibodies we used for HLA class I detection only detected the heavy 
chain, but not the trimeric complex consisting of ȕ2-microglobuline heavy chain 
and antigen (67). Therefore we should be careful using the term total loss of HLA 
class I. Third, we did not investigated the role of NK cells in patients with loss or 
downregulation of HLA class I, possibly explaining the positive prognostic effect 
of patients with loss of HLA class I expression. However, NK cell infiltration at the 
tumor site is scarce, indicating that tumor staining for NK cells might be minimally 
informative (40).
In conclusion we were able to identify local immune escape mechanisms of colon 
cancer, where the presence of Foxp3+ cell infiltration favors a better prognosis, 
indicating CTL activity. HLA-E and -G expression might play a pivotal role in dis-
tant immune escape mechanisms, where in case of loss or downregulation of HLA 
class I, HLA-E and -G expression determines distant metastases and prognosis of 
colon cancer patients. Furthermore we were able to determine three distinct sur-
vival patterns in colon cancer patients based on immune surveillance. In the future 
these findings might contribute to better treatment allocation and maybe even the 
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Colon cancer represents a major public health problem, accounting for more 
than 1 million new cases diagnosed each year and more than half a million deaths 
worldwide (1,2). While earlier diagnosis and advances in treatment have consid-
erably improved survival in recent years, further progress is needed. Challenges 
include not only the development of new, less toxic adjuvant treatment regimens 
or discovering the optimal treatment sequence incorporating new molecular tar-
geted therapeutic agents but more importantly, the optimal selection of patients 
for these adjuvant therapy strategies (3). The benefits of adjuvant chemotherapy 
have been most clearly demonstrated in patients with node-positive (stage III) 
disease, who have an approximately 30 percent reduction in the risk of disease 
recurrence and a 22 to 32 percent reduction in mortality with chemotherapy (4). 
Current guidelines therefore dictate adjuvant chemotherapy for all stage III colon 
cancer patients. The benefit of adjuvant chemotherapy in stage II disease remains 
controversial. A subset of patients within the stage II (node-negative) cohort are 
known to have a high risk of distant metastasis comparable to the stage III patient 
cohort and might therefore benefit from adjuvant treatment (5,6). Five large clini-
cal trials have addressed this benefit in populations consisting either entirely or 
predominantly of stage II disease (7–11). Based upon this data, although most trials 
show a disease-free survival benefit of adjuvant therapy in stage II, the magnitude 
of this benefit is too small to treat all stage II patients with adjuvant therapy. The 
American Society of Clinical Oncology in 2004 therefore recommended a set of 
criteria, based upon the experience in stage III disease populations and data of the 
MOSAIC study, consisting of clinico-pathologic variables based on which high risk 
stage II patients can be identified (9,12). These criteria are: fewer than 12 sampled 
lymph nodes in the resection specimen, T4 lesions, tumor perforation at clinical 
presentation, poorly differentiated tumor histology and/or peri-neural, lymphatic 
or vascular invasion (12). Recent data from the Dutch Surgical Colorectal Audit 
(DSCA) points out that in the Netherlands only 18% of the stage II patients, indi-
cated as high risk based on these recommendations, did actually receive adjuvant 
treatment (13). This implies that although the recommendations are part of the 
national guideline, they are not considered standard of care by the involved clini-
cians. This might be due to the circumstantial evidence the recommendations are 
based on. What are needed to better assist the clinicians in this process of treat-
ment allocation are better diagnostic tools for the assessment of clinical progno-
sis and therapy response. Molecular tumor-derived biomarkers can serve as such 
prognostic and predictive biomarkers. Introduction of these biomarkers, together 
with the TNM criteria and possibly the ASCO criteria, might provide clinicians with 
a more feasible and evidence-based staging system.
In this thesis we applied a tumor biology-directed approach focusing on biological 
determinants of the tumor’s growth and metastatic potential in order to indentify 
such molecular biomarkers. The focus was on prognostic biomarkers, and mainly 
for stage II and III colon cancer patients. In the first part of the thesis we focused 
on biomarkers of apoptosis and proliferation. In the second part the focus was on 








PART 1 BIOMARKERS OF APOPTOSIS AND PROLIFERATION
Apoptosis or programmed cell death is an intriguing process regulated at mul-
tiple levels. Based on the stimulus presented, two pathways initiating the apop-
totic process can be identified; an extrinsic pathway typically activated in immune 
responses and an intrinsic pathway activated for example by stimuli reflecting DNA 
damage (14). Both pathways converge at the level of the caspase cascade eventu-
ally causing proteolytic activation of the executioner caspase-3 (15). This protein 
acts as a cellular disassembly machine responsible for the morphological features 
that hallmark apoptotic cell death.
We have previously shown that the level of apoptosis in rectal cancer resection 
specimens was directly related to the development of local recurrence in clinical 
follow-up (16,17). To determine whether the pathway of apoptosis also harbors 
clinical prognostic relevance in colon cancer patients we executed an extensive 
review of the literature searching for prognostic biomarkers related to the apoptotic 
pathway in colorectal cancer (Chapter 2). We identified 26 potential biomarkers, 
studied with immunohistochemistry (IHC) in primary colorectal cancer patients of 
which expression data was related to patient outcome. The data, however, showed 
none of these single biomarkers to be of independent prognostic relevance or 
appropriately represented outcome of the apoptotic pathway. Under normal cir-
cumstances both apoptosis and proliferation play a pivotal role in the maintenance 
of tissue homeostasis (18). Disruption of either one of these processes contributes 
to the hallmarks of cancer: biological capabilities a cell acquires during the pro-
cess of tumorigenesis (19,20). Our review pointed out that multi-marker studies 
describing combined analysis of several biomarkers, related to both apoptosis and 
proliferation, showed the most promising results with respect to predicting patient 
outcome (21,22).
Previously, Michael-Robinson et al. reported on prognostic value of an AI:PI 
(apoptotic index: proliferation index) ratio in a small cohort of colorectal cancer 
patients (23). Prompted by these results and the conclusions of our review of the 
literature, we proceeded with the study described in Chapter 3. In this chapter 
combined markers of tumor levels of cell proliferation and apoptosis were tested 
for their prognostic relevance in a large cohort of colon cancer patients using IHC 
on a TMA (Tissue Micro Array). This TMA technique combined with IHC enabled us 
to perform a rapid, cost-effective and high-throughput analysis of several molecu-
lar markers at protein level (24). The Ki67 antibody was used to determine level of 
tumor cell proliferation and we determined the tumor apoptotic levels based on the 
tumor cell IHC expression levels of activated (cleaved) caspase-3. Although many 
studies, including those by Michael-Robinson et al., have used M30 IHC to deter-
mine tumor apoptotic levels, we choose to use IHC-determined expression of acti-
vated caspase-3 (23). First of all, because of our good experience with biochemical 
assays determining activated level of caspase-3 in previous studies (16,17,25). And 
secondly, studies have shown a superiority of anti-activated caspase-3 antibodies 








study revealed that combined analysis of both Ki67 and activated caspase-3-based 
levels of tumor proliferation and apoptosis into one CAP parameter (Combined 
Apoptosis Proliferation parameter) was significantly related to clinical outcome in 
a large cohort stage I-IV colon cancer patients. The direction of this correlation 
depended on both tumor location, and indirectly tumor microsatellite status, and 
TNM stage.
Since we now constituted the prognostic qualities of this combined parameter we 
further focused on the clinical value of the combined analysis of tumor apoptotic 
and proliferation levels in colon cancer patients in Chapter 4&5. In these chapters 
we studied both apoptosis and proliferation using biochemical assays. The advan-
tages of using biochemical assays in the clinical setting over immunohistochem-
istry are the highly accurate performance of these assays on only limited amount 
of fresh frozen tissue that can be easily acquired by a biopsy or during surgery. 
Furthermore, the results are less influenced by inter-observer variety (27). More 
importantly, biochemical assays provide information on a functional level of the 
enzymatic activities of a protein as opposed to providing solely expression levels 
when using IHC. As mentioned before we already had good experience with ana-
lyzing the tumor apoptotic level with biochemical assays determining the activated 
level of caspase-3 (16,25). In Chapter 4 the use of the level of cyclin-dependent 
kinase 1 specific activity (CDK1 SA), determined with a biochemical assay, as a 
predictor of tumor recurrence and patient outcome was studied. It is hypothesized 
that increased levels of intra- tumoral CDK 1 SA reflects higher tumor prolifera-
tion rate. The expression of this kinase is constitutive in cells, but the enzymatic 
activity changes according to the cell cycle phase, and thus associates with cell 
proliferation. Previously the proliferation rate of tumor cells has been studied with 
many different methods. Chapter 3 for example demonstrates the use of ki67 IHC, 
but also 3H-thumidine/BrdU incorporation and PCNA IHC have been widely used 
methods. None were found to be useful in a clinical setting (28,29). The prognostic 
value of the biochemical assay determining CDK 1 SA had already been proven in 
two large, independent cohorts of breast cancer patients (30,31). Therefore we 
choose to determine the prognostic qualities of this particular assay in colon can-
cer patients. In the study described in chapter 4, that included patient cohorts from 
both the Netherlands and Germany, the prognostic quality of CDK1 SA was stud-
ied in stage II colon cancer patients. Furthermore, the prognostic value of CDK1 
SA was compared to another frequently studied prognostic biomarkers in stage II 
colon cancer: the BRAF V600E mutation status and the high-risk identification 
criteria recommended by ASCO (12,32). CDK 1 SA was proven to be an independ-
ent prognostic predictor of distant tumor recurrence. Interestingly, high CDK1 SA 
was significantly related to a microsatellite stable tumor phenotype. This is prob-
ably due to the fact that the regulation of CDK1 activity is orchestrated at cellular 
checkpoints. The patient’s tumor microsatellite status might induce changes in the 
structure and function of proteins related to these checkpoints, especially if micro-
satellites are present in key genes in these processes, eventually affecting the level 








for clinical application the patient’s tumor microsatellite status should therefore 
always be taken into account.
In Chapter 5 we validated the prognostic quality of the combined analysis of pro-
liferation and apoptosis when both determined with biochemical assays, CKD1SA 
reflecting tumor cell proliferation and caspase-3 activity reflecting tumor cell 
apoptosis, in a cohort of stage II colon cancer patients taking into account the 
patients tumor microsatellite status. In this cohort, low levels of tumor cell CKD1 SA 
and high levels of casapse-3 activity were independent predictors of better DFS 
(CDK1 SA HR 9.6, p-value 0.029 and caspase-3 activity HR 0.5, p-value 0.03). The 
combined results of these assays, correctly classified 87.5% of the stage II MSS 
patient as high risk of developing distant metastasis.
In summary, we demonstrated the clinical importance of combined analysis of the 
level of tumor cell apoptosis and proliferation in chapter 3 and the use of a bio-
chemical assay reflecting tumor proliferation and apoptosis in chapter 4. Further-
more, in chapter 5 the results of our combined analysis were compared to a subset 
of the ASCO criteria, and showed to perform equally with respect to test specificity 
and sensitivity (12). Thus, we were able to demonstrate that the use of our apop-
tosis/proliferation parameter, and taking into account the tumor microsatellite sta-
tus, is of additive value in the high-risk patient identification.
PART 2 TUMOR-IMMUNE INTERACTIONS
The immune system has been attributed an important role in controlling tumor 
growth and metastasis (33–36). New insight emerging from the growing field of 
cancer research have led to the addition of two hallmarks, gained during tumor 
development, to the six biological capabilities tumor cells have acquired in the 
multistep process of malignant transformation as originally described by Hana-
han and Weinberg in 2000 (20,37). One of these two emerging hallmarks is the 
capability of tumor cells to evade immune destruction. It has become clear that 
tumor cells during their transformation, and in interaction with their host, create a 
so-called tumor micro-environment (38). One of the characteristics of this tumor 
micro-environment is interaction of tumor cells with the immune system. The 
tumor immune surveillance hypothesis which postulates that the immune system 
can identify cancerous cells and eliminate them, probably usually before they can 
cause harm is based on this observed interaction (39). Based on this hypothesis 
studying tumor immune-interactions provides us not only with new biomarkers as 
described in chapter 8 and 9, it also provides a possibility to develop new treat-
ment strategies for the high-risk patient cohort.
One of the new immune-based treatment strategies, the use of vaccines, exploits 
activation of the patient’s immune system as a therapeutic modality. In Chap-
ter 6 we provide a review of the literature on clinical trials in which both tumor 
cell-derived vaccines as well tumor antigen-derived vaccines are deployed. To 








response. Furthermore, the response should be uniquely target tumor cells. Based 
on the literature reviewed we therefore listed some key features required to obtain 
clinical results in colon cancer vaccine strategies. Preferably, a vaccine should tar-
get tumor-specific antigens, enhance the number of effector T cells but not the 
number of suppressive T cells, and create a T-cell friendly and supportive tumor 
micro-environment. Previously we established the safety and immunogenity of a 
p53 synthetic long peptide (p53-SLP®) vaccine (40). This vaccine is comprised of 
mutated, and therefore functionally not activated, P53 that is overexpressed in 
34-45% of the colon cancer patients while wild type p53 is expressed at low levels 
(41). Results of this study showed we were able to induce a p53- specific CD4 + T cell 
response. However, though the vaccine seemed to induce Type 1 T-helpers (Th1) 
cells, it resulted in only low amounts of key cytokines such as interferon-ࢢ (IFN-
 and IL-2. It was concluded that a p53 –specific Th-response was induced, but (ࢢ
probably not properly polarized. To optimize our vaccine we compared the design 
of our p53 synthetic long peptides (p53-SLP®) vaccine to the vaccine key features 
we described in chapter 6. We concluded that in order to polarize the  Th-response 
properly and actually benefit from tumor-specific Th-cells at the tumor site, an 
immune stimulating treatment modality should be added to vaccine.
In Chapter 7 we investigated if the addition of such an immune-stimulating treat-
ment modality, interferon-Į (IFN-Į) in addition to the p53-SLP® vaccine, is safe 
and would actually result in higher production of key cytokines such as IFN-ࢢ rep-
resenting a more Th1-polarizedresponse and possibly resulting in the presence of 
more tumor-specific CD4+ T cells at the tumor site. In this phase I/II clinical trial 11 
colorectal cancer patients were enrolled after successfully being treated for meta-
static disease. The results showed that besides from being safe, the toxicity was 
limited to Grade 1 or 2 with only small ongoing swellings at the vaccination site. All 
patients harbored p53- specific T-cells after vaccination and most patients showed 
p53-specific antibodies. More importantly, compared to the previous trial, with the 
addition of IFN-Į the frequency of p53-specific T cells producing IFN-ࢢ improved 
significantly. These data are very promising, however, the clinical introduction of 
this type of vaccination is still a long way ahead. Not only are the minimal require-
ments of a vaccine-induced immune responses to obtain a clinical tumor response 
at this moment practically undefined, the responses we were able to induce by are 
all means too small.
In chapter 8 and 9 we focused on studying the tumor micro-environment and 
tumor immune- interactions in order to identify immune-related biomarkers. These 
biomarkers might not only aid us in the identification of high-risk stage II patients, 
they might also be used in the future to select patients for vaccine-based adju-
vant therapies. For this purpose in Chapter 8 we studied the presence in tumors 
of Foxp3+ regulatory T-cells and of CD8+ cytotoxic T-cells (CTLs) in relation to 
tumor cell HLA class I expression in colon cancer patients and we related the data 
obtained to patient outcome parameters. The adaptive immune system and its key 
players, CTLs, play an important role in controlling tumor growth and metasta-








loss of one of more HLA class I alleles, that makes them less sensitive to immune 
surveillance by escaping CTL recognition (34,35,42,43). Another mechanism to 
evade immune surveillance is the attraction of immunosuppressive regulatory T 
cells into the tumor micro-environment. Both features have been shown to be of 
clinical relevance in various types of solid tumors (44–47). In our study neither the 
presence of Foxp3+ cells nor the presence of CD8+ cells was statistically significant 
related to patient outcome. A ratio, calculated based on the presence of these cells, 
however, significantly predicted clinical outcome. Relatively high numbers of CD8+ 
cells compared to the number of Foxp3+ cells was related to better distant recur-
rence free survival suggesting a mutual functional relationship (figure 4b, chap-
ter 8). Furthermore, we also included data on the tumor HLA class I status and the 
tumor microsatellite status. Although we were not able to demonstrate the precise 
effects of the HLA class I status and tumor microsatellite status on patient out-
come, the data did underline the need of a comprehensive approach when study-
ing the effect of biomarkers representing the interplay between a tumor and the 
multi-faceted immune system in predicting the patient outcome.
The goal of the study presented in Chapter 9 was to establish distinct patterns that 
reflect mechanisms involved in ‘tumor immune escape’ and relate these to patient 
outcome using a comprehensive approach based on the conclusion of the study 
described in chapter 8. Because of the advantages listed previously again a TMA of 
stage I-IV colon cancer patients the appropriate tool to study these patterns was. 
Markers included were presence of Foxp3+ cells, tumor expression of HLA class I 
(HLA-A,-B, and –C) and the expression of non-classical HLA-E and –G. The quanti-
tative data of these markers was combined into three immune-phenotypes; a high, 
intermediate, and low immune susceptible phenotype. After careful analysis the 
three profiles were found to represent significant, independent clinical prognostic 
profiles. Although we are aware of the limitations of this type of retrospective stud-
ies and the need for further evaluation and validation larger cohorts, we found the 
results to be very promising.
CONCLUSIONS AND FUTURE DIRECTIONS
This thesis focuses on finding biomarkers that reflect biological hallmarks of tumo-
rigenesis in order to develop tools that might aid in the clinical identification of 
high-risk stage II colon cancer. We found that based on biochemical assays the 
combined analysis of apoptosis and proliferation might guide this identification, 
predominantly in those patients with microsatellite stable tumors. When studying 
mechanisms involved in tumor-immune interaction it was also the combined anal-
yses of key-biomarkers that harbored clinical potential. These biomarker-based 
phenotypes might also aid in the future development of tumor vaccine-based 
therapeutical strategies for colon cancer as they might be used for patient selec-








Although the results are promising, introduction of any of the biomarker profiles 
studied in this thesis are not yet ready for clinical introduction. As described in 
chapter 2 of this thesis Pepe et al. proposed a five step program which can serve 
as a guideline for the clinical introduction of a biomarker (48). At the moment the 
status of our biomarkers does not exceed the steps 1-2; the pre-clinical explora-
tory phase and clinical assay and validation phase. There are various issues that 
need to be addressed before any of these marker profiles will make it ‘from bench 
to bedside’. For example, the role of the tumor microsatellite status needs to be 
addressed more thoroughly. Previous studies have shown that the tumor micro-
satellite is related to patient outcome, while others have suggested this is not due 
to the microsatellite status but is related to tumor location and it’s embryonic tis-
sue origin or the tumor’s mutational load (49–52). Therefore, this point needs much 
more attention and research.
Altogether the results of the studies presented in this thesis emphasize the impor-
tance of studying the tumor biological context in order to develop prognostic bio-
markers of clinical significance. Tumor growth and –progression is the result of a 
multi-step and multi-faceted process. The strength of our biology-based approach 
lies in the fact that we studied key-elements that reflect outcome of processes 
such as the regulation tumor cell apoptosis, proliferation and interaction with the 
immune system, all within the tumor micro-environment. Through combining 
results we were able to create ‘tumor phenotypes’ that reflect tumor aggressive-
ness. These combined biomarker-based phenotypes much better reflect tumor 
biology and thus clinical outcome than any approach based single marker studies, 
as most are in scientific literature. To warrant the clinical introduction of biomarker-
based phenotypes in the near future and in order to develop a tumor phenotype 
that will ultimately reflect the status of all hallmarks of cancer, these studies must 
be further extended. Based on this thesis we are able to state with confidence 
that biomarker-based phenotypes have the potential to accurately determine the 
clinical behavior of individual tumors and therefore a patient’s individual clinical 
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De afgelopen jaren is er veel aandacht besteed aan de vroegtijdige opsporing en 
behandeling van het coloncarcinoom. En niet onterecht. Dikkedarmkanker heeft 
een belangrijke impact op de volksgezondheid met wereldwijd jaarlijks ruim 1 mil-
joen nieuwe patiënten bij wie de ziekte wordt vastgesteld (1, 2). Daarbij overlijden 
er per jaar nog altijd meer dan een half miljoen mensen aan de gevolgen van deze 
ziekte. De oorzaak van overlijden is vaak het gevolg van uitzaaiingen op afstand 
(metastasen), zoals naar de lever (1).
Dankzij ontwikkelingen in de wetenschap, die hebben geleid tot o.a. eerdere diag-
nose en betere behandeling, is de overleving van mensen, bij wie deze ziekte de 
afgelopen 10 jaar werd vastgesteld, toegenomen. Desondanks valt er nog veel 
winst te behalen. De basis van de behandeling van het coloncarcinoom blijft chi-
rurgische resectie van de primaire tumor. Echter, sinds het begin van de jaren ’90 
is het duidelijk geworden dat, wanneer er sprake is van uitzaaiing naar lokale lym-
feklieren, er na resectie een belangrijke rol is weggelegd voor nabehandeling met 
chemotherapie. Het is op dit moment standaardprotocol om alle stadium III patiën-
ten deze adjuvante therapie aan te bieden. In tabel 1 wordt weergegeven hoe deze 
indeling in stadia voor dikkedarmtumoren werkt. Deze nabehandeling, ook wel 
adjuvante chemotherapie genoemd, heeft geleid tot een daling van het risico op 
terugkeren van de ziekte: voor metastasering op afstand in deze patiëntengroep 
tot 30%, en een verlaging van het overlijdensrisico naar 32% (3).
Bij stadium II patiënten is nabehandeling met chemotherapie controversieel. Voor 
een kleine groep stadium II patiënten is bewezen dat zij een grote kans hebben op 
het ontwikkelen van metastasen op afstand (met name naar de lever) wat natuur-
lijk zeer nadelige gevolgen heeft voor de overleving van deze patiënten. Deze 
patiënten zouden dus profijt kunnen hebben van een standaard nabehandeling 
met chemotherapie (4), ware het niet dat deze behandeling gepaard gaat met een 
hoge mate van morbiditeit. De algemene opvatting is dan ook dat het standaard 
nabehandelen van alle stadium II patiënten, waarvan een groot deel zonder behan-
deling nooit uitzaaiing op afstand zou ontwikkelen, niet opweegt tegen de risico’s 
van deze, in de meeste gevallen dus onnodige, behandeling (5).
Vanwege de potentiële overlevingswinst in de selecte groep stadium II patiënten 
die uitzaaiingen ontwikkelt, is er de afgelopen jaren veel aandacht besteed aan het 
identificeren van deze patiënten. De American Society of Clinical Oncology (ASCO) 
heeft in 2004 een aanbeveling gedaan waarin een aantal criteria zijn opgesteld 
die artsen moet helpen deze hoogrisicogroep stadium II colonkankerpatiënten 
te identificeren (6). Het gaat dan om patiënten waarbij bij pathologisch onder-
zoek minder dan 12 lymfeklieren in het resectiepreparaat worden aangetroffen, 
patiënten waar bij de tumor reeds tot in de buitenwand van de darm (T4-tumoren 
genoemd) is gegroeid of waarbij deze al geperforeerd is door de darmwand heen 
bij diagnose, patiënten waarvan de tumor slecht gedifferentieerd is, of patiënten 
waarbij de tumor ingroei laat zien in de kleine bloed- en of lymfevaten of rondom 
de zenuwbanen bij pathologisch onderzoek. Uit onderzoek binnen een database, 
waarin vrijwel alle patiënten zijn geregistreerd, die in 2010 in Nederland aan een 








Colorectal Audit), blijkt dat 37% van de colonkankerpatiënten werden geopereerd 
in verband met een stadium II tumor (7). Van deze patiënten werd 13% op basis 
van de ASCO-criteria ingeschat als hoog risico. Opvallend genoeg werd slechts 
18% van deze hoogrisicopatiënten daadwerkelijk nabehandeld met chemotherapie 
ondanks dat de criteria van de ASCO op dat moment al als aanbeveling waren 
opgenomen in de landelijke richtlijn ‘behandeling van dikkedarmkanker’ welke is 
na te lezen op www.oncoline.nl. We kunnen dus concluderen dat de nabehandeling 
met chemotherapie van hoogrisico stadium II patiënten in Nederland nog niet tot 
de standaard hoort. Een reden hiervoor zou kunnen zijn dat een groot deel van de 
behandelend artsen (o.a. oncologen en chirurgen) de classificatie van hoogrisico-
patiënten op basis van de ASCO-criteria onvoldoende vindt om over te gaan tot 
een dergelijke invaliderende nabehandeling. Kortom, de behandelaars van patiën-
ten met een coloncarcinoom in Nederland, maar ook in de rest van de wereld zijn 
op zoek naar een betrouwbare methode om de hoogrisico stadium II patiënten te 
kunnen identificeren.
De afgelopen jaren is er daarom wereldwijd veel onderzoek gedaan naar betere 
identificatie van deze hoogrisico stadium II patiënten. Er is met name veel winst 
behaald door studies naar het gebruik van biomarkers. Biomarkers zijn organi-
sche substanties zoals bijvoorbeeld cellen, eiwitten en genen, die in het bloed of 
het tumorweefsel van patiënten in het laboratorium kunnen worden geanalyseerd. 
Door de aan- of juist afwezigheid van deze biomarkers te analyseren, bijvoorbeeld 
in relatie tot de overleving van patiënten, kan worden bestudeerd of deze voor-
spellend zijn voor de prognose van patiënten.
Ook in dit proefschrift ligt de focus op het gebruik en de ontwikkeling van bio-
markers die informatie kunnen geven over de prognose van een patiënt met darm-
kanker. In deel 1 hebben wij gekeken naar een aantal processen die van belang 
Tabel 1
Indeling van dikkedarmtumoren naar ziektestadium op basis van de TNM 5 criteria uit 1997
Stadium T N M
I 1-2 0 0
II 3-4 0 0
III 1-4 + 0
IV 1-4 + +
Het TNM classificatiesysteem van maligne tumoren is ontwikkeld door de International Union 
Against Cancer (UICC) en wordt wereldwijd gebruikt voor de classificatie van dikkedarmtumoren. 
De T staat voor tumor en beschrijft de lokale uitbreiding. T1 betekent groei van de tumor tot in de 
submucosa, het slijmvlies van de darm, maar er niet doorheen. T2 staat voor tumorgroei tot in de 
spierlaag van de darm, de muscularis propria, maar er niet doorheen. De T3 codering wordt gebruikt 
als de tumor doorgroeit tot in de buitenlaag van de darm, de subserosa of in het omliggend vet en 
een tumor wordt als T4 gecodeerd als deze ingroeit in omgevende organen of door het buikvlies 
heen. De N staat voor mate van metastasering naar lymfeklieren. Een N0 codering betekent dat er 
geen sprake is van kliermetastasen, een N+ codering geeft aan dat dit wel het geval is. De M staat 
voor metastase op afstand. De code M0 betekent dat er geen sprake is metastasering op afstand, 









zijn voor tumorgroei en –ontwikkeling, zoals gereguleerde celdood (apoptose) en 
ongecontroleerde celdeling (proliferatie). In deel 2 hebben wij de interactie tussen 
tumoren en het afweersysteem bestudeerd.
DEEL 1 BIOMARKERS GERELATEERD AAN APOPTOSE EN PROLI-
FERATIE
Vernieuwing van cellen door celdeling is een proces dat continu plaatsvindt in vrij-
wel alle weefsels in het lichaam, maar met name in weefsels met veel slijmvlies 
zoals de darm. Om te voorkomen dat dit resulteert in woekering van cellen en 
dus tumorvorming worden oude en/of beschadigde cellen regelmatig afgebro-
ken. Dit resulteert in een balans van aanmaak en afbraak van cellen die ook wel 
weefselhomeostase wordt genoemd (8-10). Apoptose, ook wel gereguleerde cel-
dood genaamd, draagt in belangrijke mate bij aan de afbraak van deze oude en 
beschadigde cellen (11). Het is een complex proces, dat op meerdere niveaus wordt 
gereguleerd. Het proces kan door de cel zelf worden geïnitieerd; van binnenuit 
(intrinsiek), bijvoorbeeld naar aanleiding van DNA-schade, of door stimuli van bui-
ten af (extrinsiek), bijvoorbeeld door activering van het immuunsysteem (11). Beide 
routes leiden tot de activering van een bijzondere groep eiwitten, de caspases (12), 
die op basis van hun enzymatische activiteit in staat zijn een cel af te breken.
Eerder onderzoek uit ons laboratorium heeft aangetoond dat de hoeveelheid aan 
apoptotische activiteit in het tumorweefsel van patiënten met een endeldarm-
tumor significant gerelateerd is aan de mate van lokale terugkeer van tumor in 
deze patiëntenpopulatie (13, 14). In de literatuur is deze relatie (tussen de mate 
van tumorcelapoptose en de prognose van patiënten) ook vastgesteld voor dik-
kedarmtumoren (15). Bepaalde eiwitten die onderdeel zijn van het proces leidend 
tot apoptose in dikkedarmtumoren zouden daarom kunnen functioneren als bio-
markers. In Hoofdstuk 2 geven we een overzicht van de wetenschappelijk litera-
tuur die op dit moment beschikbaar is op het gebied van biomarkers gerelateerd 
aan apoptose. Hierbij hebben wij met name gekeken naar prognostische relevantie 
en specifiek ook naar studies waarin deze biomarkers met behulp van immunohis-
tochemie werden bepaald. Immunohistochemie (IHC) is een techniek waarbij de 
aanwezigheid van een bepaald eiwit kan worden aangetoond door deze te labe-
len met antilichamen die specifiek binden aan dit eiwit. In de literatuur hebben 
we 26 potentiële biomarkers, gerelateerd aan apoptose en bestudeerd met IHC, 
gevonden. De functie van deze biomarkers binnen het proces van apoptose en de 
resultaten van de afzonderlijke studies worden in het overzichtsartikel in hoofd-
stuk2 beschreven. De belangrijkste conclusie van dit artikel was dat geen enkele 
biomarker op zich zelf, dus als ‘single’ biomarker, significant gerelateerd was aan 
de klinische prognose van patiënten. Derhalve zijn deze biomarkers op dit moment 
als ‘single’ biomarkers niet bruikbaar in de kliniek voor de identificatie van hoogri-








Een verklaring voor het uitblijven van prognostische relevantie van deze zoge-
naamde ‘single biomarkers’ kan zijn dat voor het voorkomen van tumorvorming 
niet alleen een intact proces van apoptose nodig is, maar ook een goed geregu-
leerde nieuwvorming of proliferatiecyclus. Immers beide dragen bij aan weefsel-
homeostase. Ons literatuuronderzoek toonde dat een combinatie van biomarkers, 
zowel gerelateerd aan apoptose als aan proliferatie, betere resultaten geeft voor 
wat betreft het voorspellen van de prognose van patiënten. Vanwege deze betere 
voorspellende waarde van de combinatie van biomarkers zowel betrokken bij 
apoptose als bij proliferatie hebben wij een studie opgezet welke wordt beschre-
ven in Hoofdstuk 3. Hierin kijken we naar een combinatie van biomarkers, ki67 
en geactiveerd caspase-3, die respectievelijk betrokken zijn bij celproliferatie en 
apoptose. Wij bepaalden deze biomarkers op een zogenaamde ‘tissue micro array’ 
(TMA) met de eerder genoemde immunohistochemie (IHC) techniek. Het voordeel 
van het gebruik van een dergelijke TMA is dat de analyse goedkoper is en met een 
minimaal gebruik van weefsel kan worden uitgevoerd. De combinatie van de ki67 
en caspase-3 markers werd geanalyseerd op tumorweefselsamples van bijna alle 
patiënten die in een periode van 10 jaar (tussen 1990-2000) in het LUMC werden 
geopereerd aan een coloncarcinoom. De resultaten van dit onderzoek toonden 
aan dat de gecombineerde aanwezigheid van deze markers, verwerkt in de door 
ons ontwikkelde CAP (Combined Apoptosis and Proliferation) parameter, zowel 
correleerde met prognose, de locatie van de tumor in de dikke darm, als met 
tumorstadium.
Ondanks de positieve uitkomst van de studie in Hoofdstuk 3 is een dergelijke uit-
gebreide vorm van IHC voor toepassing van deze combinatie van biomarkers in de 
kliniek niet haalbaar. Alhoewel IHC relatief goedkoop is kost een dergelijke gecom-
bineerde analyse veel tijd (16). Maar een belangrijker nadeel is dat de analyse nog 
niet objectief kan worden uitgevoerd. Alle afzonderlijke bepalingen worden door 
analisten op het oog gescoord hetgeen kan leiden tot variaties tussen de ver-
schillende beoordelaars; interbeoordelaarsvariatie genoemd (16). Op dit moment 
wordt in ons laboratorium gewerkt aan een geautomatiseerde methode waarbij 
de analyse van de IHC resultaten door een computer wordt uitgevoerd Deze auto-
matische analysemethode is echter nog niet gevalideerd en voor toepassing op 
individuele patiënten relatief kostbaar. Om de klinische toepasbaarheid van onze 
parameter te realiseren werd daarom gekozen tot het ontwikkelen van een test 
waarbij zowel de mate van apoptose als proliferatie kunnen worden bepaald, op 
minimale hoeveelheid materiaal door middel van real-time testing. Het voordeel 
hiervan is dat een dergelijke analyse geen gebruik maakt van IHC en daardoor 
een gestandaardiseerde uitkomstmaat biedt die niet gevoelig is voor de eerder 
genoemde interbeoordelaarsvariatie. Voor het analyseren van de mate van apop-
tose is een dergelijke test al ontwikkeld en in het verleden met succes uitgevoerd in 
ons laboratorium (17). In deze test wordt naast de hoeveelheid van het aanwezige 
caspase-3 enzym ook de enzymatische activiteit van het eiwit bepaald. Wereldwijd 
wordt deze bepaling geaccepteerd als een marker voor de mate van apoptotische 









Een dergelijke marker, waarbij gebruik wordt gemaakt van enzymatische activiteit, 
voor tumorcelproliferatie was nog niet voorhanden voor het coloncarcinoom. In 
Hoofdstuk 4 hebben wij daarom een nieuwe marker, ontwikkeld door het Japanse 
bedrijf Sysmex, die representatief is voor de hoeveelheid tumorcelproliferatie, 
getest voor klinische relevantie in samenwerking met collegae van de techni-
sche universiteit van de Rechts an der Isar Klinikum in München. Deze marker is 
genaamd CDK1SA (‘cyclin dependent kinase 1 specific activity’). Het CDK1 eiwit 
is nauw betrokken bij de verschillende fases van celdeling, die in normale cellen 
worden doorlopen en functioneert als een poortwachter in de regulatie van dit 
proces(18). Een hoge mate van CDK1 activiteit is bewezen gerelateerd te zijn aan 
een hoge mate van celproliferatie en eerdere studies uit ons laboratorium hebben 
een klinische relevantie van deze marker met betrekking tot prognose in borstkan-
kerpatiënten aangetoond (18-20). Ter analyse van de klinische relevantie van deze 
marker met betrekking tot de stadium II coloncarcinoompatiënten werd materiaal 
afkomstig van twee min of meer gelijkwaardige patiëntengroepen uit Duitsland en 
Nederland gebruikt. De resultaten van dit onderzoek toonden dat de specifieke 
enzymatische activiteit van CDK1 (CDK1SA), in essentie op dezelfde wijze bepaald 
als de enzymatische activiteit van caspase-3, significant gerelateerd is aan de kans 
op het ontwikkelen van een metastase op afstand. Opvallend genoeg was er een 
sterke relatie met de tumormicrosatellietstatus. Microsatellieten zijn kleine repete-
rende nucleotidensequenties in het DNA. Een toename in de frequentie van deze 
repeterende sequenties ontstaat door niet goed functionerend DNA herstelsy-
steem (het MMR, mismatch repair systeem) (21-23). Dit uit zich in instabiliteit van 
het genoom wat microsatelliet-instabiliteit (MSI) wordt genoemd. Onder normale 
omstandigheden zorgen de eiwitten die het MMR vormen er voor dat fouten, die 
tijdens celdeling spontaan kunnen ontstaan en resulteren in de vorming van micro-
satellieten, worden gecorrigeerd. In sommige tumoren kunnen MMR eiwitten hun 
functie niet goed uitvoeren doordat er of wel een mutatie optreedt in het gen ver-
antwoordelijk voor de productie van deze MMR eiwitten, of doordat er te weinig 
MMR eiwitten worden geproduceerd door hypermethylering van de promotor van 
een van de betrokken genen, dit resulteert in MSI. Patiënten met tumoren waarvan 
het DNA MSI laat zien hebben over het algemeen een betere prognose (23). Wij 
concludeerden dan ook dat als CDK1SA wordt geanalyseerd ten einde een uit-
spraak te doen over de prognose van een patiënten, de tumormicrosatellietstatus 
ook altijd in overweging dient te worden genomen.
Aangezien we in hoofdstuk 4 hebben aangetoond een betrouwbare biomarker te 
hebben ontwikkeld, representatief voor de mate van tumorproliferatie, hebben wij 
in Hoofdstuk 5 gekeken naar de combinatie van deze biomarker met de reeds 
bekende biomarker voor de mate van apoptose, het geactiveerd caspase-3. In een 
patiëntengroep bestaande uit alleen stadium II colonkankerpatiënten werden de 
resultaten van beide analyses gecombineerd. We waren in staat om in dit cohort 
met behulp van onze assay in 87.5% van de stadium II patiënten met microsatel-








Kortom, de gecombineerde analyse van biomarkers die zowel betrekking hebben 
op de mate van apoptose in tumorweefsel als de mate van proliferatie, kan worden 
gebruikt om hoogrisico stadium II patiënten met colontumoren te identificeren. 
In hoofdstuk 5 werd onze classificatie, gebaseerd op gecombineerde biomarkers, 
tevens vergeleken met de classificatie in hoog- en laagrisicopatiënten op basis van 
de door de ASCO voorgestelde criteria (6). Vooralsnog was onze gecombineerde 
analyse even specifiek als sensitief in het identificeren van hoogrisicopatiënten als 
wanneer de ASCO criteria werden toegepast. Dit biedt perspectieven voor een 
eventuele, gecombineerde toepassing in de toekomst.
DEEL 2 INTERACTIE TUSSEN HET COLONCARCINOOM EN HET 
IMMUUNSYSTEEM
Een belangrijke rol in de controle van tumorgroei en de ontwikkeling van metasta-
sen is weggelegd voor het immuunsysteem(24-27). In 2000 werden door Hanahan 
en Weinberg een zestal kerneigenschappen van tumorcellen ook wel ‘Hallmarks 
of cancer development’ genaamd beschreven (28). Het betreft veranderingen die 
normale cellen moeten ondergaan om zich te ontwikkelen tot kwaadaardige kan-
kercellen. Deze kenmerken hebben betrekking op het in stand houden van de pro-
liferatie en onbeperkte celdeling, het vermijden van apoptose, het vermogen tot 
invasie van weefsel en het ontwikkelen van metastasen op afstand en het vermogen 
tot het aanzetten van bloedvatvorming (29). Voortschrijdend inzicht in het proces 
van tumorgroei en ontwikkeling leidde er in 2011 toe dat er een tweetal kenmer-
ken werden toegevoegd aan deze kerneigenschappen. Een daarvan was het ver-
mogen van tumorcellen om vernietiging door het immuunsysteem te voorkomen. 
Tijdens het proces van maligne celtransformatie vindt er een belangrijke interactie 
plaats tussen de tumorcellen en het omringende weefsel, ook wel genaamd de 
tumor-microenvironment genoemd (29). In een belangrijke hypothese genaamd 
de ‘tumor immune surveillance hypothesis’ wordt gesteld dat het immuunsysteem 
van elk mens in staat is kankercellen te identificeren en te elimineren, nog voor-
dat deze tot een kwaadaardigheid kunnen leiden (30). Deze hypothese vormde 
de basis voor de studies die worden gepresenteerd in het tweede deel van het 
proefschrift. In hoofdstuk 6 en 7 behandelen wij hoe het immuunsysteem van de 
patiënt gebruikt zou kunnen worden in de behandeling van kanker met behulp van 
zogenaamde tumorvaccins. In hoofdstuk 8 en 9 tonen wij vervolgens hoe deze 
interactie tussen de tumorcel en immuunsysteem ook kan worden gebruikt voor 
de ontwikkeling van nieuwe biomarkers.
Tumorvaccinatie
Onderzoek naar tumorvaccinaties is een veelbelovende stap in de richting van de 
ontwikkeling van nieuwe behandelstrategieën van het coloncarcinoom. Eind ver-
leden jaar nog werd immunotherapie als behandeling van kanker verkozen tot de 









soort vaccinaties gebruik gemaakt van tumorspecifieke eiwitten (genaamd anti-
genen) om het immuunsysteem te activeren en zo de tumorcellen te vernietigen. 
In Hoofdstuk 6 wordt een overzicht gegeven van de literatuur met betrekking tot 
een aantal klinische studies waarin dergelijke vaccins zijn onderzocht. Uit dit over-
zicht blijkt dat er een aantal kerneigenschappen zijn waar een tumorvaccin aan 
moet voldoen. Het vaccin moet veilig zijn in gebruik en, zoals al genoemd, gericht 
zijn tegen tumorspecifieke eiwitten. Het vaccin moet een reactie van specifieke 
T-cellen opwekken welke in staat zijn de tumorcellen te vernietigen en het moet 
een dusdanig effect hebben op de tumor-microenvironment dat deze T-cellen hun 
werk kunnen doen.
Binnen het LUMC, in een samenwerkingsverband tussen de afdeling Klinische 
Oncologie en de afdeling Heelkunde, is de afgelopen jaren gewerkt aan de ontwik-
keling van het zogenoemde p53-SLP® vaccin, een synthetisch gefabriceerd p53 
‘long peptide’ vaccin (31). Het eiwit p53 leent zich goed als doelwit voor tumor-
vaccinatie omdat het in bijna de helft van de colontumoren in grote hoeveelhe-
den wordt geproduceerd terwijl de normale variant (het wildtype) van het eiwit in 
tumoren nauwelijks voorkomt (32). Eerdere studies hebben aangetoond dat het 
vaccin voldoet aan kerneigenschappen van een vaccin: het is veilig in gebruik en in 
staat om een specifieke (CD4+) T-celreactie op te wekken (31). Deze CD4+ T-cel-
respons is cruciaal voor de werking van een vaccin. De CD4+ T-cellen zorgen er 
namelijk voor dat CD8+ T-cellen, ook wel cytotoxische T cellen genaamd, kunnen 
ontstaan die gericht zijn tegen tumorcellen. Daarnaast ondersteunen ze de CD8+ 
T-cellen in hun functie: het herkennen van de tumorcellen op basis van het antigen 
wat verwerkt is in het vaccin en destructie van deze tumorcellen. Daarin spelen 
de cytokines interferon-ڸ (IFN- ڸ ) en interleukine-2 (IL-2), geproduceerd door de 
CD4+ T-cellen, een belangrijke rol.
Helaas lieten de resultaten van de eerste studies met het p53-SLP® vaccin zien dat 
de opgewekte CD4+ T-celrespons, ook wel een Type 1 T-helperrespons genaamd, 
slechts leidde tot de productie van een zeer kleine hoeveelheid van deze belang-
rijke cytokines. De opgewekte respons was dus niet effectief genoeg. Daarom 
is getracht, kijkend naar de kerneigenschappen uit het literatuuronderzoek van 
hoofdstuk 6, het p53-SLP® vaccin te optimaliseren. De belangrijkste aanpassing 
richtte zich op het verbeteren van de tumor-microenvironment om zo de ontwik-
keling van de CD4+ T-celrespons te stimuleren. Het nieuwe vaccin bevat dan ook 
naast het originele p53-SLP® vaccin, interferon-alpha (INF-Į). Van deze stof is eer-
der beschreven dat het een positieve uitwerking heeft op het tumor-microenviron-
ment (33).
In Hoofdstuk 7 wordt de studie beschreven waarin het verbeterde vaccin werd 
getest op allereerst veiligheid maar natuurlijk ook op de mate waarin het vaccin in 
staat was een CD4+ T-celrespons te induceren. In de studie werd het verbeterde 
vaccin getest in 11 patiënten, allemaal succesvol behandeld voor gemetastaseerd 
coloncarcinoom. De resultaten lieten zien dat het verbeterde vaccin veilig was in 
gebruik; de enige bijwerkingen die werden gerapporteerd betroffen kleine zwel-








de immunologische deelstudies dat alle patiënten een specifieke T-celrespons ont-
wikkelden tegen het vaccin. Maar misschien nog belangrijker, in vergelijking tot het 
p53-SLP® vaccin alleen leverde de combinatie van het vaccin met IFN-Į significant 
meer IFN-ڸp53-specifieke T-cellen op. Kortom, door toevoeging van IFN-Į aan 
het bestaande vaccin werd het immunologisch resultaat duidelijk verbeterd. Deze 
data scheppen ruimte en mogelijkheden voor verdere ontwikkeling van het vaccin. 
Er zal met name nog veel aandacht moeten worden besteed aan het optimaliseren 
van het immunologisch resultaat. Het is namelijk nog niet bewezen dat de mate 
waarin wij nu een reactie hebben kunnen induceren ook daadwerkelijk een klinisch 
significant resultaat oplevert.
Biomarkers en de interactie tussen colontumoren en het immuunsysteem
In hoofdstuk 8 en 9 wordt, zoals eerder genoemd, aandacht geschonken aan de 
tumor, zijn omgeving op celniveau en de interactie die hier plaatsvindt tussen 
tumorcellen en het immuunsysteem. Het doel; het identificeren van biomarkers 
gerelateerd aan deze interactie welke van prognostische waarde zijn. In dit proef-
schrift wordt met name gefocussed op biomarkers van invloed op de identificatie 
van de hoogrisicopopulatie binnen het cohort van de stadium II colonkankerpa-
tiënten. Het verworven immuunsysteem, ook wel het adaptieve immuunsysteem 
genaamd, bestaat uit meerdere typen cellen. De belangrijkste, met betrekking 
tot tumorgroei en –ontwikkeling, zijn de al eerder genoemde CD8+ cytotoxische 
T- cellen (CTLs) die tumorcellen kunnen herkennen en afbreken (25). Tijdens de 
maligne transformatie kan het uiterlijk (het fenotype) van een cel dusdanig gewij-
zigd worden dat de tumorcel feitelijk onherkenbaar wordt voor het immuunsy-
steem. Dit gebeurt door veranderde expressie van bepaalde eiwitten, humaan 
leucocytenantigen (HLA) genaamd, die voor een belangrijk deel de interactie met 
het immuunsysteem reguleren (26, 27). Van het HLA bestaan verschillende groe-
pen of klassen bestaan. HLA klasse type I zorgt voor de interactie met de CTLs. 
Door verminderde expressie van de HLA klasse type I eiwitten zorgen tumorcel-
len er dus in feite voor dat ze onherkenbaar worden voor CTLs en zo ontsnappen 
aan destructie door het immuunsysteem, ook wel ‘immune surveillance’ genaamd 
(34, 35). Een andere manier om aan immune surveillance te ontkomen is onder-
drukking van de interactie tussen tumorcellen en het immuunsysteem. Cellen die 
deze uitwerking hebben op het immuunsysteem zijn regulatoire T cellen, ook wel 
‘regulatory T cells’ of Foxp3+ T-cellen genaamd (36-38). Door het aantrekken van 
deze cellen in de omgeving van de tumor wordt de aanval van het immuunsy-
steem op de tumor als het ware onderdrukt. In Hoofdstuk 8 wordt bestudeerd of 
de aanwezigheid van CTLs, regulatoire T-cellen en de mate waarin het fenotype 
van een tumor op HLA klasse I niveau is veranderd, van invloed is op de prognose 
van colonkankerpatiënten. Omdat de CTLs en regulatoire T-cellen elkaar feitelijk 
tegenwerken hebben we ook gekeken naar de ratio tussen de aanwezige cellen 
van beide groepen. En inderdaad, relatief meer aanwezigheid CD8+ T-cellen dan 
regulatoire T-cellen had een positief effect op de prognose van deze patiënten met 









studie werden meerdere factoren, zoals MSI-status, mogelijk van invloed op de 
prognose van patiënten meegenomen in de analyse. De belangrijkste conclusie 
van deze studie was dat de interactie tussen het immuunsysteem, de tumor en 
de tumoromgeving uit zoveel facetten bestaat dat ook op dit gebied meerdere 
biomarkers nodig zijn om het effect van de uitkomst van deze interactie op de 
overleving van patiënten te beschrijven.
In de studie beschreven in Hoofdstuk 9 proberen we deze ingewikkelde interac-
tie tussen tumorcel en immuunsysteem vast te leggen in aantal patronen waarin 
de verschillende markers werden gecombineerd en deze te relateren aan de kli-
nische prognose van de patiënt. Er werd gekeken naar HLA-expressie, de aan- of 
afwezigheid van Foxp3+ cellen en de tumormicrosatellietstabiliteitstatus. Daarbij 
werd uitgebreider dan in hoofdstuk 8 gekeken naar het HLA-fenotype met meer-
dere markers zoals de klassieke HLA type I markers, HLA-A,-B en –C, maar ook 
niet-klassieke markers als HLA-E en –G. Op basis van de kwantitatieve IHC data 
van deze markers konden we 3 patronen onderscheiden. Een zogenaamd hoog, 
gemiddeld of laag immuunreactief tumorpatroon welke significant gerelateerd 
waren aan de prognose van patiënten. In de toekomst zal moeten worden gevali-
deerd in onafhankelijke patiëntenpopulaties of de door ons geïdentificeerde patro-
nen inderdaad van klinisch prognostische waarde zijn.
CONCLUSIES EN EEN BLIK OP TOEKOMST
In dit proefschrift wordt op vele, uiteenlopende manieren getracht biomarkers te 
ontwikkelen welke mogelijk in de toekomst in een klinische setting op eenvoudige 
wijze toegepast kunnen worden ten einde de hoogrisico stadium II darmkanker-
patiënten te identificeren. In alle studies werd een strategie gevolgd waarbij deze 
biomarkers werden opgespoord door te kijken naar de biologie van tumorgroei 
en –ontwikkeling en enkele van de belangrijkste processen zoals apoptose, proli-
feratie en interactie met het immuunsysteem te bestuderen. Deze studies hebben 
geleid tot een biochemische test waarin zowel apoptose als proliferatie gelijktijdig 
kunnen worden geanalyseerd, maar ook tot de ontwikkeling van tumor-immuun-
reactieve patronen met prognostische implicaties. De kennis verkregen in deze 
studies zal ons in de toekomst tevens helpen met de verdere ontwikkeling van de 
toepassing van therapeutische tumorvaccinatiestrategieën.
Alhoewel de resultaten veelbelovend zijn, zijn de door ons ontwikkelde biomarker-
profielen nog niet geschikt voor klinische toepassing. In hoofdstuk 2 wordt een vijf-
stappenplan beschreven, ontwikkeld door Pepe et al., dat kan worden gebruikt als 
leidraad voor de klinische introductie van een dergelijk biomarkerprofiel (39). Op 
dit moment bevinden wij ons wat betreft onze biomarkerprofielen pas in stappen 1 
en 2 van dit plan, de zogenaamde pre-klinische ‘exploratory’ fase en de klinische 
toetsing en validatiefase. Er zijn verschillende problemen die nog aangepakt die-
nen te worden voor daadwerkelijk klinische introductie. De rol van tumormicrosa-








op prognose. Ook onze biomarkers lieten een evidente relatie zien met de tumor-
microsatellietstatus, maar hoe deze interactie precies plaatsvindt blijft onduidelijk. 
Voor eventuele klinische introductie dient deze interactie te worden verhelderd. 
Er wordt gesuggereerd dat het mogelijk niet de microsatellietstatus op zich zelf 
is die de prognostische relatie beïnvloedt, maar de locatie van de tumor en de 
daarmee samenhangende embryologische oorsprong van het weefsel waaruit de 
tumor ontstaat, dan wel mate van mutaties die samenhangen met de microsatel-
lietstatus (22, 23, 40, 41).
De resultaten van onze studies laten in ieder geval zien dat voor de ontwikkeling 
van prognostische biomarkers uitermate belangrijk is de biologische context van 
tumorgroei en –ontwikkeling als uitgangspunt te nemen. We hebben laten zien dat 
dit een gecompliceerd, uit meerdere stappen bestaand en op meerdere niveaus 
gereguleerd proces is. Door biomarkers te analyseren representatief voor een 
aantal van deze stappen zoals tumorcelapoptose, -proliferatie en interactie met 
het immuunsysteem binnen de tumoromgeving, kunnen tumorfenotypes worden 
ontwikkeld. Deze fenotypes zijn derhalve, meer dan de veelvoudig bestudeerde 
single markers, representatief voor de mate van tumoragressiviteit en daarom 
beter geschikt voor introductie als klinisch prognostische biomarkers. Op basis 
van dit proefschrift kan dan ook met vertrouwen worden gesteld dat de ontwikke-
ling van op biomarkers gebaseerde tumorfenotypen van grote klinische waarde is. 
Op basis van dergelijke fenotypen zal in de toekomst zeer accuraat het klinische 
gedrag van colontumoren kunnen worden voorspeld op basis waarvan uitspraken 
kunnen worden gedaan over de individuele prognose van patiënten. Derhalve zijn 
dergelijke fenotypen van grote klinische waarde en zullen in de toekomst veel bij-
dragen aan het bepalen van een optimale behandelstrategie, wat met name van 
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